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Respiratory viral infections (RVIs) are amongst the most significant causes of morbidity 
and mortality worldwide causing more than three million deaths annually. These highly 
contagious illnesses affect both humans and animals. In humans, they affect a wide range of the 
population, including children under five years of age (14.1% of deaths in children annually are 
caused by RVIs worldwide) and older adults (individuals >65 years of age have the highest RVI-
related morbidity and mortality rates in the United States).   
A significant global health burden is attributed to RVIs caused by the influenza virus. In 
United States, infections caused by the influenza virus result in 250,000-500,000 deaths and an 
annual health burden of about $71 billion. The influenza virus can cause both seasonal infections 
and periodic, unpredictable pandemics. Influenza outbreaks have been reported since the 14th 
century, though some records exist from 412 BC with reports of influenza-like symptoms. The 
influenza virus is notorious for undergoing antigenic shifts and drifts, causing pandemics, most 
notably the 1918 Spanish flu pandemic and the 2009 swine influenza pandemic. Amongst the 
different classes of the influenza virus, Influenza A, Influenza B, and Influenza C, the only one 
capable of undergoing re-assortments of the virus and antigenic shift is Influenza A virus. Hence, 
in order to prevent mortalities due to potential pandemic threats, there is an urgent need for new 
approaches focused on combating the influenza A virus. 
Some of these approaches include the use of antivirals such as Tamiflu (oseltamivir®) 
within the first 48 hours of infection to reduce symptoms. Even though it has been proven to be 
safe and efficacious for patients, studies have shown some influenza A virus strains resistant to 
this medication. Vaccines have been used as another effective countermeasure to prevent 
infections caused by influenza since 1945. The first influenza vaccine discovered by Thomas 
xv 
Francis and Jonas Salk for use in the US military was a whole inactivated influenza A and B 
virus. Since then, the approach towards designing flu vaccines has not changed much, except for 
the recent approval of an adjuvanted flu vaccine. The licensed influenza vaccine is still either a 
live attenuated influenza virus (LAIV; FluMist) or an inactivated virus (IIV; Flu shot). Another 
inactivated virus vaccine adjuvanted with MF59 (Fluad) is also approved by the U.S. Food and 
Drug Administration (FDA). Various adjuvants are being studied and used in subunit vaccines, 
which use only a part of the pathogen, greatly improving the safety profile of the vaccine.  
However, not many adjuvants have been approved by the FDA for human use. Current 
flu vaccines still suffer from multiple shortcomings, including reliance on 70+ year-old egg-
based production technology, inability to provide cross-protection against different virus strains, 
and high variability in the immune responses induced in individuals of different ages, to mention 
a few. The overall goal of the research described in this thesis is to outline approaches to address 
some these shortcomings by rational design of vaccines and moving away from choosing an off-
the-shelf vaccine adjuvant for everything.  
The specific focus of this work is on developing a broadly-protective influenza vaccine 
for older adults. This was achieved by analyzing the effects of different adjuvants, including two 
nanoadjuvants (polyanhydride nanoparticles and pentablock copolymer micelles) and cyclic 
dinucleotides (CDN) on aged immune cells and understanding what each of these adjuvants 
contribute to induction of a robust immune response in older adults. In addition, the potential 
mechanism of action of these adjuvants was explored with the motivation of further optimizing 
the vaccine formulation. Polyanhydride nanoparticles have been demonstrated to provide low 
inflammatory dendritic cell activation, which leads to increased CD8+ T cell memory responses. 
Pentablock copolymer micelles provide a scaffold to facilitate the crosslinking of  B cell 
xvi 
receptors to provide T-independent B cell activation leading to rapid humoral immune responses. 
They also enhance the cytosolic delivery of antigen, MHC I presentation, and CD8+ T cell 
activation. Cyclic dinucleotides enhance B cell activating factor and humoral responses in aged 
mice without the production of nitric oxide. A vaccine formulation consisting of a combination 
of these adjuvants with influenza antigens (the combination nanovaccine) was tested in this work 





CHAPTER 1.    GENERAL INTRODUCTION AND LITERATURE REVIEW 
Influenza A virus has the potential to cause considerable damage in terms of animal lives, 
human lives of all ages and impose a significant healthcare burden. Hence, to successfully 
prevent this, new and innovative vaccine approaches are essential. To design an effective 
vaccine, familiarity with the virus, its antigens, pathogenesis, immune responses to the virus, etc. 
need to be well understood. Section 1.1 will discuss the molecular attributes and components of 
the influenza A virus and its mechanism of infection. Section 1.2 will briefly elaborate on the 
different types of immune responses generated in the host against this pathogen. Section 1.3 will 
focus on aging immunity and the facets of immune responses that are affected in older adults. 
Sections 1.4 and 1.5 will discuss the current vaccine approaches available and studied in the 
literature and the reason why there is a need for next generation vaccine formulations. Lastly, 
Section 1.6 will elaborate on the novel nanomaterial-based vaccine adjuvant platforms used in 
this study and highlight their roles in providing preventative immunity. 
 
1.1 Influenza A virus 
1.1.1 Introduction 
 Influenza A virus (IAV) belongs to the Orthomyxoviridae family and has a single 
stranded negative sense RNA as its genome1. This RNA is segmented into eight strands, each 
encoding a certain protein in the virus (Figure 1.1). Due to high rate of replication errors, this 
genome allows for easier re-assortment with other viruses infecting the same host, hence using 
the host as a “mixing vessel” and lead to genetic shift. The H1N1 IAV that caused the 2009 





swine H3N2 and swine H1N2. The swine H1N2 again was a re-assortment of human H3N2, 
avian H5N1 and swine H1N1 from before 19902. 
 The genome of IAV is encased in three proteins: hemagglutinin (HA), neuraminidase 
(NA) and matrix protein 2 (M2). The protein HA is a trimer and functions as the viral-receptor 
binding protein and has 16 subtypes: H1-H16. NA, which is a tetramer, helps with the cleavage 
of the host cells and has 9 subtypes: N1-N93. The different virus subtypes are based on these two 
surface proteins, allowing for 144 unique combinations of HA and NA to form influenza A 
subtypes. All these subtypes have birds as their natural hosts but the ones with H1, H2, H3, N1, 
and N2 have been circulated in animals and humans4.  
In addition to the capsid, each RNA segment is encapsidated by nucleoprotein (NP) and 
packaged with three polymerase proteins: polymerase basic protein 1 and 2 (PB1 and PB2) and 
polymerase acidic protein (PA). NP helps with viral replication, provides structural support to 
the viral RNA and is a highly conserved protein unlike HA and NA, making it a suitable antigen 
for use in vaccines that can target cell-mediated immunity5.  
 
1.1.2 IAV mechanism of action 
IAV infection starts with the recognition of specific molecules on host epithelial cells by 
the HA receptor (Figure 1.2). After the binding of receptors, the binding of the cell to the plasma 
membrane to form an endocytic vesicle takes place, followed by internalization of the virus into 
a cellular endosome6. Most viruses utilize clathrin-dependent endocytosis, though IAV also uses 
non-clathrin dependent pathways7. The acidic pH in the endosome results in conformational 
changes in HA and activation. This activation involves the cleavage of the precursor HA at a 





disulfide bond8. The result of this is the generation an N-terminus fusion peptide that mediates 
the fusion of the endosomal membrane and the viral membrane. This allows for the release of the 
genetic material (RNA) into the cytoplasm of the host cell. Concurrently, NA cleaves the sialic 
acids from viral glycoproteins to prevent aggregation of newly formed viral particles and 
facilitate exit from the host cell. 
The M2 protein lowers the pH of the virion interior leading to the disassociation of M1 
protein from the RNP complex and transport of RNP to the host nucleus via the nuclear pore 
complex (NPC). Once within the nucleus, the viral proteins PB1, PB2, PA and NP catalyze the 
genome replication and transcription. Several host factors help with this replication8.  
After replication, M1 protein and the nuclear export protein (NEP/NS2) play an 
important role in the transport of the newly synthesized RNPs. Some host factors involved in this 
process are protein kinase Akt and PI3K9. Thereafter, the virion components transport to the 
assembly site in the cell membranes of the epithelial cells, specifically, lipid raft microdomains 
for budding and particle release from the surface10. 
 
1.1.3 Pathogenesis of Influenza A virus infection 
Aquatic birds are the major hosts of IAV. In birds, the spread of the IAV is via feces 
since it is a gastrointestinal infection in avians. This presence of IAV in the water supply and the 
highly migratory nature of aquatic birds result in the spreading of the virus to aquatic mammals, 
other mammals on land and domestic poultry11. In most mammals, IAV causes respiratory 
infection and hence spreads via aerosol droplets, contact with saliva or other respiratory 





headache. Though sometimes depending on the subtype infected with, the infections can be 
sublethal upper respiratory tract infection or lethal lower respiratory tract infection. 
The pathogenesis of the infection depends on many factors - both virulence factors and 
host immune factors12,13.  IAV first targets and infects the epithelial cells in the respiratory tract. 
In case of seasonal influenza caused by human IAVs resulting in the upper respiratory tract 
infection, the virus binds to α2-6 sialylated glycans on the epithelial cells in nasal passage, 
pharynx, trachea and bronchi via the surface protein HA14. Inflammation caused by this is mild 
and is resolved in about ten days. However, the epithelial cells in lower respiratory tract 
including the alveoli in lungs express α2-3 sialylated glycans and are less susceptible to binding 
by HA and hence infections. But this residue can be recognized by HA of highly pathogenic 
avian H5N1 influenza viruses (HPAIV)15. Mutations in HPAIV allows HA to recognize both α2-
6 and α2-3 residues leading to severe lower respiratory tract infection and pneumonia and the 
distribution and replication of virus in multiple tissue sites. In addition, for HPAIV, the cleavage 
of HA precursor as mentioned in the last section, can also be caused by ubiquitous furin at 
multiple cleavage sites leading to infection in multiple organs and death12. 
IAV infection leads to the induction of several inflammatory cytokines and chemokines 
such as IL-1β, IL-6, TNFα, CCL2, CCL3, CCL4, CCL5 and CXCL-1016. The pathogenesis of 
the influenza virus hence is also a function of the host immune responses. A decrease in type I 
IFN secretions may result in increase in virus replication and susceptibility to infection. 
However, this overabundance of antiviral response leading to the generation of a 







1.2 Immune responses to IAV 
 IAV infection leads to the activation of immune cells and the release of a plethora of 
molecules and proteins for mounting an effective defense against the pathogen and to clear it 
from the host system (Figure 1.3 and Table 1.1). The respiratory mucosal lining plays a major 
role as the innate immune responses along with phagocytic cells and the cytokines (mostly Type 
I IFNs) released by them18. Antigen-specific effector and memory B and T cells mediate the 
adaptive immune response against IAV. Antibody responses are mostly directed towards the 
surface glycoproteins, HA and NA19. Cellular immunity also plays a crucial role in proving 
protection in addition to the neutralizing antibody responses. However, IAV can evade the 
immune system in multiple ways. In order to prevent this and to strategize to boost protective 
immunity against IAV, it is critical to understand these antiviral defenses. 
 
1.2.1 Epithelial barrier - the first line of defense 
 Since IAV infects the respiratory tract, the cells in the mucosal epithelial lining form the 
first line of defense against this pathogen. This innate immune response is rapid but non-specific. 
The viral RNA is recognized as pathogen-associated molecular patterns (PAMPs) by the 
pathogen recognition receptors (PRRs) of the host immune cells. The three kinds of PRRs 
predominantly involved in the sensing of viral proteins are: Toll-like receptors (TLRs), retinoic 
acid inducible gene-I (RIG-I) receptors and NOD-like receptor family pyrin domain containing 3 
protein (NLRP3)20–22. 
 Amongst the family of TLRs, the intracellular receptor TLR7 detects the viral ssRNA 





TLR4, which are surface receptors are mostly involved in the detection of viral surface proteins 
HA and NA21.  
 RIG-I receptors get activated by detecting newly formed viral RNA in the cytoplasm. 
They bind to the uncapped 5’-triphosphates of the viral RNA which results in conformational 
changes in the repressor domain of RIG-I. This leads to the exposure of caspase activation and 
recruitment domains (CARDs)23. 
Both the TLR and RIG-I receptors start specific signaling cascades to lead to the 
activation of nuclear factor kappa-light-chain-enhancer of activated B cells (NF-κB) and 
interferon regulatory factor 3 (IRF3)24 (Figure 2.4). All these pathways eventually result in the 
production of proinflammatory cytokines and chemokines. The transcription of IFNs leads to the 
recruitment of neutrophils, macrophages, and activation of dendritic cells. This starts the 
mounting of the antiviral responses. Type I IFNs. IFNα and IFNβ, play an important role in 
limiting viral replication and the activation of IFN-stimulated gene factor-3 transcription factor 
complex (ISGF3) which transcripts hundreds of genes encoding antiviral proteins25. Type II IFN, 
IFNγ, helps with the mounting of an effective cytotoxic T cell (CTL) response26,27.  
Inflammasomes also play crucial roles in defenses against IAV. NLRP3 when activated 
by the dsRNA triggers the cleavage and the conversion of pro-IL-1β and pro-IL-18 into IL-1β 
and IL-1822. IL-1β is involved in the induction of Th17 responses. 
 
1.2.2 Innate immune cells  
 After the production of chemotactic molecules as a result of the infection of the 





to the site of infection. The secretion of IL-1 also leads to the recruitment of macrophages and 
dendritic cells to these sites of infection.  
 NK cells are one of the most effective innate effector cells. Their receptors NKp44 and 
NKp46 can recognize and bind to viral HA protein, which results in the direct lysis of the 
infected cells28. Also, in cases of antibodies bound to the infected cells, the FcγRIII receptor of 
the NK cells can bind to the Fc portion of those antibodies and lead to antibody-dependent cell 
cytotoxicity (ADCC)29.  
 In case of the infection of alveoli, the macrophages present in that tissue, originally in a 
quiescent stage, detect CCL2 produced by infected epithelial cells and get recruited. Their 
antiviral response includes the enhanced production of cytokines IL-6 and TNFα, phagocytosis 
of apoptotic infected cells, and phagocytosis of opsonized virus particles30,31. Alveolar 
macrophages have also been shown to regulate adaptive immune responses: both humoral and 
cell-mediated32. In contrast to the beneficial response, alveolar macrophages also produce nitric 
oxide synthetase (NOS2) which contributes to severe influenza virus induced pathology33,34. As 
mentioned in previous sections, infection with HPAIV is more likely to cause this pathological 
response. Hence, it is important to balance the immune responses by these macrophages to 
eliminate the inflammation in tissues. This concept will be explored in subsequent chapters as a 
part of the vaccine design. 
 Dendritic cells (DCs) are professional antigen presenting cells (APCs) and are situated 
underneath the epithelial barrier. During steady state, they constantly survey for the presence of 
foreign antigens using their dendrites which extend to the airway lumen35. In case of an 
infection, they migrate to the draining lymph nodes (dLNs) from the lungs using CCR7 which 





adaptive immune response. DCs, if themselves are infected by IAV, use proteasomes in their 
cytosol to process and present the antigen via major histocompatibility complex I (MHC I) to 
CD8+ T cells leading to a CTL response37. If the virus particles or the apoptotic epithelial cells 
are phagocytosed by the DC entering the endosome, the antigens are processed and presented via 
MHC II to CD4+ T helper cells38. Alternatively, in this route they can also present the antigen to 
CD8+ T cells by a process known as cross-presentation39. 
 
1.2.3 Humoral immunity 
 Viral antigen-specific antibodies produced by B cells against HA and NA correlate with 
protection40. Neutralizing anti-HA antibodies bind to the globular head region of the protein 
which inhibits viral entry and receptor-mediated endocytosis and also promotes ADCC41. Even 
though these antibodies might result in long-lived protection, due to the high variability in the 
globular head, most antibody responses mediated by anti-HA fail to neutralize and protect 
against heterosubtypic viruses42–44. Consequently, studies have been directed towards exploring 
induction of antibodies against the conserved stem region of HA45,46.  
 Even though anti-NA antibodies do not neutralize the virus like anti-HA antibodies, they 
play an important role in limiting the newly formed viral particles release from the cells and 
reduces the spread of infection. Anti-NA antibodies can also facilitate ADCC. 
 In addition, non-neutralizing antibodies induced against the highly conserved M2 protein 
and NP protein has also been shown to provide protective immunity, though the exact 
mechanism is unclear47,48. Moreover, these antigen-specific anitbodies are likely to provide 






 The different antibody isotypes involved in providing influenza-specific protective 
immunity are IgG, IgA and IgM in case of a primary infection51. However, IgM antibodies that 
can neutralize the virus and activate the complement system are not induced during a secondary 
infection52. Antigen-specific IgG correlates with long-term protection53. IgA is present in higher 
concentrations than the other isotypes in the mucosal secretions and plays a major role in 
clearing the infection. Nasopharyngeal -associated lymphoid tissues (NALT) and bronchus-
associated lymphoid tissues (BALT) serve as the main battlefields for the IgA antibody-forming 
cells (IgA-AFC). The antigens phagocytosed by macrophages lead to the development of these 
cells in the NALT and the development and maturation of secretory IgA (s-IgA) takes place in 
BALT54. s-IgA prevents the adhesion of viral particles to other host cells and neutralizes them. 
The administration of vaccines does not usually induce IgA unless they are intranasally 
administered, which might be an important point to consider for vaccine design55.  
 
1.2.4 Cell-mediated immunity 
 Although antibodies produced by B cells help with neutralizing the virus, facilitate 
recovery from the infection, and reduce morbidity, T cells play an important in clearing the 
pathogen and regulating the immune response. As mentioned before, viral peptides can be 
recognized by the APCs in two ways and activate both CD4+ and CD8+ T cells.  
 CD4+ T cells are activated by recognition of peptide presented via MHC II on DCs that 
have migrated from the lungs to the dLN56. This leads to the proliferation and differentiation into 
either T helper 1 (Th1) or T helper 2 (Th2) type of response depending on the cytokine milieu. 
Th1 and Th2 subsets are differentiated phenotypically by the analysis of their cytokine secretions 





producing IL-4, IL-5 and IL-1357,58. The humoral response hence gets strengthened by induction 
of class switching and affinity maturation of virus-specific antibodies. Th1 cells secrete IFNγ, 
IL-2, TNFα and regulate CD8+ T cell differentiation and activation of alveolar macrophages59–61. 
IFNγ and IL-2 are also important for the induction of memory T cell responses62. Memory CD4+ 
T cells, notably lung resident memory cells that are induced after a primary infection, have been 
shown to provide protection against a lethal IAV challenge63.  
CD4+ T cells can also differentiate into Th17 or regulatory T cells (Treg) that balance the 
immune response during infection and prevent immunopathology of infected tissues64,65. CD8+ 
T cells contribute to both homo- and heterosubtypic immunity against IAV. Naïve CD8+ T cells 
recognize viral peptides presented on MHC I of DCs in the dLNs and differentiate into CTLs. 
CTLs can migrate to the lungs and respiratory tract to clear the virus and prevent it from 
spreading. Since the epitopes detected by CTLs are derived from internal viral proteins such as 
M1, NP, which are conserved in nature, they have been shown to provide protection against 
heterologous viral challenges66. The CTLs release perforin and granzymes to cause apoptosis of 
infected cells67. Ligation of death receptors (FasL and TNF-related apoptosis-inducing ligand 
(TRAIL)) also promotes this apoptotic activity68,69. However, some studies have shown that 
granzymes might not be essential for granule-mediated cytotoxicity and induce an antiviral pro-
inflammatory environment70. Ag-specific central memory and effector memory CD8+ T cells 
formed after a primary infection, help induce a strong and rapid secondary response. The 








1.2.5 Evasion of immune responses by IAV 
 Influenza A virus can evade the host immune system by using many strategies. Normally, 
binding of the virus to host cells triggers the host immune system and the process of inhibition is 
initiated. However, due to the immense immune pressure and high mutation rates of the virus, 
escape of the virus becomes possible. All the viral proteins play different roles in evading innate 
or adaptive host responses (Figure 1.5). 
 The innate immune recognition of viral entry is antagonized by NS1 protein. NS1 inhibits 
the recognition of ssRNA by the RIG-I receptor74. It also inhibits the translocation of IRF-3 and 
NF-κB to the nucleus. Studies show that infection with IAV with a non-functional NS1 protein 
leads to stronger IFN response than an infection with wild-type virus75. PB2 and PB1 are other 
proteins that interact with MAVS and limit the production of IFNs76. The NP protein prevents 
the formation of dsRNA during replication and the recognition by cytosolic PRRs. Furthermore, 
the virus infects innate immune cells such as monocytes and NK cells and either impairs their 
machinery or kills them77,78.  
 Evasion from humoral immunity by IAV can be attributed to its ability to introduce 
random point mutations in the regions coding for antibody binding sites in HA (antigenic drift). 
These mutations are a direct result of the lack of proof-reading activity by the viral RNA which 
makes it error prone. The introduction of a completely new and antigenically different subtype 
(antigenic shift) can cause pandemics since the human population has no neutralizing antibodies 
against such strains. 
 For evading cellular immunity, IAV leads to amino acid substitutions in the CTL epitopes 
of viral proteins to hamper the presentation and processing (Figure 2.5)79. Some of these changes 





TCR anymore, mutations at the MHC I contact residues so that MHC I cannot recognize and 
bind to the antigens and present them to CD8+ T cells80,81. They can also affect processing by the 
proteasome or transport via the TAP82. 
 All these immune evasion techniques by the virus provide strong reason to rationally 
design vaccines that are ahead of these pathogens and provide protective immunity against them. 
 
1.3 Immune responses in older adults 
 As mentioned in the introduction section, the focus of this work is to address gaps in the 
immune responses of older adults and design a vaccine taking these deficiencies into 
consideration. In this section defects in the immune systems of older adults are discussed. A 
fundamental understanding of these defects would help develop vaccine technologies aimed at 
overcoming them. 
 
1.3.1 Introduction to immunosenescence and inflammaging 
 The term which is commonly used to describe the detrimental changes to the immune 
system with age - “immunosenescence” was coined by Roy Walford. His landmark book “The 
Immunologic Theory of Aging” explores the “progressively increasing immunogenetic 
diversification of dividing cell populations with age”83. After years of research it is now well 
known that immunosenescence causes poorer response to vaccination, inflammation and tissue 
damage, increases susceptibility to auto-immune reaction, and lowers capacity to mount defenses 
and clear infections84.  
 The study of mechanisms underlying this attenuation of immune responses has only 





feature of aging of the immune system is the presence of low-grade and chronic inflammation in 
the tissues. This phenomenon, termed inflammaging, has been considered to be associated with 
immunosenescence85. It is noteworthy that acute and transient inflammation resulting from the 
acute infection may be beneficial and facilitate clearing of the pathogen. However, the problem 
arises when these signs of inflammation become persistent and lead to tissue damage. Several 
studies have analyzed the mechanism of this chronic inflammation. Some of them are (i) 
accumulation of apoptotic cells (self-debris) due to improper elimination86, (ii) activated immune 
cells leading to over-production of inflammatory cytokines such as IL-6, TNFα, IL-1β and C-
reactive proteins87 (iii) persistent infiltration of immune cells to tissues leading to structural 
damages88, and (iv) increased leakage of phlogistic components across mucosal barriers of the 
oral and gut microbiota89.  
 Another feature of the aging immune system is the accumulation of oxidative damage. 
The redox stress hypothesis of aging indicates that an imbalanced production of reactive oxygen 
species (ROS) and free radicals can cause significant damage to cellular components and 
tissues90. One of the main sources of these oxygen free radicals is mitochondria, which generates 
them during the process of oxidative phosphorylation90. Nitric oxide (NO) is another oxygen 
metabolite produced in the cells and is capable of increasing apoptosis, which then contributes to 
senescence. The effect of NO production on APC functions has been well studied91,92. 
 There is constant replenishment of immune cells from hematopoietic stem cells (HSC), 
but this ability also declines due to aging93. Hence, immunosenescence not only affects the 
functions of effector and naïve immune cell populations (Table 1.2), but also affects immune cell 
precursors and the various tissues (bone marrow and thymus) where the development of immune 





1.3.2 Effect of aging on innate immune cells  
 Dysregulation of the innate immune system with aging in both laboratory rodents and 
humans have been well studied in the literature87,95. Age-related defects have been observed with 
DCs, macrophages, monocytes, neutrophils, NK cells, etc. Various signal transduction pathways 
such as the MyD88-mediated TLR pathway, are also affected.  
 Polymorphonuclear leukocytes (PMN; neutrophils, eosinophils, and basophils) are 
involved in the first response against pathogens. Defects in neutrophils include reduced 
phagocytosis of microbes, impaired signal transduction functions such as chemotactic response 
to GM-CSF, reduced receptor recruitments to lipid rafts, reduced killing activity by lower 
generation of ROS and neutrophils extracellular traps (NETs)96–98. Eosinophils and basophils in 
aged systems have been less studied but there is evidence of degranulation impairment (such as 
degranulation of eosinophil-derived neurotoxin) in human subjects99.  
 NK cell cytotoxicity decreases with aging along with decreased levels of CCL3 and 
CCL5 production. This reduction in cytolytic abilities of NK cells has been linked to impaired 
inositol triphosphate (IP3) generation, changes in zinc homeostasis and defect in perforin 
mobilization with age100–102. A class of innate immune lymphocytes, NKT cells that express a 
TCR, showed an increase in absolute numbers in older individuals. An increased production of 
IL-17 by these cells was linked to increased immune pathology after viral infection103. 
 The effect of aging on monocytes and macrophages is multi-faceted. The number of 
monocytes increase with age but the ability of monocytes to differentiate into macrophages 
decreases104. So does the functionality of the macrophages that do get converted from the 
monocytes. Impairment of TLR and costimulatory molecules function in macrophages have been 





Phagocytosis ability has mixed reviews in the literature, however an increasing number of 
studies show impairment in phagocytosis by monocytes and macrophages106. 
 Dendritic cells belong to two main subsets, plasmacytoid and myeloid DCs. mDCs can be 
further subdivided into monocyte-derived DC, Langerhans cells, etc. Aging impacts the relative 
balance in the population of these DC subsets. Hence, aging brings phenotypic and functional 
changes in DCs. Basal expression of some co-stimulatory molecules such as CD86 increases or 
remains the same. Endocytosis and pinocytosis of antigens, attributed to abnormalities in PI3K, 
decreases with aging107,108. In addition, reports of hyper-sensitivity of DCs towards self-antigen 
also increases with aging, which can potentially lead to auto-immune disorders109. The main 
function of DC-priming and activation of T cells is hampered in aged mice leading to impaired 
cytotoxic T cell abilities110.  
 
1.3.3 Decline in humoral and cellular immunity 
 Changes in the humoral immunity with aging are both qualitative and quantitative. This 
not only decreases the susceptibility to infections but also protection provided by vaccines. 
Decline in total number of CD19+ B cells, antigen specificity, class switching, and affinity 
maturation with age has been well known for more than a decade111,112. Although non-optimal T 
cell help contributes to loss in B cell function, intrinsic changes in the B cells such as decrease in 
transcription factors activation-induced cytidine deaminase (AID), E47, influences antigen-
specific responses in general113,114. The humoral response to vaccination in older adults will be 
discussed in the following sections in more detail. 
 Decline in T cell immunity with age was first speculated because of the clinical signs in 





cellular immunity is pivotal in providing protection. In humans, the number of naïve circulating 
CD4+ T cells has been reported to decrease sharply and there is an almost complete loss of 
CD8+ T cells in centenarians due to limited thymic lymphopoiesis115. Various studies in mice 
have demonstrated the reduction in ability of TCRs to form highly functional synapses with 
MHC-peptide complexes116,117. This leads to weaker signaling cascade and reduced proliferation 
of T cells in aged mice. The production of T cells with reduced helper ability, failure to 
differentiate into Th1 and Th2 phenotypes, low IL-2 production and increased Th17 and Treg 
polarization are some of the features of CD4+ T cells in aged mice118–120. For CD8+ T cells, the 
TCR repertoire takes a significant hit in aged animals, leaving them susceptible to infections121. 
However, the total memory T cell population has been reported to increase with aging, in both 
humans and mice. In the absence of strong antigenic stimulation, the emergence of virtual 
memory T cells (CD122hi CD49dlo) takes place122. 
 
1.4 Current vaccine approaches against IAV 
1.4.1 Inactivated viral vaccines 
 The licensed seasonal influenza vaccine consists of either inactivated whole virus, live 
attenuated influenza virus or recombinant virus (Table 1.3)123. Each season the circulating virus 
strains are predicted and included in the vaccine. The vaccine is either trivalent or quadrivalent, 
meaning the vaccine contains three or four strains of the virus. There is also be a high dose 
vaccine (Fluzone) available for people over 65 years of age. The standard trivalent vaccine 
(Afluria) consists of inactivated virus and is manufactured in eggs. For older adults, trivalent 






For the above inactivated virus vaccines, the virus is propagated in embryonic chicken 
eggs and purified from the allantoic fluid and inactivated using formaldehyde. Because there 
may be traces of egg proteins, two other quadrivalent vaccines, for people allergic to eggs, are 
grown in cell cultures, namely, Flucelvax and Flublok are approved for people 18 years and 
older.  
 All these vaccines need to be administered every season for protection against the 
predicted circulating virus strains. This can be cumbersome, especially in the case of a pandemic, 
because mass production of vaccine in eggs might take 6-9 months124. Mild reactions of redness 
and tenderness at the site of injection are common. These vaccines are moderately immunogenic, 
and the protection provided is mostly based on humoral immunity by generation of neutralizing 
antibodies to head region of HA or NA125. However, neither HA or NA provide cell-mediated 
immunity, which can provide cross-protection. There are also possibilities of mutations in the 
strains when grown in eggs which then will fail to provide protection against the circulating 
strain. Live attenuated viruses, although, are more immunogenic, but have the major 
disadvantage of replication and causing disease in patients. Hence, with the goal of improving 
vaccine safety and patient compliance, researchers have started to focus on subunit vaccines that 
consist of only a few antigens of the pathogen. 
 
1.4.2 Subunit vaccines 
 Subunit vaccines due to their high safety profile have been the focus of vaccine research 
against several pathogens. In addition, the antigens productions involved in the vaccine are rapid, 
consistent and easily scalable126. The flexibility of the inclusion of various antigens specific for 





vaccines. For influenza, subunit vaccines consisting of HA, NP, M2, M1 and NA are currently 
being studied by researchers.  
 Subunit vaccines based on conserved M2 proteins offer an attractive target for inclusion 
in universal flu vaccines since the N-terminal epitope of M2 (residues 2-9) shows 100% 
homology in several influenza virus subtypes127. Since the immunogenicity of single M2 
molecule is low, production of vaccines containing several copies of M2 is useful and has been 
shown to provide protection against PR8 A/H1N1, 2009 pandemic H1N1 and HPAI128. 
Similarly, subunit vaccines based on NP protein along with Ribi Adjuvant System (RAS) has 
been demonstrated to improve both humoral and cellular responses129. For HA protein, the HA1 
region is the most potent in inducing neutralizing antibodies but the HA2 subunit is more 
conserved than HA1 and can provide protection across various strains130.  
However, all these single protein or peptide-based vaccines suffer from the disadvantage 
of low immunogenicity or induction of only certain arms of the immune response. For this 
reason, amongst the several strategies attempted to improve subunit vaccines, the use of an 
adjuvant with the proteins has been the most promising. Different types of adjuvants will be 
discussed in later sections. 
 
1.4.3 Current influenza vaccine strategies for older adults 
 The current vaccines approved in the US for older adults for influenza include the high 
dose flu vaccine which has four times the amount of antigen as the regular inactivated virus 
vaccine and an adjuvanted flu vaccine, Fluad™, containing MF59 adjuvant131. In addition, the 






 However, a just ‘increasing the firepower’ approach might not bode well for vaccines for 
older adults. This is because these vaccines were originally developed for preventing infections 
in younger adults. And the immune systems of older adults and immunologically incompetent 
individuals, as we are now aware, have stark differences from those of younger adults. The 
different history of natural exposure to pathogens over the years and an over-worked immune 
system in older adults also complicates things as discussed in previous sections.  
 For adjuvanted vaccines, such as Fluad™, inclusion of only MF59, one of the very few 
approved adjuvants currently in the arsenal of FDA, might not address all the issues. MF59 has 
been named an “innately attractive adjuvant” and has been reported to work via the heavy 
recruitment of innate immune cells to the injection site and hence the triggering of a cytokine and 
chemokine driven immune response132,133. For reasons mentioned in section 1.3.1, this might not 
be the best approach for vaccines for older adults and the need for better vaccines is evident if 
the numerous studies involving older adults demonstrating weak immune responses after 
influenza vaccination are to be believed. 
 
1.4.4 Immune responses to influenza vaccination in older adults 
 Even though some measures have been taken to improve the immune responses to 
vaccination in older adults, it is far from ideal, as reflected in the burden of influenza in older 
adults discussed in the Abstract section.  
 Historically, antibody titers were considered to be the sole predictor of protective 
immunity against the influenza virus. Which is why the earliest and most well-studied reports of 
the low response to influenza vaccination in older adults is focused on humoral responses. 





neutralizing antibodies are considerably lower in older adults than in younger adults134–136. The 
hemagglutination inhibition (HAI) titers have also been reported to be significantly lower, 
especially in older adults with an already existing chronic disease137. In addition, in a study 
conducted with the inactivated virus vaccinated-older adults who use prescription drugs such as 
metformin, NSAIDs for chronic conditions, demonstrated B-cell phenotypic changes, and 
differential immune cells proportion138. In some limited studies, T cell effector functions, i.e., 
lower concentration of IFN-γ after vaccination, has been reported139.  
Hence, the vaccine design suited for an aged immune system requires a combinatorial 
approach, having different components in the vaccine targeting different deficits. Instead of just 
quadrupling the antigen dose, it must be personalized for older adults in such a way that it acts 
on improving various arms of immunity by addressing immunosenescence and inflammaging. 
One strategy is the use of different adjuvants or delivery systems. 
 
1.5 Vaccine adjuvants 
 Vaccine adjuvants have been the most researched molecules in the field of vaccinology 
ever since their conception almost a century back. It started with Gaston Ramon demonstrating 
antitoxin responses to diphtheria toxin by injecting tapioca, agar, starch with toxoids140. This led 
researchers to study materials that can aid in the generation of immune responses towards an 
antigen and the conception of adjuvants. Since then, the way adjuvants are defined and perceived 
for their modes of action have changed drastically. The following sub-sections will briefly 







1.5.1 Traditional vaccine adjuvants 
 Alum, the most widely used adjuvant has been around since the turn of the twentieth 
century when discovered by Glenny for use with diphtheria toxins141. The use of alum with 
pertussis, tetanus followed that. To date, alum has been approved by FDA and is being used in 
vaccines against numerous pathogens such as hepatitis A and B, pneumococcus, human 
papilloma virus, etc. Traditionally, adjuvants were considered antigen delivery or depot forming 
systems only. Some other popular “carriers” were oil-in-water emulsions, liposomes, virosomes 
and other mineral salts. MF59 is an oil-in-water adjuvant and has been approved for use in flu 
vaccines (Table 1.3). AS03 and AS04 are other emulsion-based adjuvants approved for usage in 
several vaccines such as Cervarix and Pandemrix. 142.  
 The mechanism of action of these traditional adjuvants was not well-understood prior to 
their approval. An increasing amount of literature is still being produced seeking to understand 
these adjuvants. The mechanism of action of alum has been demonstrated to be the formation of 
a depot at the site of injection, promotion of inflammation and induction of APCs and 
enhancement in phagocytosis of antigens143. However, alum suffers from major limitations of 
induction of high inflammatory responses with boosters leading to granulomas, non-induction of 
Th1 or cell-mediated immunity, and room temperature shelf-stability of the vaccine144.  
 Oil-in-water emulsions consisting of about 300 nm sized squalene droplets have an 
acceptable safety profile and induce more balanced IgG1:IgG2a responses than those induced by 
alum145. They are believed to act via depot formation and innate immune activation measured by 
cytokine and chemokine production by monocytes, macrophages and granulocytes133. However, 
like alum, their ability to enhance overall T cell responses is low. Monophospryl lipid A (MPLA) 





with alum. However, the biological activity of MPLA has been debated to be only when it is in 
aggregate forms and when included with other adjuvants, alteration in their structural order 
might hamper their activity146.  
 
1.5.2 New approaches towards vaccine adjuvants 
 Modern vaccines consider adjuvants to be either vehicles, immune-potentiators, or both. 
Immune-potentiators act on the immune system to enhance responses in multiple ways. The 
inventions of modern adjuvants were driven by the lack of cellular immunity, safety profiles, 
shelf-life stability in the previous vaccine formulations. In many cases, different modern 
adjuvants have been combined to yield better results. Several articles in the literature have 
reviewed extensively the different adjuvants under development147–149. A majority of these are 
emulsions, lipids, TLR agonists, many classes of polymeric systems or a combination of these. 
However, it is important to understand that all adjuvants might not be appropriate for all 
applications. There used to be a time when even for Phase III trials multiple adjuvants would be 
combined like a bedside mix without reporting their interaction with each other or the 
contribution of each component150. As our understanding of the intricacies of the immune system 
progresses, more and more evidence of the immune modulation by adjuvants is being required. 
There is a wealth of adjuvants available now demonstrating different levels of potency and 
approaches towards enhancing immune responses. But without getting engrossed in displaying 
the applicability and relevance of hundreds of different adjuvants, which seems to be the go-to 
approach recently, we must first answer some fundamental questions about the adjuvants we 
have. First, long-term safety profiles of the adjuvants need to be verified. Second, the possibility 





be beneficial. Third, exploring the benefits of having a new generation of antigen carriers for co-
delivery of antigens and co-adjuvants in a specific manner is important. Fourth, the right 
combination of adjuvants needs to be established using rational design.  
 
1.6 Next generation combination nanoadjuvants 
 The biggest challenge faced by adjuvants from conception to approval is that too many 
requirements are expected of a single adjuvant. It is difficult for a single delivery system or 
adjuvant to induce broad and long-lasting immune response in healthy and in 
immunocompromised patients. For this reason, a synergistic formulation consisting of more than 
one adjuvant maybe required. The following sections will describe the two nanoadjuvant 
platforms and the choice of the co-adjuvant in the combination nanovaccine proposed for older 
adults in this work.  
 
1.6.1 Polyanhydride nanoparticles as adjuvants 
 Biodegradable polymers such as polyesters have been used as drug delivery vehicles and 
implantable devices151. Polyesters are FDA-approved for human applications. However, when it 
comes to sensitive antigens as cargo, the degradation profiles of polyesters and their bulk erosion 
and hydrolysis mechanisms might pose formidable challenges for encapsulation of antigens. In 
the cases of bulk erosion, water penetration throughout the material due to diffusion happens 
more rapidly than the payload release. This can affect the antigen release and stability. This burst 
release of cargo might be beneficial for short-term applications, but researchers recognized room 
for improvement in such drug delivery vehicles. 
 Polyanhydrides are a unique class of polymers with characteristics well suited for both 





sets them apart from other biodegradable polymers152. Polyanhydrides consists of diacid 
monomers linked by anhydride bonds that are hydrolytically labile. However, the polymers are 
hydrophobic and exclude water from penetrating, hence stabilizing the protein payloads. 
Polyanhydrides can also be designed to be more amphiphilic and provide a suitable environment 
for proteins. One such polymer, 1,8-bis (p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) (Figure 
1.6) was created in the Narasimhan laboratory153. The release kinetics of the payload from 
polyanhydride nanoparticles (Figure 1.7) can be tuned using different diacids as monomers and 
varying the copolymer compositions, allowing the manipulation of antigen release from several 
days to years. For example, in copolymer composed of 1,6-bis (p-carboxyphenoxy) hexane 
(CPH) and CPTEG, CPH-CPH bonds will undergo hydrolysis slower than CPTEG-CPTEG 
bonds. CPTEG-CPH copolymers have been demonstrated to provide sustained release of stable 
influenza antigens154. This type of release profile enhances the activation of immune cells and 
can eliminate the requirement of booster doses for vaccines. The sustained release property of 
polyanhydrides is exploited by the FDA-approved Gliadel® wafer implants made of 
polyanhydrides for the release of an anti-cancer drug155. 
 The degradation products of polyanhydrides have been shown to be eliminated from the 
body through different excretory products and the small insoluble fragments are cleared by 
macrophages156. In contrast with alum, immunization with polyanhydride nanoparticles have 
demonstrated normal kidney and liver function and injection site inflammation157.  
 Aside from the release and safety profiles, nanoparticles made of polyanhydrides have 
been demonstrated to possess immunomodulatory capabilities, allowing the stimulation, and 
targeting of specific arms of the immune system. These nanoparticles are readily phagocytosed 





production158,159. The vaccine efficacy for polyanhydride nanoparticles have been demonstrated 
for several diseases160–162. For influenza, decreased viral load in lungs of young mice, protection 
from viral challenge has been shown following a vaccination with nanovax160. Enhancement in 
antibody titers when compared to 64-fold higher doses of soluble antigens alone demonstrate the 
dose sparing capabilities of these particles163. Expansion of CD8+ T cell populations after 
immunization with polyanhydride nanoparticles has also been demonstrated164. Overall, all these 
make them an excellent platform for vaccine adjuvants. 
 
1.6.2 Pentablock copolymer nanomicellar adjuvants 
 Amphiphilic block copolymers that undergo self-assembly to form micelles and 
hydrogels in response to environmental stimuli have been a well-studied class of materials with 
various applications such as gene and drug delivery, scaffolds, and vaccine adjuvants165. While a 
wide variety of these block copolymer exist, the triblock copolymer Pluronic® F127 has been the 
most popular due to its temperature responsive properties and is approved by FDA for delivery 
of hydrophobic drugs such as aspirin and antibiotics166. This surfactant has two hydrophilic outer 
chains of polyoxoethylene (POE) and inner hydrophobic chain of polyoxopropylene (POP).  
However, to achieve a slow and sustained antigen delivery profile essential for vaccine 
adjuvant applications, a pentablock copolymer (PBC) based on Pluronic® F127 synthesized in 
the Mallapragada laboratory was utilized167,168. This ABCBA pentablock copolymer has 
Pluronic® F127 as the inner groups and cationic poly (2-diethylaminoethyl methacrylate) 
(PDEAEM) (Figure 1.8). These outer cationic groups also provide pH-responsive micellization 
and gelation which can help antigen escape from the endosomal compartment of APCs and 





delivery by forming polyplexes with them169,170. They have also been demonstrated to provide a 
depot at the site of injection lasting more than 45 days post-injection and provide sustained 
release of a structurally stable protein antigen171. Upon immunization with these hydrogels in 
different concentrations of various antigens, mice exhibited significant enhancement in antibody 
titers, which was attributed to the depot effect172.  
Hydrogels such as the PBC hydrogels are widely used because of their many attractive 
properties, however, there is much that remains to be known about their mechanism of action. 
Understanding this might help with further improving the formulation for current applications 
and also expand their usage to other applications. 
 
1.6.3 Co-adjuvant: TLR agonists and beyond 
 Toll-like receptor agonists, natural agonists that are recognized by TLRs of the immune 
cells, have already been approved for use as vaccine adjuvants. MPLA, a detoxified version of 
LPS, is a TLR4 agonist and is used as adjuvant in commercial vaccines such as Cervarix, 
Frendrix, etc. MPLA activates the NFκB pathway via MyD88 pathway and induces pro-
inflammatory cytokines and chemokines such as IL-2, IFN-γ, CCL2, CCL3 leading to a Th1 
response and recruiting monocytes and macrophages to the infection site173.  
 Another prominent TLR agonist being used in vaccines is CpG oligodeoxynucleotides 
(ODN), a TLR9 agonist. It is already in Phase 3 clinical trials for HBV vaccine. CpG has been 
demonstrated to enhance antibody responses and polarize Th cell responses towards Th1 
phenotype. The use of CpG ODNs also lead to the induction of TNF-α, IL-1β, IL-6 and IFN-γ. 
Flagellin, TLR5 agonist, Poly I:C, TLR3 agonist, Imiquimod or Resiquimod, TLR7 agonists are 





 Most TLR agonists have one thing in common: they function via the MyD88 pathway by 
simulating the production of pro-inflammatory cytokines and innate effector molecules such as 
nitric oxide and reactive oxygen species. This process is important for the initiation of a strong 
immune response-both innate and adaptive. However, as mentioned in Section 2.3.1, it is 
worthwhile to think if this is required for the case of vaccines for older adults. It is 
understandable that T cell immunity needs to be improved since that arm of immune system is 
the most affected with aging. However, it is important to not ignore the biology of aging, which 
complicates things, and understand that single treatments are unlikely to restore totality in 
function without hurting the system.  
With the increasing understanding of the role of cellular metabolism in the determination 
of various immune cell phenotype and function, it is important to be aware of the types of 
metabolic changes the vaccines create. The links between mitochondrial function and aging have 
been reviewed extensively91,175,176. In extremely simplistic terms, it has been shown that rapid 
glycolysis contributes to inflammatory responses and fatty-acid oxidation to anti-inflammatory 
responses. The role of several innate effector metabolites has also been studied in aged immune 
cells. Therefore, the choice of co-adjuvant and consequently the immune and metabolic 
pathways to be targeted by a vaccine for older adults is not as simple as it seems. 
Cyclic dinucleotides (CDNs) do not act on TLRs but another class of PRRs called 
Stimulator of Interferon Genes (STING)177. And as the name suggests, the binding of cytosolic 
CDN to STING leads to the expression of several cytokines and chemokines, including type I 
IFNs. STING can recognize and bind to a variety of CDNs such as cyclic di-GMP, cyclic di-
AMP and cGAMP present in intracellular pathogens. In addition to enhanced innate immune 






 Infectious diseases caused by pathogens such as IAV will continue to be a growing 
concern and healthcare burden for the global aging community. In addition to effectively dealing 
with immunosenescence, the issues of providing cross-protection with better patient compliance 
through vaccines still remains. Hence, there is an urgent need to focus our research towards 
catering to these special needs of immunity in aging cells while developing vaccines. 
Vaccination strategies that have been found to work for immune systems of young adults need to 
be revisited, studied, and modified accordingly to suit older adults better. The use of a 
combination adjuvant vaccine platform based on polyanhydride nanoparticles, pentablock 
copolymer micelles and CDNs along with multiple influenza antigens shows great potential for 
influenza vaccine for older adults. 
 
1.8 Tables 
Table 1.1. Summary of the different molecules/proteins released/expressed as a result of the 
antiviral responses against Influenza A virus 
Molecules/proteins Functions 
Interferon (IFN) Types I, II and 
III 
Limits viral replication, helps cytotoxic T cell 
response43,44 
Myxovirus resistance protein (Mx) One of the mediators of IFN-induced antiviral 
response; Inhibits viral replication195 







Table 1.2. Effect of aging on different immune cells and tissues 
Table 1.1 Continued 
Molecules/proteins Functions 
CCL2 (MCP-1) Chemoattractant for monocytes, macrophages, 
lymphocytes to the site of infection200,201 
Interferon-inducible 
transmembrane protein (IFITM) 
Restricts viral entry198 
TNFα, IL-6, IL-1β Pro-inflammatory cytokines to recruit immune cells to 
enhance phagocytosis of infected cells,47,48 induction 
of lung inflammation34 
IL-18 Controls viral replication in lungs at early stage of 
infection, activates NK cells, IFNs199 
CXCL13, CCL19, CCL21 Expressed in sLO; controls lymphocytes and DCs 
trafficking; also on lung tissues (forming ectopic 
lymphoid follicles)202,203 
IgM, IgA, IgG  Virus neutralization and mucosal immunity71, 
ADCC70, activation of the complement system69 
Complement proteins (C1-C5) Formation of membrane attack complex (MAC) to 
lyse virions or infected cells204; promotion of B and T 
cell immunity205 
IL-4, IL-5, IL-13 Th2 responses, promotes B cell activation74,75 
Granzymes, perforins Cytolytic granules produced by CTLs to induce 
cytolysis of infected cells206 
FasL, TRAIL Death receptors on CTLs induce apoptosis of infected 
cells86,207 
Immune cells/tissues Defects 
Neutrophil, basophil, eosinophil 
 
 Phagocytosis, chemotaxis, degranulation, migration, 
actin polymerization 
 Membrane fluidity 
NK cells, NKT cells 
 
 Cytolysis, chemokine/cytokine production such as    
RANTES, MIP1, IL-2, IL-12 
 Numbers, IL-17 production, immune pathology 
Macrophages, monocytes 
 
TLR-induced activation and cytokine production, 
CD80 upregulation, phagocytosis 









Table 1.3. Different FDA approved seasonal influenza vaccines 
Vaccine Composition HA dose Target age Production 
Fluvirin Trivalent, subunit 45 μg  >4 years Egg 
Fluzone Trivalent, split 
virion 
45 μg >6 months Egg 
FluMist Trivalent, LAIV 106.5 FFU 2-49 years Egg 
Afluria Trivalent, split  45 μg >5 years Egg 
Immune cells/tissues Defects 
Dendritic cells 
  
Same number of pDC or mDC, LC in skin, 
pinocytosis, endocytosis of antigens, LPS-induced 
activation, PI3K signaling, migration 
Basal NF-Κb activity, CD86 expression, IL-6 and 
TNFα production 
B cells, plasma cells 
 
Affinity maturation, diversity of antibody      
production, lower number of naïve B cells 
Autoreactive serum antibodies 
CD4+ T cells, CD8+ T cells 
 
TCR synapse intensity, expansion, Th1, Th2 
differentiation, TCR diversity, IL-2 production 
Treg and Th17, virtual memory CD8 T cells 
Bone marrow 
  
Hypoxic osteoblast-enriched regions, hematopoietic 
stem cells (HSC), lymphocyte progenitors 
Production of adipocytes, skewing of HSC to 
myeloid cell formation, ROS 
Thymus 
 
Thymic epithelial cells (cortical and medullary) 
markers MHCII, keratin 8, DII4, thymocyte   
numbers, cross-talk between TECs and thymocytes 




Structural organization of marginal zone, follicle, 
macrophage capacity, B cell, FDC function, 
germinal center size 
Lymph nodes 
 
Distinct follicular region, T cell and FDC numbers, 
stromal cell structure 
Subcapsular sinus macrophages, blood endothelial 





Table 1.3 Continued 
 
Vaccine Composition HA dose Target age Production 
Flucelvax Trivalent, split 
virion 
45 μg >18 years MDCK cells 
FluBlok Trivalent, 
recombinant 










106.5 FFU 2-49 years Egg 
Fluad Trivalent, IIV + 
MF59 
45 μg >65 years Egg 
FluLaval Trivalent, split 
virion 
45 μg >18 years Egg 





180 μg >65 years Egg 
Fluarix Quadrivalent, 
split virion  














Figure 1.2. Mechanism of Influenza A virus infection (i) viral attachment and entry (ii) virus 
endosomal encapsulation (iii) release of viral RNP (iv) viral RNA replication (v) transcription 
and release of viral proteins (vi) assembly of daughter virions (vii) viral escape 
 














Figure 1.5. Evasion of the immune responses by the Influenza A virus using its antigens (i) NS 
for the inhibition of recognition of viral entry by RIG-I receptors, (ii) PB1 and PB2 for 
interacting with MAVS and limiting IFN production, (iii) NS for inhibition of translocation of 
NF-κB to the nucleus, (iv) NP for prevention of formation of dsRNA and recognition by 
cytosolic PRRs and (v) Amino acid substitutions in the TCR and MHC I contact residues to 
prevent antigen recognition and binding 






Figure 1.6. Structure of one of the polyanhydride copolymers, CPTEG:CPH 
 
 
Figure 1.7. Scanning electron microscope image of 20:80 CPTEG:CPH nanoparticles 
 






1. Suzzane Clancy. Genetics of the Influenza Virus. Nat. Educ. 1, 83 (2008). 
2. Otte, A. et al. Evolution of 2009 H1N1 influenza viruses during the pandemic correlates 
with increased viral pathogenicity and transmissibility in the ferret model. Sci. Rep. 6, 
28583 (2016). 
3. Gamblin, S. J. & Skehel, J. J. Influenza hemagglutinin and neuraminidase membrane 
glycoproteins. J. Biol. Chem. 285, 28403–9 (2010). 
4. Zambon, M. C. The pathogenesis of influenza in humans. Rev. Med. Virol. 11, 227–241 
(2001). 
5. Hu, Y., Sneyd, H., Dekant, R. & Wang, J. Influenza A Virus Nucleoprotein: A Highly 
Conserved Multi-Functional Viral Protein as a Hot Antiviral Drug Target. Curr. Top. 
Med. Chem. 17, 2271–2285 (2017). 
6. Rust, M. J., Lakadamyali, M., Zhang, F. & Zhuang, X. Assembly of endocytic machinery 
around individual influenza viruses during viral entry. Nat. Struct. Mol. Biol. 11, 567–573 
(2004). 
7. Marsh, M. & Helenius, A. Virus Entry: Open Sesame. Cell 124, 729–740 (2006). 
8. Watanabe, T., Watanabe, S. & Kawaoka, Y. Cellular Networks Involved in the Influenza 
Virus Life Cycle. Cell Host Microbe 7, 427–439 (2010). 
9. Ehrhardt, C. & Ludwig, S. A new player in a deadly game: influenza viruses and the 
PI3K/Akt signalling pathway. Cell. Microbiol. 11, 863–871 (2009). 
10. Leser, G. P. & Lamb, R. A. Influenza virus assembly and budding in raft-derived 
microdomains: A quantitative analysis of the surface distribution of HA, NA and M2 
proteins. Virology 342, 215–227 (2005). 
11. Webster, R. G., Yakhno, M., Hinshaw, V. S., Bean, W. J. & Copal Murti, K. Intestinal 
influenza: Replication and characterization of influenza viruses in ducks. Virology 84, 
268–278 (1978). 
12. Fukuyama, S. & Kawaoka, Y. The pathogenesis of influenza virus infections: The 
contributions of virus and host factors. Curr. Opin. Immunol. 23, 481–486 (2011). 
13. Capitanio, J. & Wozniak, R. W. Host Cell Factors Necessary for Influenza A Infection: 
Meta-Analysis of Genome Wide Studies. (2014). doi:10.6084/m9.figshare.1248958.v1 
14. Rimmelzwaan, G. F. & Katz, J. M. Immune responses to infection with H5N1 influenza 





15. Neumann, G., Shinya, K. & Kawaoka, Y. Highly pathogenic H5N1 influenza viruses have 
become endemic in poultry populations throughout Southeast Molecular pathogenesis of 
H5N1 influenza virus infections. (1359). 
16. Kuiken, T., Riteau, B., Fouchier, R. & Rimmelzwaan, G. F. Pathogenesis of influenza 
virus infections: the good, the bad and the ugly. (2012). doi:10.1016/j.coviro.2012.02.013 
17. Kim, K. S., Jung, H., Shin, I. K., Choi, B.-R. & Kim, D. H. Induction of interleukin-1 beta 
(IL-1β) is a critical component of lung inflammation during influenza A (H1N1) virus 
infection. J. Med. Virol. 87, 1104–1112 (2015). 
18. Chen, X. et al. Host Immune Response to Influenza A Virus Infection. Front. Immunol. 9, 
320 (2018). 
19. Eggink, D., Goff, P. H. & Palese, P. Guiding the Immune Response against Influenza 
Virus Hemagglutinin toward the Conserved Stalk Domain by Hyperglycosylation of the 
Globular Head Domain. J. Virol. 88, 699–704 (2014). 
20. Takeuchi, O. & Akira, S. Innate immunity to virus infection. Immunol. Rev. 227, 75–86 
(2009). 
21. Blasius, A. L. & Beutler, B. Intracellular toll-like receptors. Immunity 32, 305–15 (2010). 
22. Pang, I. K. & Iwasaki, A. Inflammasomes as mediators of immunity against influenza 
virus. doi:10.1016/j.it.2010.11.004 
23. Gack, M. U. et al. TRIM25 RING-finger E3 ubiquitin ligase is essential for RIG-I-
mediated antiviral activity. Nature 446, 916–920 (2007). 
24. Hale, B. G., Albrecht, R. A. & García-Sastre, A. Innate immune evasion strategies of 
influenza viruses. Future Microbiol. 5, 23–41 (2010). 
25. Randall, R. E. & Goodbourn, S. Interferons and viruses: an interplay between induction, 
signalling, antiviral responses and virus countermeasures. J. Gen. Virol. 89, 1–47 (2008). 
26. van de Sandt, C. E., Kreijtz, J. H. C. M. & Rimmelzwaan, G. F. Evasion of influenza A 
viruses from innate and adaptive immune responses. Viruses 4, 1438–76 (2012). 
27. Kreijtz, J. H. C. M., Fouchier, R. A. M. & Rimmelzwaan, G. F. Immune responses to 
influenza virus infection. Virus Res. 162, 19–30 (2011). 
28. Gazit, R. et al. Lethal influenza infection in the absence of the natural killer cell receptor 
gene Ncr1. Nat. Immunol. 7, 517–523 (2006). 
29. Hashimoto, G., Wright, P. F. & Karzon, D. T. Antibody-dependent cell-mediated 





30. Yumi Hashimoto, Takeshi Moki, Takenori Takizawa, A. S. and Y. N. Evidence for 
Phagocytosis of Influenza Virus-Infected, Apoptotic Cells by Neutrophils and 
Macrophages in Mice. J. Immunol. 178, 2448–2457 (2007). 
31. Huber, V. C., Lynch, J. M., Bucher, D. J., Le, J. & Metzger, D. W. Fc receptor-mediated 
phagocytosis makes a significant contribution to clearance of influenza virus infections. J. 
Immunol. 148, 212–217 (2001). 
32. Kim, H. M. et al. Alveolar Macrophages Are Indispensable for Controlling Influenza 
Viruses in Lungs of Pigs. J. Virol. 82, 4265–4274 (2008). 
33. Lin, K. L., Suzuki, Y., Nakano, H., Ramsburg, E. & Gunn, M. D. CCR2+ monocyte-
derived dendritic cells and exudate macrophages produce influenza-induced pulmonary 
immune pathology and mortality. J. Immunol. 180, 2562–72 (2008). 
34. Peper, R. L. & Van Campen, H. Tumor necrosis factor as a mediator of inflammation in 
influenza A viral pneumonia. Microb. Pathog. 19, 175–183 (1995). 
35. Holt, P. G., Strickland, D. H., Wikström, M. E. & Jahnsen, F. L. Regulation of 
immunological homeostasis in the respiratory tract. Nat. Rev. Immunol. 8, 142–152 
(2008). 
36. GeurtsvanKessel, C. H. & Lambrecht, B. N. Division of labor between dendritic cell 
subsets of the lung. Mucosal Immunol. 1, 442–450 (2008). 
37. Yewdell, J. W., Reits, E. & Neefjes, J. Making sense of mass destruction: quantitating 
MHC class I antigen presentation. Nat. Rev. Immunol. 3, 952–961 (2003). 
38. Kim, T. S. & Braciale, T. J. Respiratory Dendritic Cell Subsets Differ in Their Capacity to 
Support the Induction of Virus-Specific Cytotoxic CD8+ T Cell Responses. PLoS One 4, 
e4204 (2009). 
39. Banchereau, J. & Steinman, R. M. Dendritic cells and the control of immunity. Nature 
392, 245–252 (1998). 
40. Waffarn, E. E. & Baumgarth, N. Protective B Cell Responses to Flu—No Fluke! J. 
Immunol. 186, 3823–3829 (2011). 
41. de Jong, J. C. et al. Haemagglutination-inhibiting antibody to influenza virus. Dev. Biol. 
(Basel). 115, 63–73 (2003). 
42. Yu, X. et al. Neutralizing antibodies derived from the B cells of 1918 influenza pandemic 
survivors. Nature 455, 532–536 (2008). 






44. Knossow, M. & Skehel, J. J. Variation and infectivity neutralization in influenza. 
Immunology 119, 1–7 (2006). 
45. Ekiert, D. C. et al. A highly conserved neutralizing epitope on group 2 influenza A 
viruses. Science 333, 843–50 (2011). 
46. Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and 
human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009). 
47. Treanor, J. J., Tierney, E. L., Zebedee, S. L., Lamb, R. A. & Murphy, B. R. Passively 
transferred monoclonal antibody to the M2 protein inhibits influenza A virus replication in 
mice. J. Virol. 64, 1375–7 (1990). 
48. Carragher, D. M., Kaminski, D. A., Moquin, A., Hartson, L. & Randall, T. D. A novel role 
for non-neutralizing antibodies against nucleoprotein in facilitating resistance to influenza 
virus. J. Immunol. 181, 4168–76 (2008). 
49. Fiers, W., De Filette, M., Birkett, A., Neirynck, S. & Min Jou, W. A “universal” human 
influenza A vaccine. Virus Res. 103, 173–176 (2004). 
50. Ebrahimi, S. M. & Tebianian, M. Influenza A viruses: why focusing on M2e-based 
universal vaccines. Virus Genes 42, 1–8 (2011). 
51. Murphy, B. R. & Clements, M. L. The systemic and mucosal immune response of humans 
to influenza A virus. Curr. Top. Microbiol. Immunol. 146, 107–16 (1989). 
52. Fernandez Gonzalez, S., Jayasekera, J. P. & Carroll, M. C. Complement and natural 
antibody are required in the long-term memory response to influenza virus. Vaccine 26 
Suppl 8, I86-93 (2008). 
53. Jones, P. D. & Ada, G. L. Persistence of influenza virus-specific antibody-secreting cells 
and B-cell memory after primary murine influenza virus infection. Cell. Immunol. 109, 
53–64 (1987). 
54. Asanuma, H. et al. Isolation and characterization of mouse nasal-associated lymphoid 
tissue. J. Immunol. Methods 202, 123–31 (1997). 
55. van Riet, E., Ainai, A., Suzuki, T. & Hasegawa, H. Mucosal IgA responses in influenza 
virus infections; thoughts for vaccine design. Vaccine 30, 5893–5900 (2012). 
56. McKinstry, K. K., Strutt, T. M. & Swain, S. L. Hallmarks of CD4 T cell immunity against 
influenza. J. Intern. Med. 269, 507–518 (2011). 
57. Okoye, I. S. & Wilson, M. S. CD4+ T helper 2 cells - microbial triggers, differentiation 





58. Kamperschroer, C., Dibble, J. P., Meents, D. L., Schwartzberg, P. L. & Swain, S. L. SAP 
is required for Th cell function and for immunity to influenza. J. Immunol. 177, 5317–27 
(2006). 
59. Liu, S.-Y., Sanchez, D. J., Aliyari, R., Lu, S. & Cheng, G. Systematic identification of 
type I and type II interferon-induced antiviral factors. Proc. Natl. Acad. Sci. 109, 4239–
4244 (2012). 
60. Zhu, J. & Paul, W. E. Heterogeneity and plasticity of T helper cells. Cell Res. 20, 4–12 
(2010). 
61. Mosmann, T. R., Cherwinski, H., Bond, M. W., Giedlin, M. A. & Coffman, R. L. Two 
types of murine helper T cell clone. I. Definition according to profiles of lymphokine 
activities and secreted proteins. J. Immunol. 136, 2348–57 (1986). 
62. Belz, G. T., Wodarz, D., Diaz, G., Nowak, M. A. & Doherty, P. C. Compromised 
influenza virus-specific CD8(+)-T-cell memory in CD4(+)-T-cell-deficient mice. J. Virol. 
76, 12388–93 (2002). 
63. Teijaro, J. R. et al. Cutting edge: Tissue-retentive lung memory CD4 T cells mediate 
optimal protection to respiratory virus infection. J. Immunol. 187, 5510–4 (2011). 
64. Campbell, D. J. & Koch, M. A. Phenotypical and functional specialization of FOXP3+ 
regulatory T cells. Nat. Rev. Immunol. 11, 119–130 (2011). 
65. La Gruta, N. L., Kedzierska, K., Stambas, J. & Doherty, P. C. A question of self-
preservation: immunopathology in influenza virus infection. Immunol. Cell Biol. 85, 85–
92 (2007). 
66. Boon, A. C. M. et al. The Magnitude and Specificity of Influenza A Virus-Specific 
Cytotoxic T-Lymphocyte Responses in Humans Is Related to HLA-A and -B Phenotype. 
J. Virol. 76, 582–590 (2002). 
67. Domselaar, R. & Bovenschen, N. Cell death-independent functions of granzymes: hit 
viruses where it hurts. Rev. Med. Virol. 21, n/a-n/a (2011). 
68. Kägi, D., Ledermann, B., Bürki, K., Zinkernagel, R. M. & Hengartner, H. MOLECULAR 
MECHANISMS OF LYMPHOCYTE-MEDIATED CYTOTOXICITY AND THEIR 
ROLE IN IMMUNOLOGICAL PROTECTION AND PATHOGENESIS IN VIVO. Annu. 
Rev. Immunol. 14, 207–232 (1996). 
69. Ishikawa, E., Nakazawa, M., Yoshinari, M. & Minami, M. Role of Tumor Necrosis 
Factor-Related Apoptosis-Inducing Ligand in Immune Response to Influenza Virus 
Infection in Mice. J. Virol. 79, 7658–7663 (2005). 
70. Regner, M. et al. Cutting edge: rapid and efficient in vivo cytotoxicity by cytotoxic T cells 





71. DiSpirito, J. R. & Shen, H. Quick to remember, slow to forget: rapid recall responses of 
memory CD8+ T cells. Cell Res. 20, 13–23 (2010). 
72. Wherry, E. J. et al. Lineage relationship and protective immunity of memory CD8 T cell 
subsets. Nat. Immunol. 4, 225–234 (2003). 
73. Zimmermann, C., Prévost-Blondel, A., Blaser, C. & Pircher, H. Kinetics of the response 
of naive and memory CD8 T cells to antigen: similarities and differences. Eur. J. 
Immunol. 29, 284–290 (1999). 
74. Pichlmair, A. et al. RIG-I-Mediated Antiviral Responses to Single-Stranded RNA Bearing 
5’-Phosphates. Science (80-. ). 314, 997–1001 (2006). 
75. Falcon, A. M. et al. Attenuation and immunogenicity in mice of temperature-sensitive 
influenza viruses expressing truncated NS1 proteins. J. Gen. Virol. 86, 2817–2821 (2005). 
76. Guilligay, D. et al. The structural basis for cap binding by influenza virus polymerase 
subunit PB2. Nat. Struct. Mol. Biol. 15, 500–506 (2008). 
77. Boliar, S. & Chambers, T. M. A new strategy of immune evasion by influenza A virus: 
Inhibition of monocyte differentiation into dendritic cells. Vet. Immunol. Immunopathol. 
136, 201–210 (2010). 
78. Mao, H. et al. Influenza Virus Directly Infects Human Natural Killer Cells and Induces 
Cell Apoptosis. J. Virol. 83, 9215–9222 (2009). 
79. Rimmelzwaan, G. . et al. Sequence variation in the influenza A virus nucleoprotein 
associated with escape from cytotoxic T lymphocytes. Virus Res. 103, 97–100 (2004). 
80. Berkhoff, E. G. M. et al. The loss of immunodominant epitopes affects interferon-γ 
production and lytic activity of the human influenza virus-specific cytotoxic T lymphocyte 
response in vitro. Clin. Exp. Immunol. 148, 296–306 (2007). 
81. Berkhoff, E. G. M. et al. A mutation in the HLA-B*2705-restricted NP383-391 epitope 
affects the human influenza A virus-specific cytotoxic T-lymphocyte response in vitro. J. 
Virol. 78, 5216–22 (2004). 
82. Eisenlohr, L. C., Yewdell, J. W. & Bennink, J. R. Flanking sequences influence the 
presentation of an endogenously synthesized peptide to cytotoxic T lymphocytes. J. Exp. 
Med. 175, 481–7 (1992). 
83. Walford, R. L. The Immunologic Theory of Aging. Gerontologist 4, 195–197 (1964). 
84. Pawelec, G. Age and immunity: What is “immunosenescence”? Exp. Gerontol. 105, 4–9 
(2018). 
85. Fulop, T. et al. Immunosenescence and Inflamm-Aging As Two Sides of the Same Coin: 





86. Dall’Olio, F. et al. N-glycomic biomarkers of biological aging and longevity: A link with 
inflammaging. Ageing Res. Rev. 12, 685–698 (2013). 
87. Michaud, M. et al. Proinflammatory Cytokines, Aging, and Age-Related Diseases. J. Am. 
Med. Dir. Assoc. 14, 877–882 (2013). 
88. Rodier, F. & Campisi, J. Four faces of cellular senescence. J. Cell Biol. 192, 547–556 
(2011). 
89. Biagi, E., Candela, M., Franceschi, C. & Brigidi, P. The aging gut microbiota: New 
perspectives. Ageing Res. Rev. 10, 428–429 (2011). 
90. Ventura, M. T., Casciaro, M., Gangemi, S. & Buquicchio, R. Immunosenescence in aging: 
between immune cells depletion and cytokines up-regulation. Clin. Mol. Allergy 15, 21 
(2017). 
91. Van den Bossche, J. et al. Mitochondrial Dysfunction Prevents Repolarization of 
Inflammatory Macrophages. Cell Rep. 17, 684–696 (2016). 
92. Giordano, D., Draves, K. E., Li, C., Hohl, T. M. & Clark, E. A. Nitric Oxide Regulates 
BAFF Expression and T Cell-Independent Antibody Responses. J. Immunol. 193, 1110–
1120 (2014). 
93. Maicher, A., Kastner, L., Dees, M. & Luke, B. Deregulated telomere transcription causes 
replication-dependent telomere shortening and promotes cellular senescence. Nucleic 
Acids Res. 40, 6649–6659 (2012). 
94. George, A. J. & Ritter, M. A. Thymic involution with ageing: obsolescence or good 
housekeeping? Immunol. Today 17, 267–72 (1996). 
95. Pawelec, G., Solana, R., Remarque, E. & Mariani, E. Impact of aging on innate immunity. 
J. Leukoc. Biol. 64, 703–712 (1998). 
96. Mahbub, S., Brubaker, A. L. & Kovacs, E. J. Aging of the Innate Immune System: An 
Update. Curr. Immunol. Rev. 7, 104–115 (2011). 
97. Shaw, A. C., Goldstein, D. R. & Montgomery, R. R. Age-dependent dysregulation of 
innate immunity. Nat. Rev. Immunol. 13, 875–87 (2013). 
98. Shaw, A. C., Joshi, S., Greenwood, H., Panda, A. & Lord, J. M. Aging of the innate 
immune system. Curr. Opin. Immunol. 22, 507–13 (2010). 
99. Panda, A. et al. Human innate immunosenescence: causes and consequences for immunity 
in old age. Trends Immunol. 30, 325–33 (2009). 
100. Mariani, E. et al. Age-dependent decreases of NK cell phosphoinositide turnover during 





101. Mocchegiani, E. et al. Metallothioneins/PARP-1/IL-6 interplay on natural killer cell 
activity in elderly: parallelism with nonagenarians and old infected humans. Effect of zinc 
supply. Mech. Ageing Dev. 124, 459–68 (2003). 
102. Hazeldine, J., Hampson, P. & Lord, J. M. Reduced release and binding of perforin at the 
immunological synapse underlies the age-related decline in natural killer cell cytotoxicity. 
Aging Cell 11, 751–759 (2012). 
103. Stout-Delgado, H. W., Du, W., Shirali, A. C., Booth, C. J. & Goldstein, D. R. Aging 
Promotes Neutrophil-Induced Mortality by Augmenting IL-17 Production during Viral 
Infection. Cell Host Microbe 6, 446–456 (2009). 
104. Della Bella, S. et al. Peripheral blood dendritic cells and monocytes are differently 
regulated in the elderly. Clin. Immunol. 122, 220–228 (2007). 
105. Yoon, P., Keylock, K. T., Hartman, M. E., Freund, G. G. & Woods, J. A. Macrophage 
hypo-responsiveness to interferon-γ in aged mice is associated with impaired signaling 
through Jak-STAT. Mech. Ageing Dev. 125, 137–143 (2004). 
106. Hearps, A. C. et al. Aging is associated with chronic innate immune activation and 
dysregulation of monocyte phenotype and function. Aging Cell 11, 867–875 (2012). 
107. Agrawal, A. et al. Altered innate immune functioning of dendritic cells in elderly humans: 
a role of phosphoinositide 3-kinase-signaling pathway. J. Immunol. 178, 6912–22 (2007). 
108. Shodell, M. & Siegal, F. P. Circulating, interferon-producing plasmacytoid dendritic cells 
decline during human ageing. Scand. J. Immunol. 56, 518–21 (2002). 
109. Pascual, V., Banchereau, J. & Palucka, A. K. The central role of dendritic cells and 
interferon-alpha in SLE. Curr. Opin. Rheumatol. 15, 548–56 (2003). 
110. Moretto, M. M., Lawlor, E. M. & Khan, I. A. Aging mice exhibit a functional defect in 
mucosal dendritic cell response against an intracellular pathogen. J. Immunol. 181, 7977–
84 (2008). 
111. Paganelli, R., Scala, E., Quinti, I. & Ansotegui, I. J. Humoral immunity in aging. Aging 
(Milano). 6, 143–50 (1994). 
112. Ginaldi, L. et al. The immune system in the elderly: I. Specific humoral immunity. 
Immunol. Res. 20, 101–8 (1999). 
113. Linton, P.-J., Harbertson, J. & Bradley, L. M. Development of Memory CD4 Cells A 
Critical Role for B Cells in the A Critical Role for B Cells in the Development of Memory 
CD4 Cells. J Immunol J. Immunol. by guest 165, 5558–5565 (2018). 
114. Frasca, D., Diaz, A., Romero, M., Landin, A. M. & Blomberg, B. B. Age effects on B 





115. Hakim, F. T. et al. Constraints on CD4 recovery postchemotherapy in adults: thymic 
insufficiency and apoptotic decline of expanded peripheral CD4 cells. Blood 90, 3789–98 
(1997). 
116. Garcia, G. G. & Miller, R. A. Age-dependent defects in TCR-triggered cytoskeletal 
rearrangement in CD4+ T cells. J. Immunol. 169, 5021–7 (2002). 
117. Salam, N. et al. T cell ageing: Effects of age on development, survival & function. Indian 
J. Med. Res. 138, 595–608 (2013). 
118. Haynes, L., Linton, P. J., Eaton, S. M., Tonkonogy, S. L. & Swain, S. L. Interleukin 2, but 
not other common gamma chain-binding cytokines, can reverse the defect in generation of 
CD4 effector T cells from naive T cells of aged mice. J. Exp. Med. 190, 1013–24 (1999). 
119. Nishioka, T., Shimizu, J., Iida, R., Yamazaki, S. & Sakaguchi, S. CD4+CD25+Foxp3+ T 
cells and CD4+CD25-Foxp3+ T cells in aged mice. J. Immunol. 176, 6586–93 (2006). 
120. Eaton, S. M., Burns, E. M., Kusser, K., Randall, T. D. & Haynes, L. Age-related Defects 
in CD4 T Cell Cognate Helper Function Lead to Reductions in Humoral Responses. J. 
Exp. Med. 200, 1613–1622 (2004). 
121. Fulton, R. B., Weiss, K. A., Pewe, L. L., Harty, J. T. & Varga, S. M. Aged Mice Exhibit a 
Severely Diminished CD8 T Cell Response following Respiratory Syncytial Virus 
Infection. J. Virol. 87, 12694–12700 (2013). 
122. Kugelberg, E. The effect of ageing on CD8+ T cells. Nat. Rev. Immunol. 14, 3–3 (2014). 
123. Centers for Disease Control and Prevention. Seasonal Flu Shot. (2018). 
124. Fleming, D. Influenza pandemics and avian flu. BMJ 331, 1066–9 (2005). 
125. Cox, R. J., Brokstad, K. A. & Ogra, P. Influenza Virus: Immunity and Vaccination 
Strategies. Comparison of the Immune Response to Inactivated and Live, Attenuated 
Influenza Vaccines. Scand. J. Immunol. 59, 1–15 (2004). 
126. Zhang, N. et al. Advancements in the development of subunit influenza vaccines. 
Microbes Infect. 17, 123–34 (2015). 
127. Zebedee, S. L. & Lamb, R. A. Influenza A virus M2 protein: monoclonal antibody 
restriction of virus growth and detection of M2 in virions. J. Virol. 62, 2762–72 (1988). 
128. Ma, J.-H. et al. An M2e-based synthetic peptide vaccine for influenza A virus confers 
heterosubtypic protection from lethal virus challenge. Virol. J. 10, 227 (2013). 
129. Cargnelutti, D. E. et al. Enhancement of Th1 immune responses to recombinant influenza 





130. Khanna, M., Sharma, S., Kumar, B. & Rajput, R. Protective Immunity Based on the 
Conserved Hemagglutinin Stalk Domain and Its Prospects for Universal Influenza 
Vaccine Development. Biomed Res. Int. 2014, 1–7 (2014). 
131. Centers for Disease Control and Prevention. Fluzone High-Dose Seasonal Influenza 
Vaccine. Available at: https://www.cdc.gov/flu/protect/vaccine/qa_fluzone.htm.  
132. Calabro, S. et al. The adjuvant effect of MF59 is due to the oil-in-water emulsion 
formulation, none of the individual components induce a comparable adjuvant effect. 
Vaccine 31, 3363–3369 (2013). 
133. O’Hagan, D. T., Ott, G. S., De Gregorio, E. & Seubert, A. The mechanism of action of 
MF59 – An innately attractive adjuvant formulation. Vaccine 30, 4341–4348 (2012). 
134. Haralambieva, I. H. et al. The Impact of Immunosenescence on Humoral Immune 
Response Variation after Influenza A/H1N1 Vaccination in Older Subjects. PLoS One 10, 
e0122282 (2015). 
135. GOODWIN, K., VIBOUD, C. & SIMONSEN, L. Antibody response to influenza 
vaccination in the elderly: A quantitative review. Vaccine 24, 1159–1169 (2006). 
136. Lambert, N. D., Ovsyannikova, I. G., Pankratz, V. S., Jacobson, R. M. & Poland, G. A. 
Understanding the immune response to seasonal influenza vaccination in older adults: a 
systems biology approach. Expert Rev. Vaccines 11, 985–94 (2012). 
137. Myśliwska, J. et al. Immunomodulating effect of influenza vaccination in the elderly 
differing in health status. Exp. Gerontol. 39, 1447–1458 (2004). 
138. Agarwal, D. et al. Immune response to influenza vaccination in the elderly is altered by 
chronic medication use. Immun. Ageing 15, 19 (2018). 
139. Wagner, A. et al. Age-related differences in humoral and cellular immune responses after 
primary immunisation: indications for stratified vaccination schedules. Sci. Rep. 8, 9825 
(2018). 
140. Christensen, D. Vaccine adjuvants: Why and how. Hum. Vaccin. Immunother. 12, 2709–
2711 (2016). 
141. Glenny, A. T., Pope, C. G., Waddington, H. & Wallace, U. Immunological notes. XVII-
XXIV. J. Pathol. Bacteriol. 29, 31–40 (1926). 
142. Walker, W. T. & Faust, S. N. Monovalent inactivated split-virion AS03-adjuvanted 
pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines 9, 1385–1398 (2010). 
143. Ulanova, M., Tarkowski, A., Hahn-Zoric, M. & Hanson, L. A. The Common vaccine 
adjuvant aluminum hydroxide up-regulates accessory properties of human monocytes via 





144. Marrack, P., McKee, A. S. & Munks, M. W. Towards an understanding of the adjuvant 
action of aluminium. Nat. Rev. Immunol. 9, 287–293 (2009). 
145. Ott, G. et al. MF59 Design and Evaluation of a Safe and Potent Adjuvant for Human 
Vaccines. in 277–296 (Springer, Boston, MA, 1995). doi:10.1007/978-1-4615-1823-5_10 
146. Mueller, M. et al. Aggregates are the biologically active units of endotoxin. J. Biol. Chem. 
279, 26307–13 (2004). 
147. Petrovsky, N. & Aguilar, J. C. Vaccine adjuvants: Current state and future trends. 
Immunol. Cell Biol. 82, 488–496 (2004). 
148. Di Pasquale, A., Preiss, S., Tavares Da Silva, F. & Garçon, N. Vaccine Adjuvants: from 
1920 to 2015 and Beyond. Vaccines 3, 320–43 (2015). 
149. Seder, R. et al. Gaps in knowledge and prospects for research of adjuvanted vaccines. 
Vaccine 33, B40–B43 (2015). 
150. Birkett, A. J. PATH Malaria Vaccine Initiative (MVI): Perspectives on the status of 
malaria vaccine development. Hum. Vaccin. 6, 139–145 (2010). 
151. Sneh-Edri, H., Likhtenshtein, D. & Stepensky, D. Intracellular Targeting of PLGA 
Nanoparticles Encapsulating Antigenic Peptide to the Endoplasmic Reticulum of 
Dendritic Cells and Its Effect on Antigen Cross-Presentation in Vitro. Mol. Pharm. 8, 
1266–1275 (2011). 
152. Basu, A. & Domb, A. J. Recent Advances in Polyanhydride Based Biomaterials. Adv. 
Mater. 30, 1706815 (2018). 
153. Torres, M. P., Determan, A. S., Anderson, G. L., Mallapragada, S. K. & Narasimhan, B. 
Amphiphilic polyanhydrides for protein stabilization and release. Biomaterials (2007). 
doi:10.1016/j.biomaterials.2006.08.047 
154. Ross, K. A. et al. Structural and antigenic stability of H5N1 hemagglutinin trimer upon 
release from polyanhydride nanoparticles. J. Biomed. Mater. Res. - Part A 102, 4161–
4168 (2014). 
155. Kumar, N., Langer, R. S. & Domb, A. J. Polyanhydrides: An overview. Adv. Drug Deliv. 
Rev. 54, 889–910 (2002). 
156. Katti, D. S., Lakshmi, S., Langer, R. & Laurencin, C. T. Toxicity, biodegradation and 
elimination of polyanhydrides. Adv. Drug Deliv. Rev. 54, 933–61 (2002). 
157. Huntimer, L. et al. Evaluation of Biocompatibility and Administration Site Reactogenicity 






158. Petersen, L. K., Xue, L., Wannemuehler, M. J., Rajan, K. & Narasimhan, B. The 
simultaneous effect of polymer chemistry and device geometry on the in vitro activation 
of murine dendritic cells. Biomaterials 30, 5131–5142 (2009). 
159. Goodman, J. T. et al. Nanoparticle Chemistry and Functionalization Differentially 
Regulates Dendritic Cell – Nanoparticle Interactions and Triggers Dendritic Cell 
Maturation. 1269–1280 (2014). doi:10.1002/ppsc.201400148 
160. Ross, K. et al. Hemagglutinin-based polyanhydride nanovaccines against H5N1 influenza 
elicit protective virus neutralizing titers and cell-mediated immunity. Int. J. Nanomedicine 
10, 229 (2014). 
161. Ulery, B. D. et al. Rational design of pathogen-mimicking amphiphilic materials as 
nanoadjuvants. Sci. Rep. 1, 198 (2011). 
162. Joshi, V. B., Geary, S. M., Carrillo-Conde, B. R., Narasimhan, B. & Salem, A. K. 
Characterizing the antitumor response in mice treated with antigen-loaded polyanhydride 
microparticles. Acta Biomater. 9, 5583–5589 (2013). 
163. Huntimer, L. et al. Single immunization with a suboptimal antigen dose encapsulated into 
polyanhydride microparticles promotes high titer and avid antibody responses. J. Biomed. 
Mater. Res. Part B Appl. Biomater. 101B, 91–98 (2013). 
164. Huntimer, L. M. et al. Polyanhydride nanovaccine platform enhances antigen-specific 
cytotoxic T cell responses. Technology 02, 171–175 (2014). 
165. Kabanov, A. V., Batrakova, E. V. & Alakhov, V. Y. Pluronic?? block copolymers as 
novel polymer therapeutics for drug and gene delivery. J. Control. Release 82, 189–212 
(2002). 
166. Escobar-Chávez, J. J. et al. Applications of thermo-reversible pluronic F-127 gels in 
pharmaceutical formulations. J. Pharm. Pharm. Sci. a Publ. Can. Soc. Pharm. Sci. Société 
Can. des Sci. Pharm. 9, 339–358 (2006). 
167. Determan, M. D., Cox, J. P., Seifert, S., Thiyagarajan, P. & Mallapragada, S. K. Synthesis 
and characterization of temperature and pH-responsive pentablock copolymers. 46, 6933–
6946 (2005). 
168. Determan, M. D., Cox, J. P. & Mallapragada, S. K. Drug release from pH-responsive 
thermogelling pentablock copolymers. J. Biomed. Mater. Res. Part A 81A, 326–333 
(2007). 
169. Agarwal, A., Unfer, R. & Mallapragada, S. K. Novel cationic pentablock copolymers as 
non-viral vectors for gene therapy. J. Control. Release 103, 245–258 (2005). 
170. Uz, M., Mallapragada, S. K. & Altinkaya, S. A. Responsive pentablock copolymers for 





171. Adams, J. R., Haughney, S. L. & Mallapragada, S. K. Effective polymer adjuvants for 
sustained delivery of protein subunit vaccines. Acta Biomater. 14, 104–114 (2015). 
172. Ross, K. et al. Combination Nanovaccine Demonstrates Synergistic Enhancement in 
Efficacy against Influenza. ACS Biomater. Sci. Eng. 2, 368–374 (2016). 
173. Lee, S. & Nguyen, M. T. Recent advances of vaccine adjuvants for infectious diseases. 
Immune Netw. 15, 51–7 (2015). 
174. Coffman, R. L., Sher, A. & Seder, R. A. Vaccine adjuvants: Putting innate immunity to 
work. Immunity 33, 492–503 (2010). 
175. Chougnet, C. A. et al. Loss of Phagocytic and Antigen Cross-Presenting Capacity in 
Aging Dendritic Cells Is Associated with Mitochondrial Dysfunction. J. Immunol. 195, 
2624–2632 (2015). 
176. Van Der Windt, G. J. W. et al. Mitochondrial Respiratory Capacity Is A Critical Regulator 
Of CD8 + T Cell Memory Development. doi:10.1016/j.immuni.2011.12.007 
177. Danilchanka, O. & Mekalanos, J. J. Cyclic dinucleotides and the innate immune response. 
Cell 154, 962–70 (2013). 
178. Tosolini, M., Pont, F., Verhoeyen, E. & Fournié, J.-J. Cyclic dinucleotides modulate 
human T-cell response through monocyte cell death. Eur. J. Immunol. 45, 3313–3323 
(2015). 
179. Dubensky, T. W., Kanne, D. B., Leong, M. L. & Leong, M. L. Rationale, progress and 
development of vaccines utilizing STING-activating cyclic dinucleotide adjuvants. Ther. 








CHAPTER 2.    RESEARCH OBJECTIVES AND THESIS ORGANIZATION 
The overall goal of the research presented in this thesis is to develop a single dose 
combination nanoadjuvant-based vaccine formulation against Influenza A virus that can provide 
rapid, long-term, and cross-protective immunity in older adults. To achieve this objective, 
multiple influenza virus antigens including hemagglutinin, which provides neutralizing antibody 
responses, and nucleoprotein, which provides cross-protective T cell immunity, were utilized. 
These antigens were encapsulated into biodegradable, surface-eroding polyanhydride 
nanoparticles, which represent one of the adjuvants in the combination formulation based on our 
previous studies on influenza nanovaccine efficacy in young animals. Another adjuvant, self-
assembling micelles based on amphiphilic pentablock copolymer and Pluronic® F127, was also 
used with a motive to enhance the delivery of the soluble antigen and the co-adjuvants. The 
interactions between the micelle and antigen and APCs were studied. The effect of the micelles 
on B cell responses was explored as a potential mechanism of action. CDN was used as the co-
adjuvant of choice on the basis of collaborative studies which demonstrated induction of 
enhanced antibody titers and increased BAFF production in aged animals without the induction 
of nitric oxide. In addition, the immunometabolic profiles for all these adjuvants was studied to 
establish the safe usage of these adjuvants in vaccines for older adults. This combination 
nanovaccine formulation was used to immunize both young and aged animals, which led to the 
induction of high antibody titers and provided protection against a homologous influenza virus 
challenge. Finally, studies to analyze cellular immunity, particularly, memory T cell responses to 
provide protection against heterologous viral challenges were also performed. The specific goals 





SG1: Evaluate the safety profile of pentablock copolymer micelle adjuvants and analyze 
the interaction of micelles with protein antigens and APCs. 
SG2: Investigate a mechanism of action of the micelle adjuvants in terms of their unique 
ability for antigen presentation and induction of B cell responses.  
SG3: Establish the induction of protective immunity in young and aged mice upon 
immunization with the combination nanovaccine formulation and upon homologous viral 
challenge. 
SG4: Analyze T cell responses in young and aged mice immunized with the combination 
nanovaccine with implications for the induction of protective immunity after heterologous viral 
challenge. 
The following chapters in this thesis address these specific goals. SG1 is addressed in 
Chapters 3 and 4, which discuss in vivo safety and biocompatibility of the micelle nanoadjuvant 
platform and how the micelles interact with antigens and immune cells. Chapter 5 addresses 
SG2, which elucidates the mechanism of action of micelle-based nanoadjuvants and their role(s) 
in enhancing the overall immune response generated by the combination nanovaccine. Chapters 
6 and 7 summarize the results for SG3 and SG4, respectively, by investigating protective 






CHAPTER 3.    SAFETY AND BIOCOMPATIBILITY OF INJECTABLE 
VACCINE ADJUVANTS COMPOSED OF THERMOGELLING BLOCK 
COPOLYMER GELS 
Part of this work is adapted from the thesis work of Justin Russell Adams titled “Novel cationic 
pentablock copolymers as a nanovaccine delivery platform”  
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Abstract 
Injectable thermogelling polymers have been recently investigated as novel adjuvants and 
delivery systems for next generation vaccines. As research into natural and synthetic 
biocompatible polymers progresses, the safety and biocompatibility of these compounds is of 
paramount importance. We have developed cationic pentablock copolymer vaccine adjuvants 
based on Pluronic F127, a thermogelling triblock copolymer that has been approved by the FDA 
for multiple applications, and methacrylated poly(diethylaminoethyl methacrylate) (PDEAEM) 
outer blocks. These novel materials have been demonstrated to effectively create an antigen 
depot, minimally impact antigen stability, and enhance the immune response to antigens (i.e., 
adjuvanticity) in mice. In this work, we investigated the safety and biocompatibility of the parent 
triblock Pluronic gels and the cationic pentablock copolymer gels in mice. Histological analysis 





administering the block copolymer formulations. However, the subcutaneous injection of a 
thermogelling Pluronic solution induced increased levels of lipids in the blood, with no further 
deleterious effects observed from the addition of the cationic outer blocks. This hyperlipidemia 
resolved within 30 days after the administration of the Pluronic formulation. To mitigate this 
adverse effect, the vaccine adjuvant formulations were modified by adding poly(vinyl alcohol), 
which allowed gelation, while reducing the amount of Pluronic in the formulation. This modified 
formulation abrogated the observed hyperlipidemia, and no adverse effects were observed in the 
serum through biomarker analysis or at the injection site (i.e., inflammation) in comparison to 
the responses induced by administration of saline or incomplete Freunds adjuvant. These studies 
provide a foundation to developing these gels as adjuvants for next generation vaccines. 
 
3.1 Introduction 
The design of novel vaccine adjuvants and vaccine delivery systems has the potential to 
offer significant improvements over current vaccine technologies. Biocompatible synthetic 
polymers have recently been investigated as novel adjuvants and delivery systems for next 
generation vaccines 1–3. As research into natural and synthetic polymers progresses, the safety of 
these compounds is of critical concern. There is a need to balance the immunostimulatory 
properties of vaccine adjuvants with the desire to avoid injection site reactions such as pain, 
redness, and swelling (i.e., reactogenicity) that may lead to reduced patient compliance.  
  Injection site reactions may be caused by adjuvants that are often included in 
vaccine formulations. Vaccine adjuvants may contribute to antigen delivery and/or enhancing an 
immune response 1–3. Most vaccines that have been approved for human use contain potassium 





(MPLA)4. It is known that alum does not induce a cell-mediated immune response that can 
effectively clear intracellular pathogens 5,6. In addition, alum, oil-in-water emulsions (such as 
Incomplete Freund’s adjuvant, IFA) and MPLA have long been associated with inflammation 7,8.  
Amphiphilic block copolymers consisting of polyoxypropylene and polyoxyethylene 
blocks, including the widely used surfactant Pluronic F127 that has been approved by the FDA 
for other applications 9, have been evaluated as injectable drug and vaccine delivery systems 
with tunable release rates based on polymer concentration 10. These polymers can deliver antigen 
in the form of a soluble, injectable delivery system that spontaneously gels at physiological body 
temperatures creating a depot. Pentablock copolymers based on Pluronic, synthesized in our 
laboratories with cationic outer blocks (Figure 1), have been shown to electrostatically complex 
DNA and can be easily functionalized with microbial associated molecular patterns (MAMPS) to 
create pathogen-mimics that stimulate an immune response 11. Based on these characteristics, 
pentablock copolymers offer an improvement over current vaccine adjuvant technology. 
Pentablock copolymers are synthesized from Pluronic macroinitiators using atom transfer 
radical polymerization (ATRP). The addition of cationic blocks to the triblock copolymer 
increases the overall toxicity of the polymer due to a combination of the reactogenicity of the 
outer cationic bocks and the presence of residual copper catalyst from the ATRP reaction 12. To 
reduce the cytotoxic impact of the outer blocks, we have recently developed a new method of 
catalysis for ATRP 13. By replacing conventional soluble cuprous salts with easily removable 
cuprous oxide nanoparticles as the catalyst, we have shown that the pentablock copolymers have 
a lower level of copper in the final product and significantly reduced in vitro cellular toxicity.  
The unique thermoreversible properties of Pluronic F127 have led to a wide range of 





products, a previous study reported a significant increase in cholesterol and triglycerides present 
in the serum of mice administered Pluronic block copolymer hydrogels without the cationic outer 
blocks 14.  For this reason, we also tested an alternative hydrogel formulation based on 
pentablock copolymers containing cationic groups and triblock Pluronic F127 by including 
poly(vinyl alcohol) (PVA), in order to reduce the amount of F127 in the formulation, while still 
retaining the ability to form a gel at physiological temperatures. PVA (Figure 1) is a hydrophilic 
polymer with high biocompatibility and an excellent safety profile that is currently being 
investigated for a number of biomedical applications including wound healing 15. Like our 
pentablock copolymer system, PVA has gelation capabilities, often achieved through γ-
irradiation induced cross-linking or successive freeze/thaw cycles 16. Crosslinking was not found 
to be necessary for gelation when used in combination with the pentablock copolymers. This 
modified hydrogel has been shown in previous studies to have adjuvant-like properties as 
evidenced by the induction of robust antibody responses following immunization 17–19. This work 
builds upon our previous studies by systematically studying the safety and biocompatibility of 
the PVA-modified pentablock copolymer gels and demonstrates that these novel materials can be 
developed as adjuvants for next generation vaccines. 
 
3.2 Materials and Methods 
3.2.1 Materials 
Poly(vinyl alcohol) (PVA, MW = 9,000-10,000 g/mol, 80% hydrolyzed), N,N-(diethyl 
amino)ethyl methacrylate (DEAEM), Pluronic F127 (Mn = 12600, 70% PEO), ovalbumin protein 
(44 kDa), creatinine assay kit (45-MAK080)  were purchased from Sigma-Aldrich (St. Louis, 





Scientific (Pittsburgh, PA). The synthesis of N-propyl-pyridynyl methanimine (NPPM) from 1-
propylamine and 2-pyridinecarbaldehyde and cuprous oxide nanoparticles has been previously 
described 13. 
 
3.2.2 Pentablock copolymer synthesis 
Pentablock copolymer (PBC) was synthesized from Pluronic F127 via atom transfer 
radical polymerization. The synthesis of the N-propyl-pyridynyl methanimine (NPPM) ligand, 
cuprous oxide nanoparticles and Pluronic macroinitiator has been previously reported 13,20. 
Pluronic macroinitiator (10 g, 0.78 mmol) was added to a sonicated solution of cuprous oxide 
nanoparticles (0.24 g, 1.68 mmol) in toluene. The reaction flask was degassed several times by 
vacuum-nitrogen before injecting the NPPM ligand (.5 mL, 3.40 mmol) and DEAEM monomer 
(4 mL, 2.53 mmol). Several freeze-pump-thaw cycles with liquid nitrogen were used to further 
remove oxygen. The mixture was reacted inside of a water bath at 70°C and 300 RPM. After 20 
hours, the reacted product was passed through a column of basic alumina with a 1:1 
dichloromethane:toluene solution. The eluate was removed with a rotary evaporator and the 
polymer was precipitated in chilled n-heptane. The precipitant was collected using a Büchner 
funnel and left in a vacuum oven to dry overnight. The functionalization of the pentablock 
copolymers with mannose via a high yielding azide-alkyne click reaction has been previously 
reported 11. This provided polymers that were functionalized with mannose at both end blocks of 
the polymer. The block copolymers were incubated overnight on ice inside a solution of 
phosphate buffered saline at concentrations exceeding 20 wt.%. This process provided a 
hydrogel formulation that was a liquid at room temperature but gelled after administration in vivo 





3.2.3 PVA-based Modified Hydrogel Formulations 
The PVA was added to the block copolymer system by first heating a 30 wt % of the 
polymer in PBS at 80 °C for several hours to cause dissolution and the formation of a viscous 
PVA solution. This solution was pipetted into a chilled block copolymer solution at different 
concentrations and briefly vortexed. The various copolymer adjuvant formulations investigated 
are listed in Table 3.1.  
 
3.2.4 Mice 
Five to seven-week-old female  C57BL/6 mice were purchased from Jackson 
Laboratories (Bar Harbor, ME). To facilitate live animal imaging, another set of six to seven-
week-old female SKH1-E (hairless) mice were purchased from Charles River Laboratories 
(Wilmington, MA) for the in vivo imaging studies of inflammatory responses at the injection site. 
The Institutional Animal Care and Use Committee (IACUC) at Iowa State University approved 
all protocols involving animals.  
 
3.2.5 Administration of hydrogels 
To study the safety of the block copolymer formulations, a total of 16 mice per group 
were administered with formulations containing PF127 with or without non-functionalized or 
mannose-functionalized PDEAEM pentablock copolymers and PVA. Additional treatment 
groups included incomplete Freund’s adjuvant (IFA) and saline as controls.  
 In a separate experiment, SKH1-E mice (four per group) were administered 100 μL of 
the formulation to analyze inflammatory responses. Additional treatments included alum and 





cubic centimeter syringe fitted with a 26G 3/8-inch hypodermic needle. The hydrogel 
formulations were kept on ice (i.e., liquid at this temperature) until injection, at which time the 
body temperature caused the formation of a hydrogel. Serum samples were collected via the 
saphenous vein at the indicated time points throughout the experiment.  
 
3.2.6 Histopathological Evaluation 
After euthanasia of separate groups of mice at 3 days or 30 days post-injection (DPI), 
kidneys, livers, and injection site tissues were excised and fixed in formalin, embedded, 
sectioned, and analyzed by a board-certified veterinary pathologist in a blind study. Scores 
ranged from 0, indicating no change, to 5, indicating severe or diffuse changes and loss of 
normal tissue architecture. The range of histopathological score for both liver and kidney were 
from 0 to 10 and the data reported reflects a summation of the inflammatory plus necrosis scores. 
The injection site histopathological score ranged from 0 to 15 and is a summation of the 
inflammatory cell infiltrate, fibrosis, and tissue loss. 
 
3.2.7 Serum and Urine Biomarker Analyses 
Two modified formulations containing PDEAEM, PF127, and PVA (Table 1) were 
subcutaneously administered to the left flank of mice for serum biomarker analysis. In addition, 
an alum and ovalbumin (OVA) alone group were added as controls. One hundred µg of the 
model antigen OVA was added to the hydrogel and alum formulations. Serum biomarkers of 
kidney and liver function were analyzed using Vitros 5.1 Chemistry Analyzer at 1, 3, 14- and 28-
days post-injection. Multistix 10G Reagent Urine Testing Strips were used to measure glucose, 





dipped and read visually in accordance with the instructions provided by the manufacturer. 
Creatinine in the urine was measured with a separate kit. These studies were performed at the 
Clinical Pathology laboratory at the College of Veterinary Medicine, Iowa State University. 
 
3.2.8 Inflammatory Response Analysis 
ProSense® 680, which becomes fluorescently activated when cleaved by cathepsin at the 
site of inflammation, was used to evaluate the inflammatory responses. ProSense® 680 was 
synthesized as described previously 21 and administered intravenously at a concentration of 2 
nmol (150 μL) 24 h prior to imaging. The animals were imaged at 1, 3, and 8 DPI, using Kodak 
In Vivo Multispectral Imaging System FX Pro (Carestream Health, Rochester, NY) while 
keeping them under anesthesia with 2% isoflurane in 100% oxygen at 2.5 L/min. Images were 
captured using a binning of 4×4 and exposure time of 1 min. Image analysis was performed 
using ImageJ (NIH, Bethesda, MD). Mean fluorescence intensities (MFI) were calculated after 
background subtraction and drawing a region of interest (ROI) on all images.   
 
3.2.9 Statistics 
Numerical data are reported as standard error of the mean (SEM). Statistical significance 
designated as a p-value ≤ 0.05. Differences between groups were analyzed with one-way 
analysis of variance (ANOVA) followed by Tukey’s post hoc test.  
 
3.3 Results 
3.3.1 Histopathological Effects of Hydrogel Administration 
Histopathological analysis was utilized to evaluate the presence of microscopic signs of 





to no evidence of injection site reactions; furthermore, there was no evidence of systemic 
damage to the kidney or liver at 3 or 30 DPI following the administration of the block 
copolymers (Figures 3.2 and 3.3 and Table 3.2). 
 
3.3.2 Urinalysis for Evaluating Kidney Function  
Mouse urine collected at days 1, 3, 14, and 28 after hydrogel administration was tested 
for the presence of creatinine. The amount of creatinine in the urine is indicative of kidney 
function and muscle damage. Creatinine is a metabolite of creatine and if the kidneys are 
damaged, the quantity of creatinine in the urine may decrease 22. As shown in Figure 3.4, there 
was no statistical difference in the quantity of creatinine in the urine of mice administered with 
the polymer formulations when compared to the urine of animals administered with saline. 
 
3.3.3 Effect of Block Copolymer Administration on Triglyceride and Cholesterol Levels at 
Early Time Points 
Sera collected at 3 and 30 DPI were analyzed for biomarkers of kidney and liver function. 
The mice groups treated with the tri- and pentablock copolymers exhibited normal levels of 
glucose, total protein, bilirubin, and albumin in their serum samples; however, they exhibited 
elevated triglyceride and cholesterol levels indicative of hypertriglyceridemia and 
hypercholesterolemia at 3 DPI (Figure 3.5 and Supplementary Table 3.1). The mice group that 
was treated with PF127 alone exhibited the highest levels of triglycerides and cholesterol, 
suggesting that the PF127 (and not the cationic outer blocks) was responsible for this 
observation. Although the levels of triglycerides and cholesterol returned to normal by 30 DPI, 
the abnormal levels at 3 DPI posed a considerable concern from the standpoint of establishing an 





formulation, it cannot be eliminated; however, as the serum biomarker data suggests, the amount 
of Pluronic in the final formulation needs to be reduced. 
 
3.3.4 PVA-based Modified Hydrogel Formulations  
We have previously reported that the block copolymer hydrogel with PF127 and PBC 
establishes a depot at the injection site while sustaining the release of antigen 23. However, the 
high quantity of PF127 needed to form the hydrogel is responsible for elevated levels of 
triglycerides and cholesterol, as demonstrated above (Figure 3.5). Therefore, there is a need to 
preserve the ability to form the depot while simultaneously reducing the amount of PF127 used. 
A combination of PF127 and PVA has been previously explored towards establishing a 
biocompatible temperature responsive delivery device 24. In addition, the safety profile of 
subcutaneously administered PVA is well known. Repeated administration of high quantities of 
low molecular weight PVA (9,000-10,000 g/mol) has been shown to produce no abnormalities or 
systemic effects 25. For this reason, we developed modified pentablock copolymer formulations 
containing PVA (Table 3.1) and evaluated their safety and biocompatibility. 
The serum biomarker analysis at day 3 showed that mice treated with the PVA-containing 
polymer formulations had triglyceride and cholesterol values that were closer to the normal 
range (55-144 mg/dL for cholesterol; 36-96 mg/dL for triglycerides) (Figure 5 and SI Table 2), 
likely due to the reduced levels of PF127 in these formulations. 
The polymer solution of PVA and Pluronic and pentablock copolymers retained its ability 
to form a temperature dependent gel. To investigate the biocompatibility of these modified 
formulations (Table 3.1), the inflammatory responses at the site of administration were examined 





fluoresces upon activation after cleavage by proteases at the site of inflammation, allows for the 
analysis of the magnitude of inflammation using in vivo imaging.  At one DPI, acute 
inflammation was observed at the injection site of animals that received all treatment groups 
except saline (Figure 3.6). However, the inflammation caused by the Plu-PBC-PVA4 
formulation was significantly less (p ≤ 0.002) compared to that induced by alum. The injection 
site MFI for mice treated with pentablock copolymer formulation decreased by 8 DPI (not 
significantly different from saline). The inflammation induced at the injection site of alum 
treated mice at 8 DPI was significantly different (p ≤ 0.002) from that of the animals that 
received saline (Figure 3.6). 
 
3.4 Discussion 
Biocompatible amphiphilic block copolymers based on Pluronic have been used in gene 
therapy and targeted drug delivery 26–28. Our research group has previously synthesized a family 
of pentablock copolymers based on the amphiphilic Pluronic F127 triblock copolymer 20. This 
family of pentablock copolymers differs in its cationic outer blocks and, therefore, in its pH-
dependent micellization behavior, and its ability to form complexes with nucleic acids for gene 
delivery 29,30. These polymers have been synthesized with reduced toxicity by catalyzing the 
ATRP reaction with easily removable cuprous oxide nanoparticles 13. After an initial comparison 
between the pentablock copolymer families, the PDEAEM pentablock copolymer (Figure 3.1) 
was selected as a candidate for use as a vaccine delivery vehicle 11. The average molar mass of 
the biocompatible polymers in all cases was kept below 17,000 g/mol to allow for renal 
clearance 31. This polymer was successfully functionalized with D-mannose , which is a 





receptors (PRRs) on antigen presenting cells (APCs) 11. Our research group has demonstrated the 
preservation of primary, secondary and tertiary structures as well as antigenicity of released 
protein from these modified hydrogels 23. This result demonstrates the ability of the pentablock 
copolymer gel platform to form long lasting depots that can sustain the release of antigen over 
time. Although Pluronic F127 undergoes thermoreversible gelation, it does not provide 
prolonged persistence of the gel, nor does it enhance the persistence of the antigen at the site of 
injection 32. Therefore, a formulation consisting of both Pluronic F127 and pentablock copolymer 
provides the benefits of pH-dependent thermal gelation, longer lasting antigen depot formation, 
the ability of functionalization with MAMPs, while eliminating (or significantly reducing) the 
adverse effects of Pluronic F127 as further analyzed in this work. While both components of the 
gel formulation have high biocompatibility, it was important to do an extensive study of the 
safety profile of the formulation, especially taking into consideration the tissue compatibility and 
secondary reactions in the kidney and liver upon vaccine administration. This is the main focus 
of the current work.  
The presence of an antigen leads to the recruitment of various phagocytic immune cells to 
the site of administration for antigen clearance 33,34. Sometimes, however, the congregation of 
these immune cells and antigen-adjuvant complexes persist at the injection site and elicit 
continual inflammatory responses causing damage to the tissues 35. Deposition of inflammatory 
immune cells, because of the continued presence of antigen, in other organs and tissues has also 
been reported 36. Specifically, the endothelium of glomeruli in kidneys can be a site of remnant 
circulating immune complex deposits due to high turbulence in these sites, causing major kidney 
damage. In addition, deformation of hepatocytes and disruption of normal liver function has been 





Since the hydrogel formulations provide the benefits of long-term depot formation and 
slow release of the antigen, we studied their systemic effects on kidney and liver of mice 
administered with the gel formulations for 30 days post-injection. Microscopic examination of 
these tissues demonstrated the absence of any tissue lesions, necrosis, and inflammatory cell 
infiltrate (Figure 3.2 and 3.3). The scores provide evidence of  pathological results similar to 
those obtained from saline-treated mice, which corroborates the fact that the hydrogels provide 
the benefits of continual antigen presentation without having any negative impact on the organs 
because of them. Normal kidney function in mice administered with gel formulations was also 
supported by the creatinine levels (Figure 3.4) which is a marker of normal glomerular filtration 
rate (GFR) and efficient removal of creatine from the body 38,39. Other biomarkers in urine, such 
as glucose, bilirubin, and ketones were also found to be in the normal range (Table 3.2). 
However, the amounts of triglycerides and cholesterol in the serum of mice administered with 
the formulations were very high (Figure 3.5 and Supplementary Table 3.1), which was attributed 
to the presence of Pluronic F127 in the formulations. The correlation between high 
concentrations of Pluronic F127 and the onset of hypertriglyceridemia and hypercholesterolemia 
has been previously reported by other groups 40,41. Although the mechanism for elevated levels 
of circulating triglycerides and cholesterol is not clear, it has been suggested that this may be due 
in part either to the alteration of lipoprotein lipase, an enzyme responsible for hydrolysis of 
plasma triglycerides and lipid metabolism or the stimulation of 2-hydroxy-3-methylglutaryl-co-
enzyme-A (HMG-CoA) reductase, an enzyme responsible for production of cholesterol in the 
mevalonate pathway 41,42. The addition of PVA to the existing formulation and substituting a part 
of Pluronic F127, as pointed out in the previous section (Results: PVA modified hydrogel 





days post-injection (Figure 3.5 and Supplementary Table 3.2). The PVA-inclusive hydrogel 
formulations were also previously found to induce robust immune responses 23 and served as 
effective adjuvants, eliciting high antibody titers and effective protection in an influenza 
challenge study 18. 
The mechanism of action of oil emulsion adjuvants such as IFA, is their ability to induce 
inflammation at the site of injection and activate macrophages and dendritic cells and production 
of pro-inflammatory cytokines 43. However, there have been several conflicting results in the 
literature about the induction of local toxicity and pain at the injection site because of the 
inflammatory sequelae 44,45. When compared to results obtained with saline (control), the results 
of the present study indicated that IFA induced significant damage at the injection sites. Most of 
the pentablock copolymer gel formulations had injection site scores similar to saline and 
significantly different (p<0.05) from IFA up to 30 days post-injection (Figure 3.2).  
In addition, injection site reactogenicity for the modified gel formulations was evaluated 
using a fluorescent probe for imaging cathepsin activity. The use of ProSense®, a polymer-based 
probe to track cathepsin protease enzymes at the site of recruitment of inflammatory cells such as 
macrophages was reported many times 46–48. ProSense® is hydrolyzed by cathepsin B or 
proteolyzed by cathepsin L and S at the site of inflammation and gets activated 49.  An early, 
acute inflammation observed at 3 DPI for all formulations (Figure 3.6) is in agreement with 
previous studies 50. Moreover, early local inflammation helps the immune system set off a 
complex series of activation events, including release of cytokine signals and recruitment of 
immune cells 51. However, continued presence of inflammation leads to safety concerns. The 
presence of inflammation and inflammatory nodules at the site of injection of vaccine adjuvants 





allergic reactions, eczema, pain, and systemic effects, such as sleep deprivation and fever 54,55. 
Administration of alum-containing vaccines has been reported to also cause macrophagic 
myofasciitis in several animal models and humans that can persist for 10 years 44,56. Our results 
demonstrate the presence of significant inflammation due to alum until 8 days post-injection, 
whereas the inflammation due to gel formulations had diminished by this time period (Figure 
3.6).  
The results described herein demonstrate that the pentablock copolymer and PVA based 
gel formulations have favorable safety profiles for use as vaccine adjuvants. These formulations 
induced little to no local or systemic long-term toxicity, while simultaneously enhancing the 
induction of an antigen-specific antibody responses reported in our previous studies. 
 
3.5 Conclusions 
In this study, we have optimized copolymer formulations based on the safety and 
biocompatibility of formulations in a murine model. Histological analysis demonstrated that 
there were no injection site reactions or damage to the livers and kidneys observed following 
administration of the block copolymer formulations. We observed induction of an increased level 
of lipids in the blood following the subcutaneous injection of a Pluronic hydrogel. This 
hyperlipidemia was resolved by 30 days after the administration of PF127. Use of the polymer 
polyvinyl alcohol (PVA) in the hydrogel formulations allowed for the reduction in the amount of 
Pluronic from 25% to 1.8% and resulted in elimination of the Pluronic-induced hyperlipidemia, 
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3.6 Tables 
Table 3.1. Vaccine adjuvant formulations composed of Pentablock copolymer, Pluronic F127 
and/or poly (vinyl alcohol) 











Plu-PBC1 24.96 0.04 - - 
Plu-PBC2 24.6 0.4 - - 
Plu-PBC3 21 4 - - 
Plu-mPBC 24.6 - 0.4 - 
Plu 25 - - - 
Plu-PBC-PVA1 1.8 8.2 - 15 
Plu-PBC-PVA2 9.2 0.8 - 15 
Plu-PBC-PVA3 5.9 4.1 - 15 







Table 3.2. Urine biomarkers analyses of mice administered the Plu-PBC formulations (100 μL) 
and control mice at days 1, 3, 14 and 28. Levels of bilirubin, protein, nitrile and leukocytes were 













1 Plu-PBC1  60.0 ± 25.0 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 Plu-PBC2  66.7 ± 21.1 1.030 ± 0.000 6.00 ± 0.26 0.20 ± 0.00 
 Plu-PBC3 88.3 ± 24.5 1.030 ± 0.000 5.83 ± 0.17 0.20 ± 0.00 
 Plu-mPBC 33.3 ± 22.4 1.029 ± 0.001 6.42 ± 0.37 0.20 ± 0.00 
 Plu 60.0 ± 21.1 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 IFA 66.7 ± 22.4 1.029 ± 0.001 6.17 ± 0.31 0.20 ± 0.00 
 Saline 50.0 ± 22.4 1.030 ± 0.000 6.00 ± 0.26 0.20 ± 0.00 
3 Plu-PBC1 50.0 ± 22.4 1.030 ± 0.000 5.83 ± 0.17 0.20 ± 0.00 
 Plu-PBC2 50.0 ± 28.9 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 Plu-PBC3 80.0 ± 20.0 1.030 ± 0.000 6.20 ± 0.20 0.20 ± 0.00 
 Plu-mPBC 75.0 ± 25.0 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 Plu 75.0 ± 25.0 1.030 ± 0.000 5.75 ± 0.25 0.20 ± 0.00 
 IFA 80.0 ± 20.0 1.030 ± 0.000 6.00 ± 0.32 0.20 ± 0.00 
 Saline 50.0 ± 28.9 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
14 Plu-PBC1 100 ± 0.00 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 Plu-PBC2 60.0 ± 24.5 1.030 ± 0.000 6.30 ± 0.30 0.20 ± 0.00 




















 Plu 50.0 ± 28.9 1.030 ± 0.000 5.75 ± 0.25 0.20 ± 0.00 
 IFA 75.0 ± 25.0 1.029 ± 0.001 6.00 ± 0.00 0.20 ± 0.00 
 Saline 66.7 ± 21.1 1.030 ± 0.000 6.25 ± 0.36 0.20 ± 0.00 
28 Plu-PBC1 80.0 ± 20.0 1.030 ± 0.000 6.20 ± 0.20 0.20 ± 0.00 
 Plu-PBC2 80.0 ± 20.0 1.030 ± 0.000 5.80 ± 0.20 0.20 ± 0.00 
 Plu-PBC3 40.0 ± 25.5 1.030 ± 0.000 6.40 ± 0.25 0.20 ± 0.00 
 Plu-mPBC  80.0 ± 20.0 1.030 ± 0.000 6.00 ± 0.32 0.20 ± 0.00 
 Plu 75.0 ± 24.0 1.030 ± 0.000 6.00 ± 0.00 0.20 ± 0.00 
 IFA 50.0 ± 28.9 1.030 ± 0.000 6.25 ± 0.25 0.20 ± 0.00 
 Saline 50.0 ± 22.4 1.030 ± 0.000 6.00 ± 0.26 0.20 ± 0.00 
 
 
Supplementary Table 3.1: Serum biomarkers analyses of mice administered the Plu-PBC 



















































































































































































































































































16 0.3 176 5.9 3.1 223 51 0.68 123 88 
 Saline 




14 0.3 176 5.3 2.6 213 50 0.77 154 70 
 Plu-PBC2 
20 0.2 191 5.5 2.8 196 58 0.75 209 76 
 Plu-PBC3 
17 0.2 211 5.6 2.8 188 96 0.84 131 76 
 Plu-mPBC 
18 0.2 233 5.7 2.9 137 100 1.31 155 68 
 Plu 
16 0.2 309 5.9 3 130 120 1.47 180 84 
 IFA 
16 0.2 288 6 3.2 179 71 1.3 151 88 
 Saline 
17 0.1 229 5.9 3.1 189 48 1.12 117 70 
 
Supplementary Table 3.2: Serum biomarkers analyses of mice administered the 
























































































































































Figure 3.1. Schematic representation of the chemical structures of A) pentablock 




























































































































12 0.2 121 5.4 2.6 101 46 0.57 105 198 
 Plu-PBC-
PVA2 
15 0.2 150 6 3.1 153 26 1.03 224 664 
 Alum 
17 0.2 136 5.8 3 148 37 1.14 78 99 
 OVA 






Figure 3.2. Plu-PBC formulations exhibits no damage to kidney, liver, and site of 
immunization. There were no signs of toxicological effects and damage on kidney, injection site 
and liver following immunization of mice with Plu-PBC formulations tested. The tissue response 
at injection site less severe than IFA. Frames A-F are composite histopathological scores of 
kidney, injection site and liver at day 3 and day 30 for Plu-PBC formulations and control mice 
(n=4 mice per group for day 3 and n=6 mice per group for day 30); #p<0.05, ##p<0.005 for 







Figure 3.3. Effect of Plu-PBC formulations on kidney and liver. No statistical differences in 
liver and kidney weights as compared to controls. (A) Kidney and (2) liver organ weight at day 3 
post-injection for Plu-PBC and control mice (n=4 mice per treatment group).   
 
Figure 3.4. Kidney function is not altered by administration of Plu-PBC formulations. The 
data shows total creatinine present in the urine for PDEAEM:PF127-immunized and control 






Figure 3.5. Total cholesterol (A) and triglycerides (B) content in the serum of the mice, 
which received either Plu-PBC or Plu-PBC-PVA formulations and of the mice that 
received saline (controls) 3- and 30- days post-injection. The Plu-PBC formulations led to 
Pluronic-induced hyperlipidemia. PVA-based modified formulations have no adverse impact on 
cholesterol and triglyceride levels of the tested mice (n=4 mice per group for day 3 and n=6 mice 






Figure 3.6. PBC-Plu-PVA formulations induced less inflammatory response than alum at 
the site of immunization. Mice immunized with Plu-PBC-PVA formulations induced less 
inflammation than alum as demonstrated by cathepsin activity (monitored by ProSense 
fluorescence). Mean fluorescence intensity (MFI) for Plu-PBC-PVA formulations non-
significant compared to saline at day 8. (A)  Representative images of SKH1-E mice from each 
treatment group on days 1,3 and 8 post-injection (p.i.). (B) MFI of the regions of interest (ROIs) 
at the injection site. MFI significantly different from the MFI of alum denoted by A* at 1-day 
p.i., B* at 3 days p.i. and C* at 8 days p.i. p<0.005 n=4 mice per group. 
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Abstract 
As the focus has shifted from traditional killed or live, attenuated vaccines towards 
subunit vaccines, improvements in vaccine safety have been confronted with low 
immunogenicity of protein antigens. This issue has been addressed by synthesizing and 
designing a wide variety of antigen carriers and adjuvants, such as Toll-like receptor agonists 
(e.g., MPLA, CpG). Studies have focused on optimizing adjuvants for improved cellular 
trafficking, cytosolic availability, and improved antigen presentation. In this work, we describe 
the design of novel amphiphilic pentablock copolymer (PBC) adjuvants that exhibit high 
biocompatibility and reversible pH- and temperature-sensitive micelle formation. We 
demonstrate improved humoral immunity in mice in response to single dose immunization with 
PBC micelle adjuvants compared to soluble antigen alone. With the motive of exploring the 






micelles with a model antigen and demonstrated that the PBC micelles associate with the antigen 
and enhance its cytosolic delivery to antigen presenting cells. We posit that these PBC micelles 
operate via immune-enhancing mechanisms that are different from that of traditional Toll-like 
receptor activating adjuvants. The metabolic profile of antigen presenting cells stimulated with 
traditional adjuvants and the PBC micelles also suggests distinct mechanisms of action. A key 
finding from this study is the low production of nitric oxide and reactive oxygen species by 
antigen presenting cells when stimulated by PBC micelle adjuvants in sharp contrast to TLR 
adjuvants. Together, these studies provide a basis for rationally developing novel vaccine 
adjuvants that are safe, that induce low inflammation, and that can efficiently deliver antigen to 
the cytosol.  
 
4.1 Introduction 
Adjuvants have been used for almost seven decades to augment immune responses to 
antigens in subunit vaccines1–4. However, only a few, such as alum and monophosphoryl lipid A 
(MPLA), are currently approved by the United States Food and Drug Administration for use in 
human vaccines5. These adjuvants suffer from several limitations, including high reactogenicity, 
failure to provide cell-mediated immunity, and variability in the induction of immune responses 
in older adults6–8. Most vaccines or adjuvants that are currently approved or in pre-clinical trials 
work by the stimulation of pathogen recognition receptors (PRRs) on antigen presenting cells 
(APCs). This leads to the induction of inflammatory signals, such as cytokines, superoxides, and 
nitric oxide (NO)5. However, due to immunosenescence in older adults, this cytokine milieu is 
highly imbalanced leading to a state of “inflamm-aging” and an overproduction of harmful oxide 






of inflammaging in older adults necessitates the development (and exploration of mechanism of 
action) of novel vaccine adjuvants that do not induce the production of harmful analytes while 
stimulating the immune system. 
A significant amount of research has been focused on improving transport and delivery of 
antigens and adjuvants to APCs11,12. These antigens can be processed by APCs and presented via 
MHC I or MHC II pathway for the induction of effective T and B cell responses12. Studies have 
focused on pH-sensitive amphiphilic polymer-based vaccine delivery vehicles to enhance antigen 
presentation to the MHC I pathway and to induce CD8+ T cell responses that can be beneficial 
for enhancing the breadth of protection against intracellular pathogens13–15. In particular, cationic 
polymeric systems have been shown to enhance endosomal escape of the antigen due to the 
proton sponge effect and enhance cytosolic uptake of the antigen16–18.  
Amphiphilic pentablock copolymers based on Pluronic F127®, poly(ethylene oxide) 
(PEO) and poly(propylene oxide) (PPO), and cationic blocks such as 
poly(diethylaminoethylmethacrylate) (PDEAEM) have been previously studied for drug delivery 
and gene delivery19–21. Aqueous solutions of these polymers can form spherical micelles (about 
30 nm in diameter) and at higher concentrations (>20 wt.% polymer) form physical hydrogels in 
response to both temperature and pH22,23. The observation that small particle sizes of antigen 
delivery systems can enhance internalization by APCs has been widely exploited by different 
nanoparticle systems24–27. Therefore, a polymer system having both sub-100 nm size and stimuli 
responsiveness can be extremely beneficial. Hydrogels based on these pentablock copolymers 
(PBC) have been shown to provide sustained release of structurally stable antigen in vivo and 
enhance anti-ovalbumin (Ova) antibody responses28,29. We have also demonstrated in previous 






antibody titers that effected a reduction in viral load in lungs and exhibit improved vaccine 
efficacy in mice30. In this study, we prepared low concentration PBCs in aqueous solutions to 
form micelles without gelation that still enhanced antibody responses. This also eliminates any 
potential inflammatory responses associated with the high polymer concentrations needed to 
form gels31. However, little is known about the mechanism of action of PBC micelle adjuvants; 
how they interact with innate immune cells; and how these interactions lead to the induction of 
effective adaptive immunity.  
In this work, to explore the mechanism of action of these PBC micelles, we characterized 
antigen-micelle complexes using Forster Resonance Energy Transfer (FRET) spectroscopy and 
microscopy and showed that Ova associated with the micelles in the solution phase and that the 
PBC micelles enhanced Ova delivery to the cytosol in vitro in APCs. We also studied the 
stimulation of APCs with antigen-containing PBC micelles using three different approaches. In 
the first phase, we analyzed the upregulation of co-stimulatory molecules and cytokine secretion 
profile from APCs. Next, we measured the oxygen consumption rate by the mitochondria of 
APCs as a measure of stimulation. We analyzed the mitochondrial respiration and metabolic 
profile in comparison to the TLR agonist lipopolysaccharide (LPS). Finally, we studied the 
amount of innate effector molecule (such as NO and reactive oxygen species (ROS)) secretion by 
APCs upon stimulation with PBC micelles. Collectively, the studies presented here focus on the 
analysis of the responses of innate immune cells stimulated by novel PBC micelle adjuvants in 
order to understand their mechanism of action so as to develop safe and effective adjuvants with 







4.2 Materials and Methods 
4.2.1 Materials 
N,N-(diethylamino)ethyl methacrylate (DEAEM), Pluronic F127, Poly(vinyl alcohol) 
(PVA, MW=9,000-10,000 g/mol), and ovalbumin (Ova, 44 kDa) were purchased from Sigma-
Aldrich (St. Louis, MO). Alum (Alhydrogel®) and dyes for imaging and labeling were purchased 
from InVivogen (San Diego, CA). All other materials were purchased from Fisher Scientific 
(Pittsburgh, PA).  
 
4.2.2 Pentablock copolymer synthesis and characterization 
Pentablock copolymer (PDEAEM-PEO-PPO-PEO-PDEAEM) was synthesized by atom 
transfer radical polymerization (ATRP) as reported previously22. This method utilizes a 
difunctional macroinitiator prepared from commercially available Pluronic® F127. This was 
dissolved in tetrahydrofuran and reacted overnight with triethylamine and 2-bromoisobutyryl. 
The product was precipitated in n-hexane. The 2-bromo propionate Pluronic F127 was analyzed 
using 1H NMR to confirm the end group functionalization. Next, the macroinitiator and the 
monomer DEAEM were used to synthesize the pentablock copolymer by ATRP utilizing copper 
(I) oxide nanoparticles as the catalyst and N-propylpyrilidinemethanamine (NPPM) as the 
complexing ligand. Cuprous oxide nanoparticles used as catalyst were synthesized as previously 
described32. 1H NMR spectra of the resulting polymer were used to determine molecular weight. 
 
4.2.3 Labeling of PBC and antigen with fluorescent dyes 
The PBC and Ova were labeled with dyes to detect them fluorescently. We utilized an 
Alexa Fluor 594 protein labeling kit that utilizes a succinimidyl ester moiety to react with the 






according to the manufacturer’s protocol. For labeling the PBC we functionalized the end groups 
with azide following previously described28. We then utilized azide-alkyne click chemistry to 
attach alkyne functionalized Alexa Fluor 647 (Thermo Fisher Scientific, Waltham, MA) 
according to the manufacturer’s protocol.  
 
4.2.4 PBC hydrogel and micelle formulations 
A stock solution of 30% PVA was prepared in phosphate-buffered saline (PBS). For the 
hydrogel formulation, this stock solution was added to obtain a final concentration of 15 wt.% 
PVA, 5.9 wt.% Pluronic® F127 and 4.1 wt.% PBC in PBS. For the micelle formulation, a similar 
procedure was followed to obtain a final concentration of 7.5 wt.% PVA, 2.95 wt.% Pluronic 
F127 and 2.05 wt.% PBC in PBS. A micelle formulation with the fluorescently labelled PBC was 
also prepared and used in experiments as required. 
 
4.2.5 Animals 
Female C57BL/6 or BALB/c mice (6-7-week-old) were purchased from Charles River 
Laboratories (Wilmington, MA). The Institutional Animal Care and Use Committee (IACUC) at 
Iowa State University approved all protocols involving animals.  
 
4.2.6 Immunizations and evaluation of antibody titers 
To evaluate antibody responses, C57BL/6 or BALB/c mice were subcutaneously 
immunized with 100 µL of the micelle formulation, 100 µL of hydrogel formulation, or alum in 
a 1:1 ratio with Ova, all containing 50 µg of Ova. Control animals were immunized with soluble 






saphenous vein at 21 days and 35 days post-immunization. Enzyme-linked immunosorbent assay 
(ELISA) was performed to measure the total anti-Ova total IgG titers. Briefly, high binding 96-
well ELISA plates were coated with Ova overnight and blocked with 2% w/v gelatin (BD 
DifcoTM, Fisher Scientific, Hampton, NH) in 0.05% Tween-PBS solution the following day. 
Serum samples were added at a dilution of 1:200 and diluted 1:2 across the plate. After 
incubation and washing, alkaline-phosphatase-conjugated anti-mouse IgG (H+L) (Jackson 
ImmunoResearch, Westgrove, PA) was added and incubated for two hours before adding 
substrate buffer and reading the plate at 405 nm. Titer was recorded as the last dilution that 
exhibited an optical density greater than twice the background optical density. 
 
4.2.7 Generation of bone marrow dendritic cells (BMDCs) and bone marrow macrophages 
(BMMs)  
Bone marrow was harvested from femurs and tibia of BALB/c mice and differentiated to 
dendritic cells using a standard protocol33. Briefly, the bone marrow was flushed out of the bones 
using a syringe with 5 mL of RPMI media containing 1% (1 g/100 mL) pen/strep. Granulocyte 
macrophage colony stimulating factor (GM-CSF) was added on the 1st day of culture at the 
concentration of 1ng/mL . GM-CSF and medium was refreshed on days 3, 6 and 8 of culture by 
exchanging 10 mL of spent medium with fresh medium containing GM-CSF. BMDCs were 
harvested on day 10 and used in subsequent assays. The same protocol was followed for BMMs 
except using DMEM medium and macrophage colony stimulating factor (M-CSF) as the 







4.2.8 Confocal microscopy 
J774 macrophage cell line and BALB/c-derived BMDCs were used to analyze the 
cellular internalization of antigen-containing micelles using confocal microscopy. Cells were 
cultured on and allowed to adhere to round glass coverslips (VWR, Radnor, PA) in 24 well flat-
bottom cell culture plates overnight. For J774s, since they are adherent, no coating on the 
coverslips was used. However, for the BMDCs we treated the coverslips with poly D-lysine for 
12 hours before cell culture. The cells were incubated for 15 min, 30 min, 2 hours and 12 hours 
with the labeled Ova solution (20 μg/mL) and the micelle formulation (12.5 μg/mL) consisting of 
labeled PBC, together and separately as controls. For the groups treated with micelle-Ova 
complex, the micelle and Ova solutions were co-incubated for an hour before adding them to the 
cells. The cells were then stained with Hoescht 33342 solution for nuclear staining 
(ThermoFisher Scientific) as described in the commercial protocol. Anti-mouse LAMP-1 
(1D4B) (Developmental Studies Hybridoma Bank, University of Iowa) was used to stain 
lysosomes in BMDCs. The cells were then fixed and the cover slips were mounted on 
microscopic slides (VWR, Radnor, PA). A Leica SB5 X MP confocal microscope was used to 
image the cell samples and the images were analyzed using LAS AF software (Leica 
Microsystems, Wetzlar, Germany).  
 
4.2.9 FRET spectroscopy and microscopy  
AF594 tagged to Ova and AF647 tagged to the PBC (Forster radius, R0= 8.5 nm) acted as 
the donor and acceptor fluorophore, respectively for FRET analysis. Solutions with 12.5 μg/mL 
of PBC micelle formulation and 20 μg/mL of Ova were mixed together or added separately to 






Horiba Jobin Yvon, Kyoto, Japan) with slit width of 3 nm at the excitation of the donor (590 nm) 
and emission wavelengths for the two fluorophores (AF594 Em: 610 nm and AF647 Em: 660 
nm).  
For FRET microscopy, Leica SB5 X MP confocal microscope was used for slides 
prepared in a similar manner as confocal microscopic imaging using the same concentrations of 
the PBC micelle and Ova solutions. However, the settings in the microscope were changed 
according to the procedure used to measure sensitized emission for FRET34, which involves the 
measurement of acceptor emission change with the addition of the donor. The different images 
taken in order were: (a) FRET sample images in the FRET channel (donor excitation and 
acceptor emission), donor channel (donor excitation and donor emission), acceptor channel 
(acceptor excitation and acceptor emission); (b) Acceptor only sample image in the acceptor 
channel; and (c) Donor only sample image in the donor channel. The last two images were taken 
to correct for the spectral bleed-throughs in the channel to subtract the amount of radiation 
detected in the FRET channel which is not due to the energy transfer. The instrument settings 
were kept constant throughout the imaging. The bleed-through was calculated using a linear 
regression obtained by the FRET and colocalization analyzer plugin in ImageJ software (NIH, 
Bethesda, MD). Final FRET index images, heat maps in the “fire” Look-Up Table (LUT) and 
mean FRET indices  were generated by selecting regions of interest (ROIs) in the images where 
cells were present.  
 
4.2.10 In vitro APC stimulation 
BALB/c-derived BMDCs, BMMs, and J774s were plated at 5 x 105 cells/well in a 96-






pen/strep (1 g/100 mL). Stimulations were carried out overnight or for 48 hours using 12.5 
g/mL of micelles, 1 g/mL of LPS, or untreated control wells. Supernatants were collected for 
cytokine analysis and NO quantification, and cells were harvested (using cell scrappers for 
BMMs and J774s) for cell surface maker expression and mitochondrial and cell superoxide 
production by flow cytometry.  
 
4.2.11 Cytokine secretion assay 
The cell-free supernatants collected after stimulating the different cellular populations for 
48 hours were used  to evaluate the levels of cytokine secretions. BioRad BioPlex 200 system 
(Hercules, CA) was used to analyze IL-6, TNF-α, IL-1β, IL-12 and  IFNγ secretions.  
 
4.2.12 Flow cytometry 
Costimulatory marker expression on APCs was evaluated using flow cytometry. BMDCs 
at a concentration of 5 x 105 cells/200 μL were aspirated from a 96 well plate and transferred to 
polystyrene FACS tubes. Prior to labeling with specific monoclonal antibodies, Fc receptors on 
DCs were blocked to prevent non-specific antibody binding by incubating the cells with 100 
µg/mL of rat IgG (Sigma Aldrich, St. Louis, MO) and 10 µg/mL of anti-CD16/32 (eBioscience). 
Subsequently, APCs were stained with fluorescently conjugated antibodies for CD80 (Biolegend, 
PerCP-Cy5.5, clone 16-10A1), CD86 (eBioscience, FITC, clone GL1), CD40 (eBioscience, 
APC, clone 1C10), CD11c (Biolegend, APC-Cy7, clone N418), MHCII (eBioscience, AF700, 
clone M5/114.15.2) diluted at 1:50 v/v in FACS buffer .  
Mitochondrial superoxide production was evaluated using live cells stained with 






amount of reactive oxygen species (ROS) produced by the BMDCs was measured using 
CellROX Green (ThermoFisher Scientific) according to the manufacturer’s protocol.  
Fluorescent activated cell sorting (FACS) was used to quantify the internalization of 
protein and micelles into BMDCs and a macrophage cell line J774. The cells were treated with 
either the labeled Ova (20 μg/mL) or the PBC micelles (12.5 μg/mL) , or the micelle-Ova 
complex obtained after an hour of incubation of the solutions, for multiple time intervals (15 
min, 30 min, 2 hours and12 hours). After the incubation, the cells were transferred to FACS 
tubes and suspended and washed in FACS buffer to remove the excess dye not taken up by the 
cells. All the samples for flow cytometry except the MItoSOX and CellROX samples were fixed 
using BD stabilizing fixative (BD Bioscience, Franklin Lakes, NJ). Data was collected on a 
FACSCanto II (BD Bioscience, Franklin Lakes, NJ), and analyzed using FlowJo (Flowjo LLC, 
Ashland, OR). 
 
4.2.13 Extracellular flux analysis  
Metabolic effect of stimulation of BMDCs was measured using two assays. For 
measurement of oxidative phosphorylation, the oxygen consumption rate (OCR) was analyzed 
by performing an overnight stimulation of BMDCs with either 12.5 µg/mL of PBC micelles, 1 
µg/mL of LPS, or untreated control, was carried out in 5 mL polypropylene tubes. 2.5 x 105 
stimulated BMDCs were seeded into Cell-Tak (Corning, Corning NY) coated Seahorse plates 
and a mitochondrial stress test (MST) was conducted according to manufacturer’s specifications 
using kit concentrations of 1 µM oligomycin, 2 µM FCCP, and 0.5 µM rotenone and antimycin 






For measurement of acute metabolic responses and glycolysis (demonstrated by 
extracellular acidification rate, ECAR) upon stimulation, untreated BMDCs were seeded into 
Cell-Tak (Corning, Corning NY) coated seahorse plates at a density of 2.5 x 105 untreated 
BMDCs per well. Baseline metabolic activity readings were measured, and wells were 
stimulated with 12.5 µg/mL of micelle, 1 µg/mL of LPS, or medium control and metabolic 
measurements are taken over the course of the assay. All metabolic phenotyping was conducted 
on a Seahorse XFe24 (Agilent, Santa Clara, CA). 
 
4.2.14 Nitric oxide quantification 
Nitric oxide (NO) in supernatants obtained from BMDCs, BMMs and J774 cells 
stimulation for 48 hours was quantified using a Griess assay. A sodium nitrite standard curve 
was created with concentrations ranging from 100 µM to 0 µM. 100 µL of Griess reagent (Cat. 
No. 03553, Sigma-Aldrich) was added to 100 µL of standard or sample supernatant in a 96 well 
microtiter plate. Samples were allowed to react for 15 minutes at room temperature and read at 
540 nm on a SpectraMAX 190 (Molecular Devices, Sunnyvale, CA) plate reader. Experimental 
nitrite concentrations were calculated using a linear regression method. 
 
4.2.15 Statistics 
For the antibody titer data, statistical significance was determined using One-way 
ANOVA and Tukey-post t test on the log 2 transformed  titers using GraphPad (Prism 7.0, 
GraphPad Software, La Jolla, CA). For all other experiments, statistical significance was 
determined using one-way ANOVA analysis of the respective values using GraphPad and p-







4.3.1 PBC micelle nanoadjuvant enhances antibody-mediated immunity 
The ATRP method yielded PBC with outer cationic PDEAEM blocks having a molecular 
weight of 14,680 g/mol as determined by 1H NMR. The micelle formulation prepared from PBC 
was administered to mice with Ova to evaluate the induction of humoral immune responses. In 
addition, separate groups of mice were administered either soluble ovalbumin (sOVA), 
alum+Ova or a hydrogel formulation (as used in previous studies), all containing 50 µg of Ova29. 
We observed a nine-fold increase in anti-Ova antibody titers in sera of mice immunized with 
micelles when compared to sOVA at two weeks post-immunization (p.i.) (Figure 4.1).  
This fold-increase was sustained through four weeks p.i. In addition, we observed a 
significant increase in anti-OVA antibody titers in sera of animals immunized with the hydrogel 
formulation over the sOVA, consistent with our previous studies29. However, there were no 
significant differences observed between the micelle and hydrogel formulations, indicating that 
the PBC micelle enhanced humoral immunity even at much lower polymer concentration 
(compared to the hydrogel formulation). This suggests that the thermogelation or depot 
formation of the PBC hydrogel at the site of injection is not the only mechanism of action of this 
adjuvant. We also observed that the antibody titers in the animals immunized with alum+Ova, 
which were not significantly different from the titers induced in the animals immunized with 
PBC micelles at two weeks p.i, became significantly different (about four-fold higher) at four 








4.3.2 PBC micelle nanoadjuvants exhibit cytosolic uptake of antigen by BMDCs and J774 
cells 
To understand the mechanism of the action of these PBC micelles and identify factors 
that may contribute to the enhancement in humoral immunity when immunized with micelles, we 
decided to first probe their interaction with the APCs. Internalization of proteins or peptides by 
the APCs is the first step in the triggering of immune signaling to generate an immune 
response35,36. We studied the internalization of OVA-containing micelles by BMDCs and J774 
cells using confocal microscopy. We observed that the micelles (cyan) and ovalbumin (red) were 
internalized efficiently by both the cell types into the cytosol after a 30 min incubation time and 
stayed the same until the 12-hour incubation time (Figure 4.2, Supplementary Figure 4.2). 
However, we did not observe any internalization at the 15 min time point (Supplementary Figure 
4.2). After 12 hours of incubation, we could observe  antigen in BMDCs co-localized with the 
lysosomes (showed in green, Figure 4.2A).However, most of the antigen was distributed across 
the cytosol indicating antigen release from the micelles.  In addition, due to their amphiphilic 
nature, we also observed a large amount of micelles interacting with the cell membrane, 
especially in the J774 cells starting at 15 min until after 12 hours of incubation. We also analyzed 
the cells that had incorporated micelles using FACS. Almost 100% of the BMDCs and J774 cells 
were positive for the micelles as soon as 15 min and the labeling remained stable for at least 12-
hours as indicated by the clear shifts in the population in the flow cytometry plots 
(Supplementary Figure 4.1). The mean fluorescence intensity (MFI) of the micelle-positive cell 







4.3.3 PBC micelle nanoadjuvants associate with antigen and enhance their uptake 
Next, we assessed the nature of interaction of the PBC micelles with the antigen using 
FRET. We first incubated micelles with Ova labeled with dyes that exhibit FRET in solution 
phase for 15 minutes and studied the fluorescence spectrum of three solutions: (a) micelles only, 
(b) Ova only, and (c) micelles + Ova. FRET occurs if the donor and acceptor fluorophores are 
spatially proximal (less than 10 nm)37. Upon occurrence of FRET, we observed a decrease in the 
intensity of donor fluorescence (at 610 nm for the dye tagged with ovalbumin) and an increase of 
almost the same magnitude in the acceptor intensity (at 660 nm the dye tagged with the micelles) 
when both were in solution together, compared to when they were in solution separately (Figure 
4.3). These observations showed that the micelles associate with the antigen in solution phase.  
We then evaluated whether the same phenomenon occurs in the presence of immune 
cells. We incubated J774 cells and BMDCs with micelles and Ova at different concentrations 
overnight and included micelles-only and Ova-only controls. After removal of spectral bleed-
throughs and analysis of the images as described in the Methods section, we obtained mean 
FRET indices. We observed the highest FRET indices for a polymer concentration of 12.5 
µg/mL and protein concentration of 25 µg/mL (mean FRET index = 16.8 for BMDCs and = 9.6 
for J774 cells, generated using the histograms) as shown in Figures 4.4A and 4.4B. The images 
generated by the FRET analyzer plug-in provided us with an estimate of the degree of FRET 
occurring34. We observed greater FRET (as indicated by the color in the images and the heat 
map) in BMDCs than in J774 cells. We also observed some areas of very high FRET in both cell 
types (indicated by magenta color in the images).  
We hypothesized that the association of the micelles with antigen may assist the antigen 






stimulated with micelles and ovalbumin at the same concentration at which we observed the 
highest FRET. We observed about a two-fold increase in the antigen mean fluorescence intensity 
(MFI) when the BMDCs were incubated with both the micelles and antigen than with the antigen 
alone after 12-hours of incubation (Figure 4C). The amount of antigen delivered to the cells also 
increased from 15 min to 12 hours of incubation and we observed significantly more antigen at 
the 1-hour and 2-hours incubation periods for BMDCs than after 15 min or 30 min of incubation. 
(Supplementary Figure 4.3). We observed a slight (although not significant) increase in antigen 
MFI when J774 cells were used.  
 
4.3.4 APC stimulation by PBC micelle nanoadjuvants 
While these previous experiments provided us valuable information about micelle-
antigen interactions, an understanding of how immune cells perceive the antigen when it is 
adjuvanted with micelles is necessary. The activation of APCs such as DCs is an important part 
of the induction of innate and adaptive immune responses. DCs are activated by recognition of 
damage associated molecular patters (DAMPs) or microbial associated molecular patterns 
(MAMPs), and undergo maturation and upregulate different cell surface markers38,39. To 
characterize the same, we assessed the expression of CD40, CD80, CD86 and MHCII in BMDCs 
and BMMs using flow cytometry when stimulated with PBC micelles for 48 hours. Overall, we 
observed little to no significant upregulation of these markers in BMDCs (Figure 4.5) or BMMs 
(Supplementary Figure 4.4) with PBC micelles, compared to negative controls. The positive 
control, LPS however, induced significantly higher levels of these surface markers, consistent 






We also analyzed the levels of different cytokine secretions by the APCs. The cytokine 
milieu often determines the fate of various immune responses. We did not observe any secretion 
of the pro-inflammatory cytokines, IL-6, TNF-α, IL-1β, IL-12, IFNγ from BMDCs and BMMs 
(Figure 4.5, Supplementary Figure 4.4 and data not shown) in response to the PBC micelle 
formulations. We observed very high levels of pro-inflammatory cytokines secreted by APCs 
stimulated with LPS (Figure 4.5 and Supplementary Figure 4.2). Altogether, these data 
demonstrate the low APC-stimulating characteristics of the PBC micelles unlike traditional TLR-
agonist adjuvants, such as LPS.   
 
4.3.5 Immunometabolic profile of PBC micelle nanoadjuvants 
Recent advances in the field of immunometabolism have described the relationship 
between DC activation and the corresponding metabolic changes41–43. Several hours post-
exposure to TLR ligands, BMDCs exhibit a dramatic shift to a dependence on aerobic glycolysis 
for survival and generation of ATP44. This effect is driven by the nitrosylation of electron 
transport chain (ETC) molecules after production of large amounts of NO as a result of 
encounter with TLR ligands45. As a result, BMDCs exhibit a distinct immediate glycolytic burst 
upon activation with TLR ligands. This provides a rapid and sensitive method to detect whether 
BMDCs were actively recognizing and responding to a particular adjuvant formulation46. Resting 
BMDCs were measured for baseline glycolytic activity and then exposed to LPS, PBC micelle, 
or medium control. Medium acidification rates were recorded as a measure of glycolytic activity. 
Immediately upon exposure to LPS, BMDCs exhibited an increase in glycolytic rate, while 
exposure to the micelle formulation showed levels of glycolysis similar to the control over the 






To evaluate the metabolic consequences of exposure of BMDCs to PBC micelles, we 
probed mitochondrial respiratory function with a mitochondrial stress test (Figure 4.6B). Several 
parameters, such as basal respiration, ATP production, maximum respiration and spare capacity 
were measured using sequential injections of different drugs47. Addition of oligomycin, an 
inhibitor of ATP synthase, complex V, provided the ATP production rate. The addition of FCCP, 
which is a protonophore drives the ETC to function at its maximal rate, provided the maximal 
and spare respiratory capacity of the cells. Addition of rotenone, which shuts down the ETC 
provided the rate of non-mitochondrial respiration to be subtracted. We found that all these 
parameters for BMDCs stimulated with micelles were not different from the control cells, while 
stimulation with LPS led to decreased ATP turnover and decreased respiratory capacity (Figure 
4.6B).  
 
4.3.6 PBC micelles do not induce detrimental ROS and NO production by APCs 
Upon encounter with a pathogen or MAMPs, cells of the innate immune system induce 
the production of antimicrobial innate effector molecules48,49. These largely consist of various 
types of reactive oxygen and reactive nitrogen species. Since little to no upregulation of 
costimulatory molecules or increases in pro-inflammatory cytokine secretion was exhibited in 
response to the PBC micelles, we sought to determine if there was induction of ROS and NO in 
APCs upon encounter with the micelles. NO production was quantified from supernatants 
collected from BMDCs stimulated with micelle, LPS, or unstimulated controls and quantified via 
Griess assay. After 48 hours of stimulation, LPS stimulation resulted in a marked accumulation 
of nitrite in the supernatants while PBC micelle stimulation resulted in no accumulation of nitrite 






Figure 4.5). BMDCs were also analyzed for mitochondrial superoxide and cytosolic ROS 
production. Similar patterns were observed in that LPS induced the production of large amounts 
of both superoxide and cytosolic ROS while stimulation with PBC micelles resulted in no 
measurable increase in the production of these molecules (Figures 4.7B and C). 
 
4.4 Discussion 
Adjuvants have played a major role in enhancing vaccine efficacy1,21,50. The mechanisms 
of action of adjuvants range from creating a depot, induction of inflammation, controlled release 
of antigen, and acting as DAMPs. There has been a significant amount of research on 
synthesizing new adjuvants, understanding their mechanism(s) of action, and improving them for 
different applications51. There are multiple viewpoints on the desirable characteristics of next 
generation vaccine adjuvants51–53. There is a need to design new adjuvants and understand and 
exploit their immunomodulatory properties to specifically suit certain types of host immune 
systems, such as those of older adults and immunocompromised patients. 
In this work, we showed that amphiphilic PBC micelle-based adjuvants can act as 
effective carriers for enhanced delivery of antigens to APCs and induce robust adaptive 
immunity without the production of NO and superoxides linked to the generation of an overt 
inflammation. Hydrogels formed by PDEAEM and Pluronic F127®-based PBCs have been 
previously demonstrated to induce robust antibody responses as vaccine adjuvants and vaccines 
formulated with these materials effectively protected animals against viral challenge29,54. In the 
present work, we demonstrated that immunizing animals (C57BL/6 mice) with PBC micelles, at 
a significantly lower polymer concentration than previously reported55, enhanced anti-Ova 






were still significant at 4 weeks p.i. compared to sOva alone, we observed a slight decrease in 
titers from 2 weeks to 4 weeks p.i. Our hypothesis is that the antigen-containing micelles may 
facilitate crosslinking the B cell receptor (BCR) and provide a rapid and low affinity antibody 
response56,57. This may be beneficial for presentation of the antigen or a co-adjuvant to the 
receptors of immune cells in orientations exposing certain conformational epitopes of the antigen 
to crosslink multiple BCRs and provide an initial high burst of antigen, resulting in rapid 
induction of antibody; however, another adjuvant in combination with the micelles may be 
required for induction of robust long-lasting immunity58. We also observed similar trends in 
enhancement of humoral immunity and improved vaccine efficacy with influenza antigens 2 and 
4 weeks p.i. for PBC micelles alone and in combination with another vaccine adjuvant, 
polyanhydride nanoparticles54. We repeated the experiment with Ova adjuvanted with micelles 
administered to BALB/c mice and observed similar enhancement in antibody responses (data not 
shown).  
From previous studies, we had concluded that both the depot effect formed by hydrogels 
and the outer cationic blocks of the polymer contributed to enhanced antibody titers55. Since the 
PBC micelle concentration used in the present studies do not form a depot at the injection site, 
unlike the hydrogels, we hypothesize that the observed enhancement in humoral immunity may 
be attributed to the association of the antigen and the PBC micelles. There is significant interest 
in designing vaccine carriers to enhance cytosolic uptake of antigens resulting in enhanced 
presentation via the MHC I pathway and induction of CD8+ T cell responses53,59. In this context, 
pH-responsive polycationic gene delivery systems, such as the PBC micelles, are known to 






associated gene using a proton sponge effect15,60. Hence, we studied if these micelles associate 
with antigen in a similar manner and deliver them to the cytosol.  
We observed intracellular localization of the micelles and the associated ovalbumin into 
the cytosol of both BMDCs and J774 cells starting at an incubation period of 30 min and lasting 
until 12 hours (Figure 4.2, Supplementary Figure 4.1 and 4.2 ). Ova is known to be internalized 
after 15 min of incubation with APCs61. However, we did not observe a significant amount of 
internalization by the cells incubated with PBC micelles plus Ova in the first 15 min in either 
BMDCs or J774 cells (Supplementary Figure 4.2 and 4.3). Other studies have shown that 
subsequently increasing amounts of Ova are detected after 15 min in the cytosol due to 
endosomal escape caused by the association with the carrier17. We showed association of Ova 
with the PBC micelles by FRET, in which energy transfer between fluorophores takes place in a 
non-radiative manner when they are separated by a distance referred to as the Forster radius for 
the two dyes (8.5 nm for our fluorophore system)62–64. We observed the transfer of energy from 
donor to acceptor using the spectral emission curve at specific concentrations of the antigen and 
the micelles in solution (Figure 4.3). A similar technique was utilized previously for studying 
complexation of DNA with the PBC micelles37,65. We utilized the same concentrations for 
studying FRET in vitro with APCs using sensitized emission and a confocal microscope. Even 
though we did not calculate the numerical value of FRET efficiency, the FRET index image 
demonstrated the degree of FRET occurring quantitatively. The areas of strong association of the 
micelles with Ova as indicated by the FRET index image (Figure 4.4) within the cytosol 
indicated that the micelles transported the antigen to the cytosol. This hypothesis was supported 
by the FACS analysis, which quantitatively demonstrated enhanced uptake of Ova by BMDCs 






with cells, the amount of Ova internalized steadily increased over 12 hours of incubation. (Figure 
4.4C and Supplementary Figure 4.3). It is also worthwhile to note that we observed both stronger 
association of micelles with Ova and enhanced uptake of Ova in BMDCs than in J774 cells. The 
micelles appeared to be localized more around the cell membranes of the cells. Some studies 
have demonstrated that amphiphilic molecules such as Pluronic can incorporate themselves into 
the lipid bilayer of the membranes and facilitate protein transport across it66,67.  
All these observations have particular relevance to the rational design of vaccine 
formulations for older adults and immunocompromised populations. The current strategy in 
commercial vaccines for older adults (e.g., high dose Fluzone) is to deliver four times the amount 
of vaccine dose as the normal dose. In this context, the ability of the PBC micelles to increase the 
overall antigen internalization can be beneficial for vaccine delivery in older adults68.  
Many adjuvants or immune potentiators, including the licensed adjuvant MPLA, act via 
the engagement of various receptors on innate immune cells and their stimulation, which can be 
measured by the upregulation of cell surface marker expression and cytokine secretion69. 
However, for PBC micelles, as demonstrated in Figure 4.5 and Supplementary Figure 4.2, we did 
not observe any significant upregulation of these markers. Therefore, it appears that these 
micelles do not act as traditional immune stimulants or innate immune cell activators, such as 
TLR ligands. Indeed, the activation of APCs through TLRs may not always be desirable, 
especially when TLR agonists induce excessive NO production, which can cause cellular stress 
and contribute to acute inflammatory state of the immune system49,70,71. Higher amounts of NO 
production by inflammatory immune cells has been linked to lower B cell activation, diminished 
antibody responses, lower class-switching, and generation of more short-lived plasma cells then 






production of NO or any cellular or mitochondrial ROS (Figure 4.7 and Supplementary Figure 
4.3) while still enhancing antibody production (Figure 4.1).  
Finally, an analysis of the metabolic profile of APCs stimulated with the PBC micelles 
demonstrated low mitochondrial stress when compared to LPS (Figure 4.6). Rapid glycolytic 
activity as demonstrated by the TLR agonists in extracellular flux analysis has been reported to 
contribute to inflammation73. In a separate study using cathepsin activity, we have demonstrated 
that micelles do not induce inflammation at the site of injection31. Combined with the glycolytic 
activity of the micelles demonstrated in this work (Figure 4.6), this suggests that a potential 
benefit of micelle adjuvants would be to avoid adverse inflammatory reactions. 
Overall, all these findings demonstrate that these PBC micelles, while not activating 
APCs in a way that traditional TLR agonists do, can still act as effective adjuvants for enhancing 
antibody responses in the context of low inflammation and increasing antigen trafficking into the 
cytosol of APCs. Given the enhanced intracellular localization of antigen in the presence of the 
PBC micelles, this observation is likely beneficial for designing an effective vaccine regimen to 
enhance host immune responses that have impaired APC functionality due to underlying 
inflammation and potentially to induce cytotoxic T cell responses. 
 
4.5 Conclusion 
In this work, we demonstrated that a low concentration of an amphiphilic pentablock 
copolymer that undergoes pH sensitive micellization in aqueous solution can enhance adaptive 
immune responses in mice without forming a gel depot. We showed that the PBC micelles 
associate with antigens and deliver them to the cytosol of APCs. We also demonstrated that these 






evidenced by the lack of co-stimulatory molecule expression, cytokine secretion, induction of 
NO and ROS, and immunometabolic profiles. Therein, we found that PBC micelle-based 
nanoadjuvants do not generate mitochondrial stress and do not create a harmful inflammatory 
environment. These attributes make the PBC micelle adjuvants attractive candidates in the 
design of vaccines for older adults and immunocompromised patients.  
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Figure 4.1. Pentablock copolymer (PBC) micelles enhanced antibody titers in C57BL/6 
mice 2- and 4- weeks post-immunization. Serum collected at 14 and 28 dpi were used to 
evaluate anti-OVA total IgG titers using ELISA. Statistical differences between the treatment 
groups within each time-point were determined using one-way ANOVA and Tukey-post t test on 
the log 2 transforms of the titer dilution values. * indicates p<0.05 and **** indicates p<0.0001. 
Data are representative of two independent experiments with C57BL/6 mice and one 










Figure 4.2. Pentablock copolymer (PBC) micelles efficiently traffic antigen to the cytosol. 
A) Bone marrow derived dendritic cells (BMDCs) and B) J774 cells were incubated with 
micelles and ovalbumin (i.e., antigen) for 12 hours over glass coverslips. Cell components were 
stained following the incubation and cells were fixed and transferred to glass slides for imaging. 
Scale bars indicate 5 μm in A and 50 μm and 5 μm in the first four and last columns of B, 
respectively. Nuclei were stained with Hoescht (blue), lysosomes were stained with anti-LAMP-
1 (green). Ovalbumin antigen (AF594) and PBC micelles (AF647) are denoted by red and cyan, 








Figure 4.3. Pentablock copolymer (PBC) micelles associated with ovalbumin in solution 
phase. Micelles (12.5 mg/mL) and ovalbumin (20 mg/mL) were labelled with AF647 and 
AF594, respectively. The fluorescence spectra were measured for micelles only, ovalbumin only, 
and micelles plus ovalbumin mixtures. Arrows indicate decrease in AF594 (donor) fluorescence 







Figure 4.4. Pentablock copolymer (PBC) micelles associated with ovalbumin intracellularly 
and enhanced the uptake of ovalbumin in BMDCs. FRET microscopic analysis of A) BMDCs 
and B) J774 cells demonstrated strong association of micelles with protein with FRET indices of 
16.8 and 9.6 respectively. Histograms in the far right represent the mean FRET indices with the 
heat map for the ‘fire’ Look-Up Table (LUT) used in the FRET index images. Excitation and 
emission wavelengths (Ex/Em) used to image are: Donor channel: 590 nm/620 nm, Acceptor 
channel: 650 nm/665 nm and FRET channel: 590 nm/665 nm.  C) Ovalbumin uptake was 
increased two-fold when delivered with micelles in BMDCs. Statistical significance was 







Figure 4.5. Pentablock copolymer (PBC) micelles did not activate innate immune cells as 
exhibited by cell surface markers expression and less inflammatory cytokines secretions. A) 
BALB/c-derived BMDCs and B) J774 cells at a concentration of 2.5 ͯ 106 cells/mLwere 
stimulated with different treatment groups (PBC micelles at the concentration of 12.5 μg/mL and 
LPS at 1 μg/mL) for 48 hours. Flow cytometry was used to measure the cell surface marker 
upregulation. Cytokine secretion was evaluated from the supernatants collected after stimulation. 
Data is expressed as mean with standard error of mean. Statistical differences were determined 







Figure 4.6. Treatment of BMDCs with pentablock copolymer (PBC) micelles did not induce 
a glycolytic shift in their metabolic profile. A) Kinetic stimulation test and B) Mitochondrial 
stress test for BMDCs stimulated with different treatment groups (PBC micelles at the 
concentration of 12.5 μg/mL and LPS at 1 μg/mL) was performed overnight using extracellular 
flux analysis . Extracellular acidification rate (ECAR) and oxygen consumption rate (OCR) are 
represented by millipH/min and pmol/min. The figure on top right represents ECAR value at 61 
minutes and figures in the bottom right represent different measures of the mitochondrial 
respiration derived from B as indicated in the text using standard methods. * indicates p<0.02, ** 








Figure 4.7. Pentablock copolymer (PBC) micelle adjuvants did not induce the production of 
NO or ROS by APCs. A) Nitric oxide production by BMDCs, B) BMDC mitochondrial 
superoxide production, and C) Reactive oxygen species production in the BMDC cytosol were 
measured in the supernatants and cells stimulated with the treatment groups (PBC micelles at the 
concentration of 12.5 μg/mL and LPS at 1 μg/mL) for 48 hours using Griess assay and flow 
cytometry. Data is expressed as mean with standard error of mean. Statistical differences were 







Supplementary Figure 4.1. Mean fluorescence intensity (MFI) of micelle-positive  A) BALB/c-
derived BMDCs and B) J774 cells. Cells were stimulated with 12.5 µg/mL of PBC micelles labeled 
with AF647 for multiple lengths of time washed and fixed in FACS buffer. Internalization was 
measured using flow cytometry and the MFI was determined using FlowJo software. A 
representative histogram demonstrating the shift in the cell population treated with micelles 
(shown in gray, solid outline) compared to control (shown in black, dotted outline) is shown for 
C) BMDCs and D) J774 cells after 12-hour (720 min) incubation. Data representative of three 







Supplementary Figure 4.2. Trafficking of antigen into A) BALB/c-derived BMDCs and B) 
J774 cells incubated for 15 min with pentablock copolymer (PBC) micelles (12.5 µg/mL) and 
antigen (20 μg/mL); C) BMDCs and D) J774 cells incubated for 2 hours with PBC micelles-
antigen complex. Cells seeded at a concentration of 2.5 ͯ 106 cells/mL on glass coverslips were 
incubated with the micelles and ovalbumin for the required amount of time. Scale bars indicate 
A)  50 μm and B), C) and D) 5 μm. Nuclei were stained with Hoescht (blue). Ovalbumin antigen 
(AF594) and PBC micelles (AF647) are denoted by red and cyan, respectively. Data are 






Supplementary Figure 4.3. Time-course of the ovalbumin cellular uptake when incubated with 
pentablock copolymer (PBC) micelles for A) BMDCs and B) J774 cells. The cells were  
incubated with the micelle-Ova complexes, micelle formulation, Ova (ie. protein) alone and 
unstimulated control for the indicated times and mean fluorescence intensity (MFI), based on 
Ova uptake, was calculated using FlowJo software. Data represented as mean of triplicates with 








Supplementary Figure 4.4. Pentablock copolymer (PBC) micelles did not show significant 
upregulation of costimulatory molecules in bone marrow macrophages and did not induce pro-
inflammatory cytokine secretion. BMMs at a concentration of 2.5 ͯ 106 cells/mL were stimulated 
for 48 hours with micelle or LPS (PBC micelles at the concentration of 12.5 μg/mL and LPS at 1 
μg/mL) . Cell surface markers, MHCII, CD80 and CD40 upregulation were analyzed using flow 
cytometry and cytokine secretion in supernatants were analyzed using Multiplex bead assay. 
Data represented as mean with standard error of mean. Statistical significance indicated by 







Supplementary Figure 4.5. PBC micelle adjuvants do not induce nitric oxide in J774 cells and 
bone marrow macrophages. Cells were stimulated with micelles and controls for 48 hours. 
Supernatants were collected to analyze NO production using Griess assay. Data represented as 
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Abstract 
Host antibody responses are pivotal for providing protection against infectious diseases. 
Design of vaccine adjuvants, therefore, have primarily focused on augmenting antibody 
responses. Self-assembling micelles based on pentablock copolymers (PBC) have been 
previously shown to enhance antibody responses in vivo while providing a safer and low 
inflammatory adjuvant platform than traditional adjuvants such as alum or lipopolysaccharides. 
This type of immune response is especially important for certain vaccine applications, such as 
vaccines for older adults. Here, we report that the mechanism of enhancement of antibody 
responses by PBC micelles is by activation of B cells via cross-linking of B cell receptors. These 
PBC micelles act as scaffolds for antigen presentation to B cells leading to the generation of 
antibodies not just in vivo, but also in vitro. We have also shown that any block copolymers that 
form micelles do not display this mechanism of action involving B cell receptor crosslinking , 
indicating that tailor-made design of adjuvant(s) is required,  as opposed to being able to use an 







Varying demographics of the population, leading to variability in the host immune 
responses to vaccines, and emerging pathogens pose serious threats to global health. Efficient 
preventive measures for such threats require creative solutions, such as better approaches for the 
design of vaccine adjuvants. One such approach is the use of vaccine adjuvant(s) specifically 
designed to accommodate the needs of an application. In this context, understanding how an 
adjuvant works to enhance a certain arm of the immune system is important. Given that a robust 
B cell response is crucial for providing protection against many infectious diseases 1–4, 
mechanistic studies exploring the interaction of adjuvants with B cells have important 
implications for both existing and new vaccine adjuvants. 
Self-assembly driven micellar systems of many sizes and chemistries have been 
extensively used for drug and vaccine delivery 5. Their small sizes (usually <100 nm), flexibility 
for functionalization, and their ability to deliver antigens to the draining lymph nodes and 
antigen presenting cells (APCs), are among some of the properties that make them  promising 
platforms for vaccine adjuvants. 
Pluronic® F127, a triblock copolymer that undergoes temperature responsive 
micellization, has been approved by FDA for drug delivery applications6. Amphiphilic 
pentablock copolymers (PBC) based on Pluronic® F127 and cationic blocks of 
poly(diethylaminoethylmethacrylate) (PDEAEM) as the two end groups, can undergo both 
temperature and pH-responsive self-assembly to form micelles above the critical micellar 
concentration (CMC) 7. These PBC micelles have been shown to associate with antigens (Ag) to 
form PBC micelle-Ag complexes and increase antigen delivery to the antigen presenting cells 






antibody responses in mice. However, the underlying mechanism of action of these PBC 
micelles in the context of B cells is unknown. In addition, from those previous studies, we have 
found that they neither activate APCs nor lead to the induction of innate effector molecules, 
nitric oxide, reactive oxygen species and pro-inflammatory cytokines. This enhancement in 
humoral immune response while inducing less inflammation is especially beneficial for vaccine 
design for older adults 9,10. Traditional adjuvants such as toll-like receptor (TLR) agonists, alum 
and MF59  induce deleterious inflammatory responses along with the increase in the antibody 
responses, which might not be suitable for those applications 11–14.  
There are several reports in the literature focusing on many different micelle-based 
adjuvants 15–19. The immune-enhancing characteristics of many of these micellar adjuvants are 
similar to the aforementioned traditional adjuvants and in contrast to the PBC micelles- they 
activate APCs, induce the secretion of pro-inflammatory cytokines and lead to antibody 
responses with kinetics similar to that of the traditional adjuvants 20–23. This dissimilarity in 
characteristics of the immune response generated by the PBC micelles and traditional adjuvants 
might be a result of the differences in the material properties and mechanisms involved.  
In this work, we summarize our efforts on exploring the underlying mechanism behind 
the B cell responses induced by PBC micelles and some key material properties contributing to 
it. First, we explored the differences in in vivo antibody responses generated by either PBC 
micelles or by a traditional adjuvant, monophosphoryl lipid A (MPLA). On account of these 
differences in immune-enhancing mechanisms by different types of adjuvants, we endorse the 
use of a combination of adjuvants to achieve a synergistic augmentation in the efficacy of 
vaccines suited for the application. We have previously reported a combination of these PBC 






24.  Next, we propose and demonstrate that it is the cross-linking of B cell receptors (BCRs) by 
PBC micelles that leads to B cell activation. For this, we utilized Nur77 antibody which is 
expressed on B cells only upon antigen-receptor engagement25. After confirming the engagement 
of BCRs with the PBC micelle-Ag complexes, we explored the cross-linking induced- B cell 
proliferation in vitro by PBC micelle-Ag complexes, leading to the production of antigen-
specific antibodies. Lastly, we explored if this cross-linking of BCRs by PBC micelles could be 
exploited for in vitro production of antibodies specific to antigens of a diverse array of pathogens 
such as recombinant fusion protein consisting of fraction 1 & variable antigen from Yersinia 
pestis (F1-V) and Spike protein from SARS-CoV-2. 
 
5.2 Materials and Methods 
5.2.1 Materials 
N,N-(diethylamino)ethyl methacrylate (DEAEM), Pluronic® F127, and hen egg white 
lysozyme (HEL), IgG from rat serum, Triton X-100 were purchased from Sigma-Aldrich (St. 
Louis, MO). Goat anti-mouse IgM F(ab’)2 fragment, goat anti-mouse IgM Fab fragment and 
alkaline-phosphatase-conjugated anti-mouse IgM were purchased from Jackson 
ImmunoResearch Laboratories, Inc. (West Grove, PA). Endotoxin-free ovalbumin (OVA) was 
purchased from InVivogen (San Diego, CA). Y. pestis fusion protein F1-V (NR-4526) was 
obtained from the Biodefense and Emerging Infections Repository (Manassas). Antibodies for 
flow cytometry (PE anti-mouse CD19, APC/Cy7 anti-mouse B220, Zombie Aqua viability kit, 
PE-Cy7 anti-mouse Nur77 and PerCp-Cy5.5 anti-mouse CD3, anti-CD16/32) and purified anti-






was purchased from BD Bioscience (Franklin Lakes, NJ). All other chemicals and materials 
were purchased from Fisher Scientific (Pittsburgh, PA).  
 
5.2.2 Pentablock copolymer micelle synthesis and characterization 
The pentablock copolymer (PBC) was synthesized by atom transfer radical 
polymerization (ATRP) process as previously reported26. This involves the formation of a 
difunctional macroinitiator from Pluronic® F127 as the first step. Next, the macroinitiator and 
the monomer, DEAEM are reacted utilizing copper (I) oxide nanoparticles as the catalyst and N-
propylpyrilidinemethanamine (NPPM) as the complexing ligand. The molecular weight of the 
resulting PBC was determined using 1H NMR. For the micelle formulation, a stock solution of 
50 mg/mL total polymer concentration (either PBC or Pluronic® F127) was prepared in 
phosphate-buffered saline. The stock solution was diluted to the required concentrations and 
mixed with the antigens prior to stimulation of cells. For characterizing the size, zeta potential 
and CMC of PBC and Pluronic® F127 micelles, dynamic light scattering was used in Zetasizer 
Nano S (Malvern PANalytical, Westborough, MA). 
 
5.2.3 Animals 
Female BALB/c and C57BL/6 mice (6-8-week old or 20-22 months old) and C57BL/6-
Tg(IghelMD4)4Ccg/J mice (6 weeks old) were purchased from Jackson Laboratory (Bar Harbor, 
ME). The Institutional Animal Care and Use Committee (IACUC) at Iowa State University 







5.2.4 Immunization and serum collection 
To evaluate antibody responses, C57BL/6 mice were subcutaneously immunized with 
100 µL of the PBC micelle (5 mg per dose) formulation or MPLA (10 µg per dose) formulation, 
or MPLA and PBC micelle formulation with either HEL or OVA antigen (50 µg). Control 
animals were immunized with soluble HEL or OVA in PBS (50 µg in 100 µL) (i.e., no 
adjuvant). Serum samples were collected via the saphenous vein at 2-, 4-, 6-, 8- and 10-weeks 
post-immunization. 
 
5.2.5 Tissue isolation and cell culture 
A cell suspension from the spleens of mice (BALB/c and C57BL/6) collected after 
euthanasia was prepared using a hand-held tissue homogenizer. The tissue culture media used 
consisted of RPMI 1640, 1% (1 g/mL) pen/strep and 10% fetal bovine serum. Lysis was 
performed to remove erythrocytes from the cell suspension and the resulting splenocytes were 
washed with media before counting the cells. One set of splenocytes was labeled with 
carboxyfluorescein succinimidyl ester (CFSE) for analyzing cell proliferation post-stimulation. 
The cells were stained with CFSE on day 0 after isolation from spleens using standard procedure 
and stimulated with different treatment groups for 4-5 days. 
After stimulation, cells were stained with antibodies for flow cytometry. The other set of 
splenocytes was directly used for stimulation and collection of supernatants 10 days post-
stimulation. For the plating, the splenocytes (with or without CFSE stains) were plated in 96-well 
U-bottom tissue culture plates at the density of 5 x 105 cells/well with 200 L of media in each 







5.2.6 Flow cytometry 
B cell proliferation was detected using in vitro labeling of cells with CFSE and analysis 
by flow cytometry. Distinct generations of proliferating cells can be monitored by dilutions of 
CFSE stain on the cells as viewed on the flow cytometry plots. For the flow cytometry 
procedure, the cells were transferred into polystyrene FACS tubes and labelled with Zombie 
Aqua dye for tracking viable cells post-stimulation using manufacturer’s instructions. Next, Fc 
receptors on the cells were blocked using 100 µg/mL of rat IgG and 10 µg/mL of anti-CD16/32 
and stained with specific antibodies for surface markers (CD19, CD3 and B220) to detect the B 
cells in the splenocytes. For intracellular staining of Nur77 antibody, following surface staining, 
cells were washed with PBS and then fixed with 4% p-formaldehyde. After washing the cells 
again with PBS, 0.1% Triton X-100 was used for permeabilization, following that, Nur77 Ab at a 
1:50 dilution was used to stain the cells. After all the staining, cells were washed in FACS buffer 
to remove excess dye and samples were fixed prior to analysis. The flow cytometry data was 
collected on FACSCanto II (BD Bioscience, NJ) and analyzed using FlowJo (FlowJo LLC, 
Ashland, CA). 
 
5.2.7 Cytokine analysis 
The cell-free supernatants were collected after 10 days of stimulation by centrifuging the 
culture plates to let the cells form a pellet at the bottom of the wells. These supernatants were 
used to measure the level of cytokine, TNFα. BioRad BioPlex 200 system (Hercules, CA) was 







5.2.8 Evaluation of antibody titers 
The antibody (Ab) levels in the sera collected from immunized animals at various time-
points and in the cell-free supernatants after 10 days of in vitro stimulation with various 
treatment groups were measured using enzyme-linked immunosorbent assay (ELISA). Briefly, 
high-binding 96-well plates were coated with antigens (HEL or OVA or F1-V), blocked with 2% 
w/v of gelatin in 0.05% Tween-PBS solution. Sera samples were added to the plates starting at 
1:200 dilution and then diluted 1:2 across the plate. Supernatants samples were added to the 
plates at a starting dilution of 1:3 and then diluted 1:3 across the plate. Alkaline-phosphatase-
conjugated anti-mouse IgM or anti-mouse Ig(G+M) were used as the secondary Ab. The plates 
were read at 405 nm after adding the substrate and the titer was recorded as the last dilution that 
exhibited an optical density value greater than twice the background optical density. 
 
5.2.9 Statistical Analysis 
All the data was analyzed using GraphPad Prism 8 software for statistical significance. 
For Fig. 1-4, one-way analysis of variance (ANOVA) was used followed by Tukey’s post-hoc 
test for multiple comparisons. For Fig.5, Kruskal Wallis and Mann Whitney tests were used to 
determine statistical significance. 
 
5.3 Results 
5.3.1 Material characterization 
The purity and molecular weight of the synthesized pentablock copolymer was 
determined using 1H NMR. The spectrum showed various characteristics peaks (Supplementary 
Fig. 1A and B) consistent with our previous work 26 and the average molecular weight was 






determined using dynamic light scattering (DLS) was 30.4 nm (±2.7 nm), the zeta potential value 
was +5.82 mV (±0.89 mV) with a CMC of about 0.3 μg/mL. The mean diameter of Pluronic® 
F127 micelles was found to be 27.1 (±3.2 nm) and the zeta potential value was -0.30 mV (±0.17 
mV) consistent with literature values 27,28.  
 
5.3.2 Kinetics of in-vivo Ab responses with PBC micelles and synergistic responses with 
traditional adjuvants 
We had previously analyzed the antibody responses in mice immunized with PBC 
micelles and ovalbumin (Ova) up to 4 weeks post-immunization and had found the enhancement 
in response to be rapid but short-term. Since we did not observe APC activation with PBC 
micelles, we hypothesized that the response predominantly consisted of IgM antibodies due to 
the lack of T cell help. Hence, we studied the nature and kinetics of in vivo antibody responses 
until 10 weeks post-immunization using two model antigens-Ova and hen-egg white lysozyme 
(HEL) (Fig. 1A). We compared the response of PBC micelles to that of a traditional adjuvant, 
MPLA. Mice immunized with PBC Micelle-HEL exhibited significantly higher anti-HEL serum 
Ab titers 2- and 4-weeks post-immunization (p.i.), compared to mice immunized with soluble 
HEL (Fig. 1B). However, upon investigating the serum anti-IgM response at the same time-
points, we found that the Ab response consisted of predominantly anti-IgM antibodies (Fig. 1C). 
The anti-HEL Ig(G+M) titer induced by PBC micelle-HEL was not significant from that induced 
by soluble HEL at 8- and 10-weeks p.i. Hence, the kinetics of the Ab response to PBC micelle-
HEL showed the onset of rapid and high titers at early time-points but waning without providing 
long-term (week 6 and week 8) enhancement in Ab responses, compared to soluble HEL. In 
contrast, mice immunized with a traditional adjuvant, monophosphoryl lipid A (MPLA)+HEL, 






time-point, but exhibited predominantly anti-HEL IgG antibody response peaking at week 4 p.i. 
with low levels of IgM response (Fig. 1B and C). Interestingly, immunization using a 
combination of PBC micelles and MPLA with HEL led to a synergistic enhancement in the Ab 
responses compared to soluble HEL alone at all the time-points p.i. with the response being 
predominantly IgM at early time-points and class-switching to IgG at later time-points (after 
week 4). The Ab isotype and kinetics of the response was found to be similar for another 
antigen-OVA, although immunization with OVA had better antibody responses overall, 
especially, for the mice immunized with a combination of PBC micelles and MPLA (Fig. 1D and 
E).  
 
5.3.3 PBC micelle-Ag engagement with BCRs  
We explored the underlying mechanism of B cell activation that leads to the observed in 
vivo responses in mice immunized with PBC micelle-Ag. From our previous studies we had 
determined that the PBC micelles associate with antigens. Hence to gauge the engagement of 
PBC micelle-Ag complexes with the BCRs, analysis of endogenous Nur77 protein expression in 
B cells stimulated with PBC micelle-Ag was performed and compared with TLR4 agonist, LPS 
and micelles of another type of block copolymer, Pluronic® F127. Nur77 is a well-studied 
specific marker for Ag-receptor signaling for both B and T cells in mice and humans and reflects 
the receptor signaling strengths 25,29. We found that Nur77 was induced in murine splenic B cells 
(CD19+) upon stimulation with PBC micelle-Ag complexes at levels similar to anti-IgM F(ab’)2 
stimulation (Fig. 2A).  The Nur77 induction was also studied at different time-points of 
stimulation. Although 2 hours post-stimulation the Nur77 induction for PBC micelle-Ag group 






post-stimulation for both the groups, which declined to basal levels by 24 hours post-stimulation. 
Similar kinetics have been observed in the literature for Nur77 induction 30. In contrast, 
lipopolysaccharide (LPS), a TLR-4 agonist did not trigger Nur77 induction, consistent with the 
literature 30 (Fig. 2B). Cells stimulated with Pluronic® F127 micelle-Ag were also tested and 
failed to effectively induce Nur77, indicating the non-engagement of BCRs with these micelles. 
5.3.4 B cell activation via cross-linking of BCR with PBC micelles 
The predominantly IgM antibody response generated by PBC micelles in vivo, non-
activation of APCs and the engagement of PBC micelle-Ag with BCRs led us to explore B cell 
activation by cross-linking of BCRs. To test our hypothesis, B cell proliferation from splenic 
cells isolated from C57BL/6 wild-type (WT) mice was investigated by using carboxyfluorescein 
diacetate succinimidyl ester (CFSE) proliferation assay 31. To demonstrate BCR cross-linking, 
anti-IgM F(ab) fragments were used with or without PBC micelles to stimulate the splenic cells. 
Anti-IgM F(ab’)2 (10 μg/mL) was used as the positive control for the experiment. Anti-CD40 (5 
μg/mL) was added to all treatment groups except unstimulated medium only control, to provide a 
costimulatory signal. The schematic of the experiment is shown in the upper panel of Fig. 3A. 
The total viable B cell population (Zombie Aqua-CD3-CD19+B220+) was found to be lower for 
the cells stimulated with F(ab) fragments alone (10 μg/mL), PBC micelle alone (10 μg/mL) and 
unstimulated controls (medium only) compared to the cells stimulated with either F(ab’)2 or PBC 
micelle-F(ab) groups, indicating that only these two stimulation groups provided the required 
survival signal to B cells (Supplementary Fig 2A).  
Investigating the CFSE expression in the B cells, we found multiple proliferation peaks 
(CFSElo) corresponding to daughter populations for the cells stimulated with either F(ab’)2 or 






F(ab) fragments alone or PBC micelle alone (has CFSEhi parent peak only). It was noteworthy 
that for the PBC micelle-F(ab) treatment group, provision of anti-CD40 signal was not required 
for B cell activation and proliferation. However, we observed relatively higher number of viable 
B cells when anti-CD40 was present (Supplementary Fig. 2B). The percentage of B cells that 
proliferated was found to be similar for F(ab’)2 and PBC micelle-F(ab) groups at 80-90% (Fig. 
3B). We also tested and observed the same effect with B cells isolated from spleens of aged WT 
mice as well (Fig. 3C). As an additional measure of B cell activation and proliferation, we 
measured the concentration of the cytokine, TNFα in the supernatant of the cells stimulated with 
various groups for 10 days, since TNFα  has been reported to be produced by B cells after T- 
independent BCR cross-linking 32. Cells stimulated with either F(ab’)2 or with the PBC micelle-
F(ab) groups showed significantly higher levels of the cytokine than those stimulated with either 
F(ab) or PBC micelle or unstimulated controls (Fig. 3D). 
Furthermore, the B cell cross-linking- induced proliferation was investigated for various 
concentrations of PBC micelle-F(ab) and proliferation was observed for as low as 1 μg/mL of 
PBC micelles (Supplementary Fig. 2C). Interestingly, the effect was not observed for PBC 
unimers (concentration at 0.1 μg/mL- below the CMC for PBC), or for Pluronic® F127micelles 
at 10 μg/mL (Supplementary Fig. 2D), indicating that polymer properties such as chemistry, and 
the micellar phase are pivotal for this cross-linking.  
 
5.3.5 Ag-specific B cell proliferation with PBC micelle-Ag complexes 
To investigate if the cross-linking of BCRs applies for PBC micelle-Ag complexes, a 
similar experiment was performed where splenic cells from WT mice (both Balb/c and 






(Fig. 4A). Both model antigens (HEL and Ova) used for the study showed similar results. Clear 
distinction was observed between the total number of viable B cells when stimulated with Ag 
alone vs with PBC micelle (Supplementary Fig. 3A). In terms of B cell proliferation, 
significantly higher percentage of proliferation with multiple daughter peaks (CFSElo) was 
observed after stimulation with PBC micelle-Ag compared to Ag alone (Fig. 4A and B). The 
concentration of the cytokine TNFα was also significantly higher in supernatants of the cells 
stimulated with PB micelle-Ag, compared to Ag alone (Fig. 4C). Next, we analyzed if these 
proliferated B cells secreted antigen-specific antibodies. We measured anti-IgM titers in the 
supernatants of the cells post 10 days of stimulation with different antigens with or without PBC 
micelles. We observed significantly higher levels of anti-HEL or anti-OVA titers when 
stimulated along with the micelles, compared to the antigen-only stimulation (Fig. 4D and E). 
The supernatant samples from cells stimulated with all the antigen groups were analyzed for 
antigen-specific IgM. The titers for non-specific antibodies with PBC micelle-Ag group were 
found to be negligible. We used anti-F(ab’)2 again for stimulation of the cells and observed B 
cell proliferation significantly higher than for PBC micelle-Ag complexes; however the antigen 
specific antibody response indicated that these B cells were producing a low level of non-specific 
antibodies, insignificant to the medium-only control group. Similar to the PBC micelle-F(ab) 
stimulation, provision of anti-CD40 signal was not required for B cell activation and 
proliferation with PBC micelle-Ag; however, it was required for Ab production (Supplementary 
Fig. 3B). Again, no significant B cell proliferation was observed for cells stimulated with 
antigens either in combination with PBC unimers, or with Pluronic® F127 micelle sat 10 μg/mL 






5.3.6 PBC micelle as scaffold for Ag presentation to B cells  
We sought to investigate the proliferation of B cells with PBC micelle-Ag in a transgenic 
(Ighel Tg) mouse model 33. These mice have majority of BCRs on splenic B cells specific to 
HEL. Our hypothesis was that due to this increase in Ag-specific BCR repertoire, there would be 
increased PBC micelle-Ag-BCR engagement and hence, increased B cell proliferation 
(compared to WT mice). Splenic cells isolated from these mice were cultured and stained with 
CFSE on day 0, following which, they were stimulated with HEL (10 μg/mL), PBC micelle (10 
μg/mL) or with PBC Micelle-HEL. At least five proliferation peaks (CFSElo) for the 
corresponding daughter populations (Fig. 5A) were observed for the B cells stimulated with PBC 
Micelle-HEL. The viable B cell population post 4 days of stimulation was also the greatest for 
this group (Supplementary Fig. 4A). We did observe a small peak with some proliferated cells 
with the HEL or PBC micelle-only groups that were similar to the unstimulated controls. The 
percent proliferated B cells were at about 80% with this Tg mouse model (compared to about 
40% for WT mice) (Fig. 5B and 4B), supporting our hypothesis. We measured the 
concentrations of TNFα and anti-HEL IgM in the supernatants and found significantly higher 
levels of the antibody and cytokines from cells stimulated with PBC micelle-HEL, compared to 
HEL (Fig. 5C and D). The anti-HEL IgM titers in supernatants of cells stimulated with PBC 
micelle-HEL for this Tg mouse model was found to be about 2.5 times higher than that from the 
WT mice, correlating with the higher proliferation (Fig 4B and D, 5B and C). A surprising 
finding was that, even though most B cells from the Tg mice were HEL specific, we observed 
similar levels of B cell proliferation with PBC micelles-OVA and PBC micelle-bovine serum 
albumin (BSA) (Fig. 5B). But, from the anti-HEL IgM measurements in the supernatants, we 






BSA similar to PBC micelle-HEL (Fig. 5C). From searching in the immune epitope database (a 
free resource funded by NIAID), we did not find any B cell epitopes that are common between 
HEL, OVA and BSA, which could have led to the activation of HEL- specific B cells upon 
stimulation with OVA or BSA. Our hypothesis is that the PBC micelles must be acting as a 
scaffold for the antigens that are able to stimulate the B cells and lead to the generation of 
antigen-specific antibodies. In contrast, stimulation with Pluronic® F127 micelle + HEL or PBC 
unimers + HEL did not lead to B cell proliferation (Supplementary Fig. 4C). 
 
5.3.7 In-vitro antibody production by PBC micelle-Ag complexes 
 Since we observed anti-IgM antibodies in the supernatants of the B cells stimulated with 
the PBC micelle-Ag groups for the model antigens, we sought to determine if the same holds 
true for antigens of pathogens and if the PBC micelles could be used as a platform for the 
production of antibodies in vitro. We used the Spike protein from the novel SARS-CoV-2 and 
recombinant fusion protein, F1-V from Yersinia Pestis to test the same. We also evaluated B cell 
proliferation using CFSE similar to previous experiments and observed results consistent with 
the experiments with the model antigens, where PBC micelle-Ag groups exhibited daughter cell 
populations but Ag only or with Pluronic® F127 micelle + Ag or PBC unimers + Ag groups did 
not (Fig. 6A, B, D and E). As a result, in the supernatants of the cell culture, we observed anti-
Spike IgM or anti-F1-V IgM for only the cells stimulated with PBC micelle-Ag (Fig. 6C and F) 
with the respective antigens. Even though we observed proliferation in the cells stimulated with 
anti-IgM F(ab)2 , we  did not observe antigen-specific antibodies in the supernatants of these 






molecules such as anti-CD40, to provide a co-stimulatory signal, could serve as a novel method 
for efficient production of antigen-specific antibodies. 
 
5.4 Discussion 
Host immune response generated towards a vaccine is very complex and diverse in 
nature, with the B cell response being an essential contributor towards conferring protective 
immunity. Hence, the design of vaccine adjuvants has largely been geared towards improving the 
B cell and antibody responses 34. Understanding the mechanisms of B cell activation by 
adjuvants that drive such protective antibody responses are subjects of thorough research and 
have implications for healthcare worldwide.  
However, the mechanism underlying B cell activation by polymeric micelle adjuvants is 
relatively unknown. In this study, we used our cationic PBC micelle adjuvants to explore the 
same. While pursuing this, interestingly, we also found that the same mechanism does not apply 
to all types of micelle adjuvants and hence calls for the use of the appropriate adjuvant chemistry 
for a given application instead of following the one-size-fit-for-all approach.  
The enhancement in the in vivo antibody response provided by the PBC micelles 
compared to the soluble antigen only, was found to be atypical of that provided by a traditional 
adjuvant such as MPLA (Fig. 1). Although, immunization with both PBC micelle and MPLA 
provided a synergistic enhancement in the Ab response, in addition to the IgM production due to 
the cross-linking of BCRs by the PBC micelles, MPLA facilitates immunoglobulin isotype 
switching. Hence, utilizing a combination of vaccine adjuvants might be beneficial since both Ab 






It is well known that, unlike T cells, B cells can recognize antigen in its native form and 
their activation can be mediated in a T cell-independent manner 35. This process involves the 
cross-linking of the BCRs by repetitive antigen epitopes. The results from our study demonstrate 
that the PBC micelles that have been shown previously to associate with antigens 8 can cross-link 
the BCRs leading to B cell activation. We first studied the interaction of the PBC micelle-Ag 
complexes with the BCRs by analyzing Nur77 expression. Nur77/NR4A1 belongs to a subfamily 
of orphan nuclear receptors (NR) known as NR4A (encoded in the Nr4a1-3 gene) 29. It has come 
to be known for its role in important cell survival and inflammatory signaling events. Nur77 
expression has been shown to be rapidly induced due to Ag receptor signaling in B lymphocytes 
36. The engagement of BCRs with PBC micelle-Ag complexes led to the induction of a strong 
BCR signal that was similar to that induced by anti-IgM F(ab’)2 (Fig. 2). Other micelles such as 
the non-ionic Pluronic® F127 or PBC unimers did not exhibit Nur77 expression, as a first 
indication in support of our hypothesis that the material properties, chemistry and ability to form 
micelles, play a crucial role in the interaction with antigens and the BCRs. 
As a proof-of-concept experiment demonstrating BCR cross-linking with PBC micelle, 
we utilized anti-IgM F(ab’)2 and anti-IgM F(ab) fragments. The earliest report of the cross-link 
model of B cell activation had also utilized these and showed that the monomeric F(ab) 
fragments do not activate B cells, whereas the dimeric F(ab’)2 did 
37. From our study, we 
concluded the same and that the monomeric F(ab) fragments when used along with the PBC 
micelle for stimulation of splenic cells, led to the induction of B cell survival and proliferation 
signals (Fig. 3).  
We demonstrate with two model antigens that the presence of PBC micelles with an 






alone, owing to the cross-linking of BCRs (Fig. 4). The epitope density of antigens has been 
previously linked with antigen recognition and the efficiency of B cell response 38,39. There have 
also been reports of engineered synthetic particles that can exhibit repetitive orientation of 
antigens 40. The PBC micelles by virtue of their association with antigens might be orienting 
them to create repetitive, high epitope density to cross-link BCRs. Furthermore, use of vaccine 
adjuvants that create similar multivalent display of antigens have shown to lead to a balanced 
Th1/Th2 response 41. This might be specifically beneficial for vaccine adjuvant design for older 
adults against respiratory pathogens that induce Th2 response-mediated inflammatory lung 
pathology 42,43.  
In addition to increasing the valency of antigens by using PBC micelles, we showed that 
the recognition of PBC micelle-antigen complexes by BCRs is also proportional to number of 
antigen-specific BCRs repertoire, using a transgenic mouse model with splenic cells consisting 
of HEL-specific BCRs. Greater B cell proliferation was accompanied by higher antibody 
secretions from B cells from these Tg mice compared to WT mice (Fig. 5). Interestingly, these 
HEL-specific B cells stimulated with either OVA or BSA with the PBC micelles induced cell 
proliferation and anti-HEL IgM production. Since, these antigens do not share any known B cell 
epitope, the PBC micelle must be acting as a framework/scaffold to present the epitopes to the 
BCRs in a way that is recognized and generates signal for activation. Similar idea of utilizing 
self-assembled materials to act as scaffolds in applications for vaccines and drug delivery has 
been reported before 44.  
We also demonstrated that this type of B cell activation by PBC micelles can prove to be 
beneficial in the context of providing an efficient and fast method for production of antibodies in 






and can prove to be effective therapy for new and emerging diseases 45,46.  Antigen-specific 
antibodies that bind to the antigen of a virus ( Spike protein from SARS-CoV-2) and a bacterium 
(F1-V from Y. pestis) were found to be produced in the supernatants of the cells stimulated with 
PBC micelles-Ag complexes, indicating the versatility of this platform (Fig. 6).  
It is noteworthy that the presence of anti-CD40 was not required for inducing B cell 
proliferation; however, we observed greater degree of proliferation with anti-CD40 and its 
addition was a requirement for the production of Abs (Supplementary Fig. 2B, 3B and 4B). This 
is consistent with reports in the literature showing that the engagement of both the BCR and 
CD40 leads to a synergistic activation of B cells through distinct cellular pathways and the 
costimulatory signal is required for forming an efficient synapse 47,48. According to another 
report, maximal B cell proliferation can be achieved without anti-CD40 signal (T cell help); 
however they failed to differentiate into antibody-producing cells (plasma cells) 49. 
Lastly, but more importantly, our studies showed that cross-linking of BCRs is neither 
induced by using only polymeric strands that have not formed micelles (PBC unimers below 
CMC) nor by all self-assembled micelles (such as non-ionic Pluronic® F127). Even though 
Pluronic® F127 triblock copolymer is a part of the PBC, and forms micelles of the same size, it 
appears that the outer cationic blocks of PDEAEM in the PBC contribute greatly towards this 
cross-linking effect.  
In summary, The PBC micelles provide a promising platform not only for vaccine 
adjuvants but also for the production of antibodies which could be used as therapeutic. For 
vaccine applications, a combination of vaccine adjuvants is required for generating an optimal 
immune response which calls for recognizing the mechanism of action of these adjuvants. 






implicates the cross-linking-induced B cell activation to be a potential mechanism of action for 
PBC micelle adjuvants. Whether other similar micelle-based adjuvants have the potential to 
generate BCR cross-linking and enhance B cell activation, that remains to be seen.  
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Figure 5.1. In vivo antibody responses for PBC micelle adjuvants
 
(A) Schematic of the in vivo experiment for subcutaneous immunization (nape of neck) of mice 
with PBC micelle (5 mg/100 μL dose), or monophosphoryl lipid A (MPLA, 10 μg/100 μL dose), 
or a combination of PBC micelle and MPLA, with either HEL or OVA (50 μg/dose). (B) anti-
HEL Ig(G+M), (C) anti-HEL IgM, (D) anti-OVA Ig(G+M) and (E) anti-OVA IgM antibody 
titers in sera collected from saphenous vein bleeds from mice 2-, 4-, 6-, 8- and 10-weeks post-
immunization. Data are represented as mean ± SEM. Data were analyzed using Kruskal-Wallis 






(B) and (C) and n=5 for (D) and (E), ns= not statistically significant. Comparisons with p values 
shown only for groups of interest. 
 
 
Figure 5.2. Pentablock copolymer (PBC) micelle-anti-IgM Fab crosslink B cell receptors 
and induce B cell proliferation. (A) Upper panel: Schematic of the experiment showing 
stimulation of wild-type (WT) murine spleen cells with anti-IgM F(ab’)2 (10 μg/mL), or anti-
IgM F(ab) (10 μg/mL), or PBC micelle (10 μg/mL), or PBC micelle-anti-IgM F(ab) (10 μg/mL 
each). Anti-CD40 (5 μg/mL) was added to all the treatment groups except unstimulated controls. 
Lower panel: Corresponding representative histograms for the stimulation groups with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) expression for viable B cells (Zombie-
CD3-CD19+B220+) from flow cytometry. The histograms (blue lines) were generated 5 days 
after proliferation. Peaks for CFSE-unstained cells (dark grey, filled) and CFSE-stained non-
proliferated cells (light grey, filled) are also shown. (B) Percent proliferated viable B cells from 
spleens as determined by CFSElo gating for young mice. (C) Percent proliferated viable B cells 
from spleens as determined by CFSElo gating for aged mice. (D) Concentration of the cytokine, 






culture, splenic cells (0.5x106/well) were stimulated in 96 well U-bottom plates. Data are 
represented as mean ± SEM. Data were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test, n=5, ns=not statistically significant. In addition to the 
significance denoted in the image with the respective p values, mean values for anti-F(ab’)2 and 
PBC micelle-anti-IgM F(ab) are also statistically significant from control for (B), (C) and (D) 








Figure 5.3. Pentablock copolymer (PBC) micelle-anti-IgM Fab crosslink B cell receptors 
and induce B cell proliferation. (A) Upper panel: Schematic of the experiment showing 
stimulation of wild-type (WT) murine spleen cells with anti-IgM F(ab’)2 (10 μg/mL), or anti-
IgM F(ab) (10 μg/mL), or PBC micelle (10 μg/mL), or PBC micelle-anti-IgM F(ab) (10 μg/mL 
each). Anti-CD40 (5 μg/mL) was added to all the treatment groups except unstimulated controls. 
Lower panel: Corresponding representative histograms for the stimulation groups with 
carboxyfluorescein diacetate succinimidyl ester (CFSE) expression for viable B cells (Zombie-
CD3-CD19+B220+) from flow cytometry. The histograms (blue lines) were generated 5 days 






proliferated cells (light grey, filled) are also shown. (B) Percent proliferated viable B cells from 
spleens as determined by CFSElo gating for young mice. (C) Percent proliferated viable B cells 
from spleens as determined by CFSElo gating for aged mice. (D) Concentration of the cytokine, 
TNFα in supernatants of cells stimulated with different treatment groups for 10 days. For cell 
culture, splenic cells (0.5x106/well) were stimulated in 96 well U-bottom plates. Data are 
represented as mean ± SEM. Data were analyzed using one-way analysis of variance (ANOVA) 
followed by Tukey’s post hoc test, n=5, ns=not statistically significant. In addition to the 
significance denoted in the image with the respective p values, mean values for anti-F(ab’)2 and 
PBC micelle-anti-IgM F(ab) are also statistically significant from control for (B), (C) and (D) 







Figure 5.4. Pentablock copolymer (PBC) micelle-Ag complexes enhance B cell proliferation 
and antibody production (A) Schematic of experiment showing stimulation of murine spleen 
cells with anti-IgM F(ab’)2 (10 μg/mL) as positive control, or antigen (Ag: hen egg white 
lysozyme (HEL) or ovalbumin (OVA), or PBC micelle (10 μg/mL), or PBC micelle-Ag (10 
μg/mL each). Anti-CD40 (5 μg/mL) was added to all the treatment groups except unstimulated 
controls. Corresponding representative histograms for the stimulation groups with CFSE 
expression (blue lines) for viable B cells (Zombie-CD3-CD19+B220+) generated 4 days after 






proliferated viable B cells from spleens as determined by CFSElo gating for young WT mice. (C) 
Concentration of the cytokine, TNFα in supernatants of cells stimulated with different treatment 
groups for 10 days. (D) anti-HEL IgM titers and (E) anti-OVA IgM titers in the supernatants of 
cells stimulated with different treatment groups. For cell culture, splenic cells (0.5x106/well) 
were stimulated in 96 well U-bottom plates. Experiments were performed with cells from both 
C57BL/6 and Balb/c mice. Data are represented as mean ± SEM. Data were analyzed using one-
way analysis of variance (ANOVA) followed by Tukey’s post hoc test, n=4, ns= not statistically 
significant. In addition to the significance denoted in the image with the respective p values, 
mean values for anti-F(ab’)2 and PBC micelle-Ag groups in (B) and (C) and PBC micelle-Ag 
groups  in (D) and (E) are also statistically significant from control with p<0.0001. PBC micelle, 







Figure 5.5. Ag presentation to B cells by pentablock copolymer (PBC) micelle in transgenic 
(Tg) mice. (A) Representative histograms for CFSE stained (blue lines) viable B cells (Zombie-
CD3-CD19+B220+) 4 days post-stimulation of splenic cells from C57BL/6-
Tg(IghelMD4)4Ccg/J mice with various treatment groups (anti-IgM F(ab’)2, HEL , OVA, BSA, 
PBC micelle at 10 μg/mL). Anti-CD40 (5 μg/mL) was added to all the treatment groups except 
unstimulated controls. Peaks for CFSE-unstained cells (dark grey, filled) and CFSE-stained non-
proliferated cells (light grey, filled) are also shown. (B) Percent proliferated viable B cells as 
determined by CFSElo gating. (C) Concentration of the cytokine, TNFα and (D) anti-HEL IgM in 
the supernatants of cells stimulated with different treatment groups for 10 days. For cell culture, 






mean ± SEM. Data were analyzed using one-way analysis of variance (ANOVA) followed by 
Tukey’s post hoc test, n=4, ns= not statistically significant. In addition to the significance 
denoted in the image with the respective p values, mean values for PBC micelle-Ag groups in 
(B), (C) and (D) are also statistically significant from control with p<0.0001. PBC micelle, HEL, 








Figure 5.6. PBC micelles serve as a platform for in vitro antibody production. Splenic cell 
population obtained from WT C57BL/6 mice or Balb/c mice were stimulated in 96-well U-
bottom plates at a density of 0.5x106/well. Anti-CD40 (5 μg/mL) was added to all the treatment 
groups except unstimulated controls. Spike protein from SARS-CoV-2 (10 μg/mL) and F1-V 
from Y. pestis (10 μg/mL) was used with or without PBC micelle (10 μg/mL) or Pluronic® F127 
micelle (10 μg/mL) or PBC unimers (10 μg/mL). (A) Histograms depicting CFSE levels of B 






Percent proliferated viable B cells as determined by CFSElo gating. (C) anti-Spike protein IgM 
titers measured in the supernatants of the stimulated cells after 10 days. (D) Histograms 
depicting CFSE levels of B cells stimulated with various treatment groups with or without F1-V 
for 4 days. (E) Corresponding percent proliferated viable B cells as determined by CFSElo gating. 
(F) anti-F1-V IgM titers measured in the supernatants of the stimulated cells after 10 days. Data 
are represented as mean ± SEM. Data were analyzed using one-way analysis of variance 
(ANOVA) followed by Tukey’s post hoc test, n=2-4, ns= not statistically significant. PBC 
micelle, Spike protein, F1-V, Pluronic® F127 micelle and PBC unimers are not significant from 








Supplementary Figure 5.1. Characterization of pentablock copolymer (PBC) micelle and 
Pluronic® F127 micelle. (A) Chemical structure of PBC micelle, PDEAEM: Poly-
(diethylamino)ethyl methacrylate, POE: Polyoxyethylene, POP: Polyoxypropylene. Reversible 
temperature and pH dependent self-assembly leading to micellization. (B) H1 NMR spectra of the 
PBC with corresponding peaks for bonds denoted with letters and  (C) Size of PBC micelle and 







Supplementary Figure 5.2. Stimulation of splenic cells from WT mice. Cells stimulated with 
PBC micelle, Pluronic® F127 micelle and anti-IgM F(ab). (A) Representative B cell gating 
strategy and percentage of B cell populations for different stimulation groups. (B) Comparison of 
B cell population and CFSE expression with or without stimulation with anti-CD40 for the PBC 
micelle-anti-IgM F(ab) group. (C) Representative CFSE expression for cells stimulated with 
various concentrations of PBC micelle-anti-IgM F(ab). (D) B cell population and CFSE expression 
for cells stimulated with Pluronic® F127- anti-IgM F(ab) and PBC unimer-anti-IgM F(ab). The 
CFSE histograms denoted by solid black lines with cell generations indicated with numbers, 
unstained control demoted with dark grey shaded histogram and CFSE stained non-proliferated 







Supplementary 5.3. Stimulation of splenic cells from WT mice. Cells stimulated with PBC 
micelle, Pluronic® F127 micelle and antigens- hen egg white lysozyme (HEL), ovalbumin (OVA), 
recombinant fusion protein from Y. pestis (F1-V). (A) Representative B cell gating strategy and 
percentage of B cell populations for different stimulation groups. (B) B cell populations and CFSE 
expression without stimulation with anti-CD40 for the PBC micelle-anti-IgM HEL group. (C) B 
cell population and CFSE expression for cells stimulated with Pluronic® F127-HEL, Pluronic® 
F127-OVA and PBC unimer-HEL. The CFSE histograms denoted by solid black lines with cell 
generations indicated with numbers, unstained control demoted with dark grey shaded histogram 








Supplementary 5.4 Stimulation of splenic cells from C57BL/6-Tg(IghelMD4)4Ccg/J mice. 
Cells stimulated with PBC micelle, Pluronic® F127 micelle and antigens- hen egg white lysozyme 
(HEL), ovalbumin (OVA), bovine serum albumin (BSA). (A) Representative B cell gating strategy 
and percentage of B cell populations for different stimulation groups. (B) B cell populations and 
CFSE expression without stimulation with anti-CD40 for the PBC micelle-anti-IgM HEL group. 
(C) B cell population and CFSE expression for cells stimulated with Pluronic® F127-HEL and 
PBC unimer-HEL. The CFSE histograms denoted by solid black lines with cell generations 
indicated with numbers, unstained control demoted with dark grey shaded histogram and CFSE 
stained non-proliferated peak denoted by solid light gray histogram. 
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Immunosenescence poses a formidable challenge in designing effective influenza 
vaccines for aging populations. While approved vaccines against influenza viruses exist, their 
efficacy in older adults is significantly decreased due to the diminished capabilities of innate and 
adaptive immune responses. In this work, the ability of a combination nanovaccine containing 
both recombinant hemagglutinin and nucleoprotein to provide protection against seasonal 
influenza virus infection was examined in young and aged mice. Vaccine formulations 
combining two nanoadjuvants, polyanhydride nanoparticles and pentablock copolymer micelles, 
were shown to enhance protection against challenge compared to each adjuvant alone in young 






aged mice, while both nanoadjuvants did not induce proinflammatory cytokine secretion which 
may be detrimental in aged individuals. In addition, the combination nanovaccine platform was 
shown to induce demonstrable antibody titers in both young and aged mice that correlated with 
the maintenance of body weight post-challenge. Collectively, these data demonstrate that the 




Influenza A virus (IAV) is a significant health threat to elderly populations, with up to 
90% of influenza-related deaths occurring in patients 65 years and older1. In addition, 
hospitalization rates due to influenza are two-fold higher in older adults and account for 
approximately $10.4 billion in U.S. medical costs each year2,3. Although the use of existing 
influenza vaccines may provide protection, these vaccines often have significantly lower efficacy 
and/or significant variability with respect to their performance in aged individuals1,4. For 
example, older adults were particularly affected during the 2017-2018 influenza season (which 
had a high severity of 48.8 million cases in the U.S.), by accounting for 70% of influenza-
associated hospitalizations and 90% of influenza-related deaths5. 
Considering these major public health challenges, it is important to understand the 
changes in aging-related immune functions and use this information to design new and improved 
vaccines for older adults. Immunosenescence, the decline in immune function with age, 
constitutes defects in both innate and adaptive immunity6. These defects include the decline in 
haematopoietic stem cell function7, decreased B cell numbers8, reduced phagocytic ability of 






“inflamm-aging” is another consequence of immunosenescence, leading to the presence of an 
increased basal intrinsic inflammation in the immune system12,13. All of these age-related 
immune deficiencies often lead to poor antibody production (which typically doesn’t correlate 
with protection in older adults) and T cell responses post-vaccination14. Although recent studies 
have sought to improve responses in older adults through multiple or high dose immunizations, 
there is an urgent need to improve vaccines for older adults15,16. Thus, novel vaccine 
technologies may be required to induce protection against influenza in older adults. 
Nanovaccines composed of polyanhydride nanoparticles and pentablock copolymers 
represent a novel platform for the design of subunit influenza vaccines. In particular, 
polyanhydride nanoparticles have been demonstrated to provide sustained release of 
encapsulated influenza antigens while enhancing antigen stability17. In addition, polyanhydride-
based nanovaccines have been shown to induce anti-hemagglutinin (HA) antibody titers capable 
of neutralizing influenza virus, inducing antigen-specific CD4+ and CD8+ T cell responses, 
including lung-resident memory phenotypes18 and providing protection against challenge4. 
Similarly, pentablock copolymers based on Pluronic F127 and polydiethylaminoethyl 
methacrylate (PDEAEM) represent another effective platform for affording sustained release of 
antigen, depositing the antigen in the cytosol, and promoting the rapid development of antibody 
titers19,20. Our previous work has shown that combination nanovaccines consisting of both 
polyanhydride nanoparticles and pentablock copolymers provided the greatest protection against 
influenza in young mice compared to either nanoadjuvant alone21. That being said, older adults 
often require vaccines which stimulate the immune system without exacerbating the already 
inflamed state22. Cyclic dinucleotides (CDNs), which are STING activators, have been 






inflammatory profile of traditional TLR agonist adjuvants23. In addition, CDN stimulation of 
dendritic cells from aged mice has been shown to induce greater amounts of B cell activating 
factor (BAFF), which is important for germinal center maintenance and B cell survival24,25.  
Herein, we describe the formulation of a combination nanovaccine based on these two 
nanoadjuvants, incorporating the hemagglutinin (HA) and nucleoprotein (NP) antigens from 
H1N1 IAV, and demonstrate the ability of the combination nanovaccine to provide protection 
against seasonal influenza virus. These nanovaccines enhanced dendritic cell activation, while 
limiting detrimental inflammation. Additionally, the combination nanovaccine combined with 
CDNs induced measurable anti-HA antibody titers in aged animals and limited weight loss post-
challenge. Furthermore, the data demonstrated that a single dose of the combination nanovaccine 
was shown to provide protection against influenza virus in both young and aged animals. 
Collectively, the data presented here demonstrates the ability of the combination nanovaccine to 
reduce clinical disease following IAV infection in aged animals. 
 
6.2 Materials and Methods 
6.2.1 Polyanhydride nanoparticle synthesis 
Monomers of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-bis(p-
carboxyphenoxy)hexane (CPH) were synthesized as previously described26,27. Next, 20:80 
CPTEG:CPH polymer was synthesized via melt polycondensation. The resulting molecular 
weight, composition, and purity of the polymer were characterized with 1H nuclear magnetic 
resonance spectroscopy (1H NMR; DXR 500, Bruker, Billerica, MA). 
Nanoparticles containing 1 wt. % H1 hemagglutinin (HA) and 1 wt. % nucleoprotein 






Briefly, HA and NP proteins obtained from Sino Biological (Beijing, China) were dialyzed to 
nanopure water and lyophilized overnight. Next, 20 mg/mL of 20:80 CPTEG:CPH polymer 
containing 1 wt. % of each HA and NP was dissolved in methylene chloride. The solution was 
sonicated for 30 s to ensure that the polymer was dissolved and the protein evenly distributed. 
The solution was then poured into chilled pentane (-10°C; 1:250 methylene chloride:pentane) 
and the resulting particles collected via vacuum filtration. Nanoparticle morphology and size 
were verified with scanning electron microscopy (FEI Quanta 250, FEI, Hillsboro, OR). 
 
6.2.2 Pentablock copolymer micelle synthesis 
A novel pentablock copolymer (PDEAEM-POE-POP-POE-PDEAEM) was synthesized 
by atom transfer radical polymerization29. A difunctional macroinitiator prepared from 
commercially available Pluronic®-F127 was dissolved in tetrahydrofuran and reacted overnight 
with triethylamine and 2-bromoisobutyryl. The product was precipitated in n-hexane and 
characterized using 1H NMR to confirm the end group functionalization. Next, the 
macroinitiator and the DEAEM monomer were used to synthesize the pentablock copolymer 
utilizing copper (I) oxide nanoparticles as the catalyst and N-propylpyrilidine methanamine as 
the complexing ligand30. The resulting pentablock copolymer was characterized with 1H NMR 
to determine purity and molecular weight. 
 To formulate the micelles used in Figure 6.1, a stock solution of 30% poly(vinyl 
alcohol) (PVA; 10 kDa) was prepared in phosphate buffer saline (PBS) and added to a chilled 
solution of the pentablock copolymer (4.1 wt. %) and Pluronic® F-127 (5.9 wt. %). Additional 
PBS containing HA, NP, and/or nanoparticles was added to the micelles resulting in a total of 25 






protein and/or nanoparticles throughout the micelle solution used. In order to improve 
injectability of the formulation, later experiments (Figure 6.7) utilized a reduced concentration of 
polymer. The final formulation was prepared similarly with 7.5 wt. % PVA, 2.95 wt. % 
Pluronic® F-127 and 2.05 wt. % pentablock copolymer. 
 
6.2.3 Inactivated virus 
Influenza A/Puerto Rico/8/34 (H1N1) virus was purified from infected chicken embryo 
allantoic fluid. A sterile petri dish containing 2 mL of allantoic fluid (40,960 HAU/mL) was 
placed within 12 inches of a UV light inside a biosafety cabinet for 30 min. After inactivation, no 
evidence of infectious virus was found based on a MDCK plaque assay. UV-inactivated virus 
was frozen at -80°C until 1 h prior to immunizations, at which point the UV-inactivated virus 




Female (6-8 week old) BALB/c mice were purchased from Charles River Laboratories 
(Wilmington, MA). Aged (~18 mo) mice were obtained from the National Institute of Aging 
(Bethesda, MD) or Charles River. All mice were housed under specific pathogen-free conditions 
where all bedding, caging, water, and feed were sterilized before use. Animal procedures were 








All mice were immunized subcutaneously with a total of 20 µg HA and 20 µg NP. In 
experiments using a two dose regimen (Figure 6.1, 6.2, and 6.4), mice were immunized twice 
(day 0 and 21) with the following: Saline, Soluble (10 µg HA + 10 µg NP in PBS), Nanoparticle 
(5 µg HA + 5 µg NP encapsulated in 500 µg nanoparticles co-delivered with 5 µg HA + 5 µg NP 
in PBS), Micelle (10 µg HA + 10 µg NP in 100 µL of micelles), and Combination 
Nanoadjuvants (5 µg HA + 5 µg NP encapsulated in 500 µg nanoparticles co-delivered with 5 µg 
HA + 5 µg NP in 100 µL of micelles). In experiments using a single dose regimen (Figure 6.4) 
mice were administered the following: Combination Nanovaccine (5 µg HA + 5 µg NP 
encapsulated in 500 µg nanoparticles co-delivered with 15 µg HA + 15 µg NP in 100 µL of 
micelles), inactivated virus (50 µL containing 819 HAU administered intramuscularly into the 
rear flank), or saline. In the study demonstrating vaccine efficacy in aged mice (Figure 6.7), 5 µg 
of cyclic dinucleotides (CDNs; dithio-RP,RP-cyclic di-guanosine monophosphate) provided by 
Aduro Biotech (Berkeley, CA) were included in the combination nanovaccine. 
 
6.2.6 Antibody titers 
Antibody titers were determined using an enzyme-linked immunosorbent assay (ELISA). 
First, 100 µL of blood was isolated from the saphenous vein of each mouse and centrifuged for 
10 min at 10,000 x g. The serum was separated and stored at 4°C until further analysis. High 
binding, flat-bottomed 96 well plates were coated with 100 µL/well of 0.5 µg/mL HA or NP 
protein in PBS. After incubating overnight at 4°C, the wells were emptied and blocked for 2 h at 
room temperature with 2% (w/v) gelatin in PBS with 0.05% Tween (PBS-T). Next, the plates 






Serum samples from immunized mice were added to each well beginning with a 1:200 dilution 
and performing 1:2 serial dilutions across the plate. After incubating overnight at 4°C, the plates 
were washed three times with PBS-T and incubated for 2 h at room temperature with 100 
µL/well of 1:1000 Alkaline Phosphatase-conjugated anti-mouse IgG H&L (Jackson 
ImmunoResearch, West Grove, PA). The plates were again washed with PBS-T before adding 
100 µL/well of substrate buffer (50 mM sodium carbonate, 2 mM magnesium chloride, pH 9.3) 
containing 1 mg/mL p-nitrophenylphosphate (Fisher Scientific, Pittsburgh, PA). The optical 
density (405 nm) was recorded after 30 min. Titer was defined as the reciprocal of the last serum 
dilution that produced an optical density greater than twice the value of background (i.e., average 
optical density of saline administered mice). 
 
6.2.7 Virus microneutralization 
Serum samples were diluted 1:3 with receptor destroying enzyme (RDE; Denka Seiken, 
Tokyo, Japan) diluted according to the manufacturer’s instructions and incubated in a water bath 
at 37°C overnight. Next, the samples were heat inactivated by incubating in a water bath at 56°C 
for 1 h before adding media (DMEM with 1% Pen/Strep, Invitrogen, Carlsbad, CA) to bring the 
final serum dilution to 1:20. The serum samples (25 µL/well) were subsequently added to 96 
well, round bottom plates in duplicate and 1:2 serial dilutions were performed down each 
column. Next, 25 µL of virus stock (A/PR/8/34; 2,000 TCID50/mL) were added to each well. 
After incubating for 1 h at 37°C, the samples were transferred to 96 well plates seeded with 90% 
confluent Madin-Darby Canine Kidney (MDCK; BEI Resources, Manassas, VA) cells. The cells 
were incubated for 1 h at 37°C before washing with HBSS (Invitrogen) and adding 100 µL 






MA). After three days of incubation (37°C, 5% CO2), 50 µL of each well was transferred to a 96 
well, V-bottom plate. Next, 50 µL of 0.75% turkey red bloods cells (Lampire, Hershey, PA) in 
HBSS was added to each well. The plates were incubated at room temperature for 45 min before 
reading the plates. The microneutralization titer was taken to be the last dilution of serum with 
the appearance of a button. 
 
6.2.8 Virus challenge 
Original influenza virus stocks (A/PR/8/34) were obtained from the Influenza Division of 
the Center for Disease Control and Prevention. The virus was propagated in the allantoic cavity 
of embryonated hen’s eggs, harvested after three days, and purified using a discontinuous 
sucrose gradient. The biological activity was determined using a hemagglutination assay and 
diluted to 10 HAU/mL before administering to mice. In the final experiment observing the 
vaccine efficacy of combination nanovaccines in aged mice, the virus stock was diluted to 100 
HAU/mL before administering to mice. 
Mice were challenged intranasally with live virus 35-42 days following the first 
immunization. Briefly, mice were anesthetized in a chamber with 3% isoflurane in 100% O2 at a 
flow rate of 2.5 L/min. Next, 50 µL of the prepared virus was pipetted onto the nares of the nose 
before recovering from anesthesia. All mice were monitored twice daily after challenge with 
body weight collected once per day. Animals were removed from study after losing greater than 
25% their original body weight. A subset of mice was euthanized three days post-challenge for 
bronchoalveolar lavage (BAL) and lung tissue. The total IgG anti-HA antibody titer was 






6.2.9 Virus load 
Lung tissue was extracted and homogenized before quantitative reverse-transcription 
polymer chain reaction (qRT-PCR). A commercially available one-step real-time multiplex RT-
PCR kit (VetMAX™-Gold SIV Detection Kit; Life Technologies, Austin, TX), designed to 
target viral matrix and nucleoprotein genes, was used to amplify influenza viral RNA. The PCR 
reaction was set up in a 25 µL volume containing 12.5 µL of 2X multiplex RT-PCR buffer, 1.0 
µL nuclease-free water, 1.0 µL of influenza virus primer probe mix, 2.5 µL of multiplex RT-
PCR enzyme mix and 8.0 µL of RNA template (i.e., extract) or controls. Xeno™ RNA Control 
supplied with the kit was included as an internal control for RNA purity to assess possible PCR 
inhibition from samples. Influenza Virus-Xeno™ RNA Control (1000 copies/µL) included in the 
kit was used as a positive amplification control (PAC). Nuclease-free water was used as a no 
amplification control. Thermocycling was performed in a 7500 Fast PCR System (Applied 
Biosystems, Foster City, CA) under the following conditions: reverse transcription at 48°C for 
10 min, reverse transcriptase inactivation/initial denaturation at 95°C for 10 min, and 40 cycles 
of amplification and extension (95°C for 15 s and 60°C for 45 s).   
Samples with cycle threshold (Ct) values < 38 were recorded as positive for influenza A 
viral RNA, whereas samples with Ct values > 38 were recorded as negative as per 
manufacturer’s instructions. However, the data were collected until the end of run (40 cycles) 








6.2.10 Characterization of aged dendritic cell response in vitro 
Spleens from aged mice were collected after euthanasia following IACUC protocols. 
Single cell suspensions of spleen cells were isolated after treatment with Collagenase D and 
mechanical grinding of the spleens with RPMI media. A pan dendritic cells (DCs) negative 
selection kit (Miltenyi Biotech, Bergisch Gladbach, Germany) was used to isolate CD11c+ DCs 
from the total spleen cells using the manufacturer’s protocol. Briefly, the spleen cells were 
incubated with the antibody cocktail and magnetic microbeads provided in the kit and run 
through AutoMACS ProSeparator (Miltenyi Biotech) to collect the negative selection pool of 
CD11c+ DCs. Following isolation, 2.5x106 - 5x106 spleen DCs were stimulated for 48 h with 
the following treatment groups: nanoparticles (500 μg/mL), micelles (12.5 μg/mL), LPS (1 
μg/mL) and unstimulated control with or without a soluble model antigen (ovalbumin; sOva, 20 
μg/mL). 
Following stimulation, the upregulation of costimulatory molecules were evaluated using 
flow cytometry. DCs were stained with antibodies for different co-stimulatory molecules, 
namely, CD80 (Biolegend, PerCP-Cy5.5, clone 16-10A1), CD11c (Biolegend, APC-Cy7, clone 
N418), MHCII (eBioscience, AF700, clone M5/114.15.2), CD86 (eBioscience, FITC, clone 
GL1) and CD40 (eBioscience, APC, clone 1C10). The cells were blocked prior to labelling by 
using 100 μg/mL of rat IgG (Sigma Aldrich) and 10 μg/mL of anti-CD16/32 (eBioscience). 
Supernatants from the splenic DCs stimulated with different treatment groups were collected and 
analyzed for the presence of cytokines and chemokines using MILLIPLEX® MAP mouse 
cytokine/chemokine magnetic bead panel (Millipore Sigma, Burlington, MA) on a Bio-Plex 200 








Statistical significance (p ≤ 0.05) among treatments was determined using GraphPad 
(Prism 7.00, GraphPad Software, La Jolla, CA). Briefly, the Kruskal-Wallis and Mann-Whitney 
tests were used to compare vaccine formulations in all antibody or virus load data. A repeated 
measures ANOVA was used to determine significance of weight loss post-challenge. The log 
rank Mantel-Cox test determined significance of survival data. Finally, statistical significance 
among treatment groups in dendritic cell experiments was determined using a Tukey T-test. 
 
6.3 Results 
6.3.1 Nanoadjuvants enhanced immune response post-vaccination 
To assess the combination of nanoadjuvants (i.e., nanoparticles and micelles), young (6-8 
wk old) BALB/c mice were subcutaneously immunized twice (day 0 and 21) with each dose 
containing 10 µg of recombinant HA and 10 µg of recombinant NP derived from A/PR/8/34 
virus. Serum samples were collected 35 days after the first immunization and analyzed for anti-
HA antibody titers. As shown in Figure 6.1A, all nanoadjuvanted formulations induced 
significantly greater antibody titers in comparison to soluble antigen alone. In addition, mice 
receiving formulations containing the pentablock copolymer micelles demonstrated the greatest 
mean antibody titers. 
At 42 days post-immunization, the mice were intranasally challenged with live 
A/PR/8/34 virus. Three days post-challenge, six mice within each group were euthanized and 
their lung viral load was quantified. The lungs of mice administered the nanoadjuvant 
formulations showed a significant reduction in viral load, with the lungs of animals administered 






mice administered soluble antigen (Figure 6.1B). Furthermore, no virus was detected in most of 
the mice (5/6) receiving the combination nanoadjuvant formulation at three days post-challenge 
compared to mice administered nanoparticle (2/6) or micelle (4/6) formulations alone.  
Finally, the remaining mice were weighed daily for eight days post-challenge. The saline-
administered mice began to lose weight three days post-challenge, and continued to lose up to 
20% their original body weight (Figure 6.1C). In contrast, all vaccinated mice maintained their 
body weight post-infection regardless of nanoadjuvant formulation used and were significantly 
different compared to saline controls. 
 
6.3.2 Assessing the efficacy of a single dose vaccine regimen using combination 
nanoadjuvants 
Although the combination nanoadjuvants induced robust immune responses with a prime-
boost regimen in young mice, vaccines that elicit protection in a single dose are ideal. To 
ascertain the efficacy of a single dose combination nanoadjuvant formulation against influenza 
virus infection, the responses of young mice receiving two doses (day 0 and 21) or a single dose 
of the combination nanoadjuvant formulation were compared. Regardless of vaccine regimen, all 
mice received a total of 20 µg HA and 20 µg NP. Serum was collected at day 32 post-
vaccination and analysed for the presence of anti-HA and anti-NP antibodies (Figure 6.2A). The 
young mice developed antibody responses against both HA and NP antigens, regardless of 
regimen. 
Mice were challenged intranasally with live A/PR/8/34 at day 35, after which their body 
weight and survival were monitored for 14 days. Regardless of administration regimen, the 






young mice demonstrated 100% survival compared to non-vaccinated, infected control mice with 
approximately 40% survival (Figure 6.2C). 
 
6.3.3 Combination nanovaccine protected young mice from IAV challenge 
After demonstrating that a single dose nanoadjuvant formulation induced protection in 
young mice, the efficacy of the single dose combination nanovaccine was compared to that 
induced by inactivated influenza virus (i.e., similar to a traditional influenza vaccines as opposed 
to recombinant antigens) and saline controls. 
Serum microneutralization titers were measured at 35 days post-immunization. While 
mice immunized with the inactivated IAV demonstrated a significant microneutralization 
response, combination nanovaccine-administered mice did not have a titer significantly greater 
than that of saline controls (Figure 6.3A). However, when the anti-HA total IgG antibody titers 
were measured in BAL fluid three days post-challenge, animals immunized with either the 
combination nanovaccine or inactivated IAV had significantly higher anti-HA titers compared to 
saline controls (Figure 6.3B). 
Mice were challenged 42 days post-immunization and monitored for weight loss, virus 
load in the lungs three days post-challenge, and survival. While mice receiving saline lost 25% 
of their body weight and were removed from study within 5-6 days, the combination 
nanovaccine protected mice from challenge (Figure 6.3C). Weight loss in mice administered the 
combination nanovaccine and inactivated virus was limited to ~5-10%, and no significant 
differences were observed between the two groups. In addition, the combination nanovaccine 






challenge (Figure 6.3D), and protected 100% of the mice in contrast to saline controls (Figure 
6.3E). 
 
6.3.4 Combination nanoadjuvant formulations for aged mice 
Similar to nanoadjuvant optimization in young mice, we examined the immune responses 
of single and two dose regimens in aged mice. As expected, antibody production in aged mice 
was lower in comparison to that in young mice. While the two-dose formulation induced greater 
anti-HA antibody production in aged mice compared to the single dose vaccine, both regimens 
generated similar levels of anti-NP antibody (Figure 6.4A).  
 After virus challenge, the aged mice displayed significantly less weight loss post-
challenge compared to non-immunized controls, regardless of regimen (Figure 6.4B). Also, both 
the single dose and two dose regimens induced similar levels of protection (~85%) in aged mice 
(Figure 6.4C). 
 
6.3.5 Nanoparticles enhanced activation of dendritic cells isolated from aged mice 
Following vaccination with the combination nanoadjuvants, we observed that aged mice 
(Fig. 4) had reduced serum antibody responses in comparison to young mice (Figure 6.2). 
However, despite the absence of demonstrable antibody in aged mice, the combination 
nanovaccine formulation protected against virus challenge suggesting that other immune 
mechanisms (e.g., cell-mediated immunity) may be at play. Indeed, cell-mediated immunity (i.e., 
CD8+ T cells) has been suggested as a better correlate of protection in older adults compared to 
antibody31. However, it is known that age-related immune deficiencies, including poor dendritic 






nanoadjuvants to enhance DC activation in young mice has been demonstrated32,33, we examined 
the ability of nanoadjuvants to activate DCs isolated from aged mice. 
Splenic DCs isolated from aged mice were stimulated with the nanoadjuvants for 48 h 
and the upregulation of costimulatory markers was examined via flow cytometry. The 
upregulation of CD86, CD80, and CD40 in conventional DCs (CD11c+ MHCII+) was found to 
be significantly enhanced when stimulated with nanoparticles (Figure 6.5A). In contrast, we did 
not observe any significant upregulation of the cell surface markers when stimulated with 
micelles, which is consistent with our previous findings in young splenic DCs20. Additionally, 
two sub-populations of conventional DCs were analyzed: CD8α+ (Figure 6.5B) and CD103+ 
(Figure 6.5C). CD8α+ DCs have been shown to efficiently cross-present exogenous antigens to 
CD8+ T cells leading to an effective CTL response34,35. The α4βE integrin CD103 expressed on 
DCs also plays an important role in the migration of DCs and the induction of T cell-mediated 
responses, especially in mucosal surfaces such as the lung epithelium36. The nanoparticles 
significantly enhanced the expression of co-stimulatory molecules on CD8α+ and CD103+ DCs 
(Figure 6.5B & 5C, respectively) while micelles did not activate either DC subpopulation. 
While secretion of pro-inflammatory cytokines is important for the activation of immune 
responses, they may prove detrimental in the already increased inflamed state of older adults 
(i.e., “inflamm-aging”). The supernatants harvested from DCs recovered from aged mice were 
examined for secretion of cytokines. The data demonstrated DCs from aged mice stimulated with 
nanoparticles or micelles did not significantly increase the secretion of pro-inflammatory 
cytokines (Figure 6.6A & B, respectively). In contrast, LPS (i.e., TLR4 agonist) significantly 







6.3.6 Combination nanovaccine protected aged mice from IAV challenge 
The nanoadjuvants were shown to stimulate to DCs from aged mice (Figure 6.5&6), 
however, we noted that the antibody response of aged mice was not robust (Figure 6.4). In this 
regard, CDNs have been shown to induce robust and long-lasting antibody titers following a 
single immunization23. Thus, CDNs (i.e., a STING agonist) was included in the combination 
nanoadjuvant formulation in order to improve the immune response following administration in 
aged mice. Due to the minimal weight loss observed in control aged mice (Figure 6.4), the virus 
dose was increased by ten-fold (5 HAU) to examine vaccine efficacy. 
Serum was collected from aged mice 35 days post-immunization and examined for the 
presence of anti-HA and anti-NP antibody titers. While the combination nanovaccine + CDN 
formulation and inactivated IAV induced significant anti-HA IgG antibody titers, the responses 
to NP were minimal to none (Figure 6.7A&B). Although no significant differences were 
observed in microneutralization titers, the combination nanovaccine + CDN formulation induced 
an average titer that was an order of magnitude greater than that induced by the inactivated IAV 
control (Figure 6.7C). Clinically, mice administered the combination nanovaccine + CDN 
formulation lost approximately 10-15% of their body weight and 60% of the mice survived the 
lethal challenge, as did the aged mice receiving the inactivated IAV control (Figure 6.7D&E).  
 
6.4 Discussion 
Other than the use of higher dose vaccines (e.g., Fluzone High-Dose), the design and 
development of more effective vaccines for older adults is largely unmet. Immunosenescence in 
aging individuals often leads to poor immune responses after vaccination14, and thus, novel 






nanovaccines based on polyanhydride nanoparticles and pentablock copolymer micelles have 
previously shown success against infections with low pathogenic H5N1 influenza virus in young 
animals37, the current work demonstrates the ability of nanovaccines to induce protection in both 
young and aged animals against seasonal H1N1 IAV. 
Immunosenescence involves age-related immune deficiencies in both the innate and 
adaptive immune responses such as poor antigen presentation38, reduced T cell help39,40, and low 
antibody production. In this context, vaccine formulations composed of multiple adjuvants may 
engage immune signalling/activation pathways differently for optimal efficacy. For example, 
studies have shown elevated levels of inflammatory factors including IL-1β, TNF-α, IL-6, IL-17 
in aged animals41,42, which are linked to poorer vaccine responses22. In addition, defects in 
cytokine production from DCs have been highly correlated with poor antibody responses43. 
While acute and transient inflammation is an important part of the defence and clearance of 
pathogens, chronic and persistent inflammation in elderly can be detrimental. An aged immune 
system requires a careful balancing of innate immune activation and optimal induction of 
adaptive immune responses. In this work, the polyanhydride nanoparticles were found to activate 
dendritic cells with little to no inflammation as represented by reduced pro-inflammatory 
cytokine secretion in comparison with a TLR4 agonist (Figure 6.6). In addition, the expression of 
co-stimulatory molecules such as CD80, CD86, CD40 are also known to be diminished in aged 
mice44. In this work, the nanoparticles significantly enhanced upregulation of co-stimulatory 
molecules in conventional, CD8α+, and CD103+ DCs (Figure 6.5). Indeed, CD8α+ DCs have 
been shown to efficiently cross-present exogenous antigens to CD8+ T cells leading to an 
effective CTL response. Furthermore, CD103+ DCs play an important role in the uptake of 






induction of T cell mediated responses, especially at mucosal surfaces such as the lung 
epithelium45.  
In addition to enhanced DC responses, polyanhydride nanoparticles have also been 
demonstrated to enhance the induction of antigen-specific cytotoxic T cells46 and promote 
production of virus neutralizing antibodies. Likewise, pentablock copolymer micelles provide a 
matrix within which both antigen and nanoparticles are maintained as well as promote the rapid 
and sustained development of high antibody titers19. As a case in point, although animals 
administered the HA and NP in each adjuvant alone generated robust antibody titers (Figure 6.1), 
combining the two nanoadjuvants (i.e., nanoparticles and micelles) produced the greatest mean 
titer and reduction in viral load in the lungs. Thus, we hypothesize that formulations utilizing 
combination adjuvants would effectively activate multiple immune pathways and would 
overcome immune deficits in older adults resulting in more efficacious vaccines.  
The ability to formulate a single dose vaccine, especially for seasonal IAV vaccines, is 
ideal for improved patient compliance and efficiency of vaccine distribution to a naïve 
population. Previously, polyanhydride nanovaccines have been shown to induce elevated 
antibody titers with suboptimal doses of antigen47. However, the onset of these antibody 
responses are typically delayed due to the slow release kinetics of antigen from the particles. In 
addition, higher doses of antigen are often necessary in developing effective vaccines for older 
adults48,49. In this work, we hypothesize that a large initial bolus of soluble antigen adjuvanted by 
the pentablock copolymer micelles may more effectively initiate the induction of an immune 
response while the sustained release of antigen from the nanoparticles promotes the maturation 






formulated as a single dose resulted in similar efficacy as a two-dose immunization regimen in 
both young and aged mice (Figure 6.2 & 6.4). 
Protection against IAV involves multiple immune pathways, especially in older adults, 
including mucosal immunity, non-neutralizing antibody, and T cell immunity. Generation of 
mucosal immunity is often important when considering respiratory pathogens such as IAV. 
Indeed, the pulmonary tract contains immunoreactive sites enriched with B and T cells that may 
respond quickly upon exposure50. Our data demonstrates that although serum antibody responses 
were diminished, robust titers were observed in the BAL fluid suggesting that perhaps some 
mucosal immunity played a role in subsequent protection from challenge (Figure 6.3). In this 
regard, intranasal IAV nanovaccines have been shown to induce local and systemic immunity 
resulting in protection against both homologous and heterologous IAV challenge18. Thus, 
vaccination strategies that allow for intranasal administration of combination nanovaccines and 
enhance mucosal immunity in older adults may be explored in future studies. 
Although anti-HA titers are important, it is known that vaccines incorporating multiple 
antigens, especially conserved viral proteins, may be necessary for protection against 
heterologous IAV strains. Recently, non-neutralizing antibodies in cooperation with antigen-
specific CD8+ T cells were demonstrated to provide immunity against IAV challenge53, 54. 
With respect to the data presented in this work, the aged mice generated a greater anti-NP 
antibody response compared to their anti-HA antibody response (Figure 6.4) suggesting that 
while the combination nanovaccine provided protection in both young and aged mice, the 
mechanisms of protection in aged mice may rely on the breadth of the immune response (i.e., 






While outside the scope of this work, it is vital to note that recent evidence suggests that 
T cell responses may correlate better to protection against IAV in older adults. The T cells 
typically respond to epitopes present on conserved, internal viral proteins such as NP. As a 
result, CD8+ T cell responses play a central role in enhancing viral clearance and greatly 
contribute to providing heterologous protection against subsequent infections. Therefore, vaccine 
formulations that enhance cell-mediated immune responses towards these conserved epitopes 
would be beneficial for older adults. Indeed, polyanhydride nanovaccines have previously been 
demonstrated to enhance cytotoxic T cell responses and promote development of immunological 
memory including tissue-resident memory T cells18,46. In addition, while the combination 
nanovaccine induced low neutralizing antibody titers in young mice, 100% protection was 
achieved suggesting that cellular immune responses may be, in part, responsible for protection 
(Figure 6.3). These cellular immune responses coupled with the demonstrable antibody response 
to NP antigen in aged mice (Figure 6.4) suggest that the combination nanovaccine formulation 
induced cell-mediated immune mechanisms of protection to be explored in future studies. 
Finally, we hypothesize that the appropriate selection of unique nanoadjuvants allows for 
the induction of robust immune responses in aged mice without exacerbating the state of 
inflammation in aged mice resulting in protective immunity against influenza virus. Indeed, the 
combination of multiple nanoadjuvants in this work was found to provide protection in aged 
mice against influenza virus as evidenced by minimizing weight loss and enhancing survival 
post-challenge relative to saline controls (Figure 6.7). We speculate that in addition to the 
benefits previously discussed, the polyanhydride nanoparticles provide sustained delivery of 
antigen which may induce cross priming of CD8+ T cells and aid in the development of T cell 






antibody responses51. Therefore, the inclusion of micelles and CDNs, which induce high 
antibody titers early post-immunization, are beneficial co-adjuvants. Finally, the micelles may 
provide a depot of antigens and/or nanoadjuvants and encourage delivery of antigen to the 
cytosol. These nanoadjuvants used concomitantly set the stage for the development of an 
efficacious single dose influenza virus nanovaccine for older adults. 
 
6.4 Conclusions 
Due to age-related immune deficiencies, the development of successful influenza 
vaccines for older adults is an unmet need. In this work, the efficacy of a combination 
nanovaccine based on polyanhydride nanoparticles and pentablock copolymer micelles that 
contained the IAV HA and NP antigens was demonstrated in both young and aged mice. The 
combination of two nanoadjuvants was shown to induce elevated antibody titers resulting in 
reduced viral load and 100% protection in young mice. Together, these data provide evidence 
that a combination nanovaccine platform based on pentablock copolymer micelles and 
polyanhydride nanoparticles is a promising technology to rationally design influenza vaccines 
for older adults. 
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Figure 6.1 Nanoadjuvants enhanced immune response after prime-boost vaccination in 
young mice. (A) Anti-HA total IgG antibody titers 35 days after primary immunization. Dotted 
line represents limit of detection. (B) Virus titers assessed three days post-challenge. Numbers 
below each group indicate number of mice with detectable viral load. (C) Body weight 
monitored for eight days post-challenge. Statistical differences in titer were determined using 
Kruskal-Wallis and Mann-Whitney tests. Different letters indicate significant differences. n=12. 
Statistical differences in body weight were determined with a repeated measure ANOVA. n=6. p 








Figure 6.2 Combination nanoadjuvants optimized for single dose regimen in young mice. 
(A) Antibody titer 32 days after immunization with a single dose or two dose (day 0 and 21) 
regimen. Dotted line indicates limit of detection. *indicates significant differences determined by 
Kruskal-Wallis and Mann-Whitney tests. (B) Body weight monitored for 14 days post-challenge. 
Significant differences between single dose (*) or two dose (#) regimens and saline controls at 
individual time points are indicated. Different letters indicate significant differences overall as 
determined with a repeated measure ANOVA. (C) Survival of mice 14 days post-challenge. * 
indicates statistical differences via the log rank Mantel-Cox test. n=7. p ≤ 0.05. Error bars 







Figure 6.3 Combination nanovaccine protected young mice from IAV challenge. (A) 
Microneutralization titers 35 days after primary immunization. (B) Anti-HA total IgG titer in 
BAL fluid three days post-challenge. Dotted line represents limit of detection. (C) Body weight 
14 days post-challenge. (D) Virus titers assessed three days post-challenge. (E) Survival 14 days 
post-challenge. Statistical differences in titer were determined using Kruskal-Wallis and Mann-
Whitney tests. n=8-16. Statistical differences in body weight were determined with a repeated 
measure ANOVA. Statistical differences in survival determined via the log rank Mantel-Cox 
test. Different letters indicate significant differences. n=8. p ≤ 0.05. Error bars represent standard 







Figure 6.4 Optimization of combination nanoadjuvants in aged mice. (A) Optical density of 
total IgG ELISA 32 days after immunization with a single dose or two dose (day 0 and 21) 
regimen. *indicates significant differences determined by Kruskal-Wallis and Mann-Whitney 
tests. (B) Body weight monitored for 14 days post-challenge. Significant differences between 
single dose (*) or two dose (#) regimens and saline controls at individual time points are 
indicated. No statistical significance observed overall. (C) Survival of aged mice 14 days post-








Figure 6.5 Nanoparticles activated innate immune cells from aged mice. CD86, CD80, and 
CD40 mean fluorescence intensity (MFI) of (A) CD11c+, (B) CD8α+, and (C) CD103+ dendritic 
cells isolated from the spleens of aged mice. Statistical differences determined via Tukey t-test. * 
indicates significant difference compared to unstimulated control. # indicates significant 








Figure 6.6 Nanoadjuvants do not induce pro-inflammatory cytokine secretion from resting 
splenic DCs recovered from aged mice. Cytokine secretion (presented in red as fold change 
over an unstimulated control) in the supernatant of aged mice splenic DCs stimulated with (A) 
nanoparticles, (B) micelles, or (C) LPS. Cytokines that are considered inflammatory are shaded 
in pink. An expanded view of the data is presented on the right for clarification. Data was 







Figure 6.7 Combination nanovaccine protected aged mice from IAV challenge. (A) Anti-HA 
and (B) anti-NP total IgG antibody titers and (C) microneutralization titer 35 days after 
immunization. Dotted line represents limit of detection. (D) Body weight 14 days post-challenge. 
(E) Survival 14 days post-challenge. Statistical differences in titer were determined using Kruskal-
Wallis and Mann-Whitney tests. Statistical differences in body weight were determined with a 
repeated measure ANOVA. Statistical differences in survival determined via the log rank Mantel-
Cox test. Different letters indicate significant differences. n=8-9. p ≤ 0.05. Error bars represent 
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Many influenza virus vaccines, including the current licensed flu shot and Flumist, focus 
on their induction of hemagglutinin (HA)-targeted neutralizing antibodies (NAb). A shortcoming 
for such vaccines is the variability in vaccine effectiveness both across age groups and against 
different viral strains. To overcome this formidable challenge, vaccines that mediate both Nab 
responses as well as mount an effective cell-mediated immunity in both young and aged are 
needed. In this work, we characterized T cell responses generated in young and aged mice after 
immunization with a subunit combination nanovaccine consisting of multiple adjuvants - 
polyanhydride nanoparticles, pentablock copolymer micelles and a STING agonist, cyclic 
dinucleotides, and a two influenza antigens - HA and nucleoprotein (NP). Our data demonstrate 
that mice immunized with the combination nanovaccine mounted a robust recall T cell response 






cell-mediated immune response with multiple routes of immunization - subcutaneous and a 
combination of subcutaneous and intranasal. Collectively, our results demonstrate that an 
optimal combination of adjuvants and immunization routes is important for generating an 
effective T cell response which can lead to heterologous protection against influenza A virus. 
 
7.1 Introduction 
Out of the 131 Influenza A virus subtypes identified in nature, A(H1N1) and A(H3N2) 
subtypes routinely infect humans causing seasonal infections. From time to time, subtypes such 
as the highly pathogenic avian influenza (HPAI H5N1) and A(H1N1)pdm09 have been known to 
cause outbreaks and pandemics1–3. The seasonal influenza vaccine consists of three to four either 
live attenuated or inactivated strains of the virus, depending on the dominant strains circulating 
each season4. This guesswork approach leads to variable vaccine effectiveness (VE). For 
example, the overall VE for influenza vaccines ranged from 19-48% between 2015-20205. 
Another challenge is the low VE (14% in 2019-20) and higher rates of flu-related hospitalization 
(50-70%) in older adults (>65 years old) owing to immunosenescence - the deterioration of 
immune system with age6–8.  
Traditionally, for vaccine-induced protection against influenza infection, generation of 
anti-HA NAb has been considered the gold standard9. However, considering the aforementioned 
challenges, research has increasingly focused on additional ways to confer broadly protective 
immunity against influenza virus. A few of these strategies include alternative routes of 
immunization, generation of NAb targeted towards the more conserved epitopes in the HA-stalk 
region, use of matrix proteins and NP, and induction of robust cytotoxic T cell (CTL) 






adjuvants has been shown to be more effective in preventing influenza infections than parenteral 
vaccination, owing to the induction of robust mucosal immunity14,15. Therefore, in order to 
enhance T cell responses in both young and older adults, in addition to an optimal combination 
of adjuvants and antigens, the optimal route(s) of immunization also need to be considered. 
We have previously shown that immunization with a combination of polyanhydride 
nanoparticles, pentablock copolymer micelles and cyclic dinucleotides (CDN) with HA and NP 
induces robust antibody responses and protective immunity in both young and aged mice against 
a homologous influenza challenge16. Supplementation of this effective humoral immune 
response with a cellular response towards conserved antigens would result in a promising, 
broadly protective vaccine formulation. Polyanhydride nanoparticles have been demonstrated to 
enhance T cell response with a memory phenotype by providing a sustained release of the 
antigen17 . An intranasal administration of HA- and NP-encapsulating polyanhydride 
nanoparticles have been shown to induce protective B and T cell immunity18. Micelles composed 
of a pentablock copolymer (PBC) based on Pluronic® F127 and polydiethylaminoethyl 
methacrylate (PDEAEM), have been demonstrated to enhance B cell responses and cytosolic 
delivery of antigen to the antigen presenting cells (APC)19,20. In addition, our previous work with 
cyclic dinucleotides showed that CDNs enhanced antibody responses in aged mice, with the 
induction of a metabolical profile that was different from that induced by TLR agonists21.  
In this work, we analyzed the T cell response generated by a combination nanovaccine 
with polyanhydride nanoparticles, PBC micelles, and CDNs immunized via both subcutaneous 
and intranasal routes. We analyzed T cell responses in the lungs, lymph nodes, and spleens 3 and 
8 days post-challenge with live influenza virus and demonstrated the ability of the combination 






Additionally, the nanoadjuvants also enhanced MHC I antigen presentation and B3Z CD8+ T cell 
activation in vitro. 
 
7.2 Materials and Methods 
7.2.1 Materials  
Chemicals for polymer synthesis including acetic acid, dimethyl formamide, methylene 
chloride, pentane, potassium carbonate, sodium hydroxide, sulfuric acid, and toluene were 
purchased from Fisher Scientific (Fairlawn, NJ). 1-methyl-2-pyrrolidinone, dibromohexane, 
hydroxybenzoic acid, N,N-dimethylacetamide, triethylene glycol, N,N-(diethylamino)ethyl 
methacrylate (DEAEM), Pluronic® F127 were obtained from Sigma Aldrich (St. Louis, MO). 4-
fluorobenzonitrile was purchased from Apollo Scientific (Cheshire, UK). 
H1N1 A/Puerto Rico/8/34 hemagglutinin (HA) and nucleoprotein (NP) were purchased 
from Sino Biological (Beijing, China). Cyclic dinucleotides (cyclic di-GMP; CDNs) were 
provided by Aduro Biotech (Berkeley, CA). Antibodies used for flow cytometry were purchased 
from BioLegend (San Diego, CA), BD Biosciences (San Jose, CA), Miltenyi Biotec (Auburn, 
CA) or Fisher Scientific. NP147-155-MHC I tetramer (H2-K(d)) was obtained from the National 
Institutes of Health Tetramer Core Facility (Atlanta, GA). 
 
7.2.2 Mice 
Female BALB/c mice were purchased from Charles River Laboratories (Wilmington, 
MA). Young mice were approximately 6-8 weeks old and aged mice were approximately 18-20 
months old at the time of immunization. Young Tg (DO11.10)10Dlo/J transgenic mice were 






pathogen-free conditions with all bedding, caging, water, and feed sterilized prior to use. All 
animal procedures were conducted with the approval of the Iowa State University Institutional 
Animal Care and Use Committee. 
 
7.2.3 Nanomaterials synthesis and characterization 
Polyanhydride nanoparticles (PA-NP) were produced as previously described22,23. 
Briefly, a 20:80 molar ratio of 1,8-bis(p-carboxyphenoxy)-3,6-dioxaoctane (CPTEG) and 1,6-
bis(p-carboxyphenoxy)hexane (CPH) diacids were polymerized via melt polycondensation24,25. 
The resulting polymer was characterized by 1H-nuclear magnetic resonance spectroscopy 
(Bruker DXR 500, Billerica, MA) to ensure purity and appropriate molecular weight (5,200 
g/mol). Next, nanoparticles were synthesized by dissolving the polymer with 1 wt.% HA and 1 
wt.% NP (for in vivo experiments) using 20 mg/mL solution of 20:80 CPTEG:CPH in methylene 
chloride. The solution was sonicated for 30 s to ensure uniform distribution of the proteins. The 
solution was then precipitated into chilled pentane (-10°C; 1:250 methylene chloride:pentane) 
and the resulting particles were collected by vacuum filtration. Nanoparticle size and 
morphology were confirmed with scanning electron microscopy (FEI Quanta 250, FEI, 
Hillsboro, OR). 
Pentablock copolymer (PBC) based on DEAEM and Pluronic® F127 was synthesized by 
atom transfer radical polymerization process as previously reported26. The purity and molecular 
weight (14,600 g/mol) of the resulting polymer was determined using 1H-nuclear magnetic 
resonance spectroscopy (Bruker DXR 500). For the micelle formulation, a stock solution of 100 






wt.% Pluronic® F127. This stock solution was diluted to desired concentrations and mixed with 
HA and NP antigens to prepare the vaccine formulations.   
 
7.2.4 Cell culture and in vitro assays 
Bone marrow-derived dendritic cells (BMDCs) were harvested from femurs and tibia of 
C57BL/6 mice using a standard protocol19. For the MHC I-SIINFEKL presentation assay, 
BMDCs were plated in 96-well U-bottom plates at a density of 0.5x106 cells/well. They were 
stimulated for 24 hours with 5 µg/well of ovalbumin (OVA) with or without the following 
treatments: 100 µg of 20:80 CPTEG:CPH nanoparticles; 5 µg/mL of micelles; 0.5 µg/mL of 
CDNs; 5 µg/mL of CpG; 1 µg/mL of MPLA. CpG and MPLA were used as control (TLR) 
adjuvants. The cells were then washed and stained with anti-CD11c and anti-MHC I-SIINFEKL 
antibodies for flow cytometry. 
We obtained the B3Z CD8+ T cell hybridoma cell line, specific for the SIINFEKL 
peptide of OVA, as a kind gift from the Shastri laboratory (University of California, Berkeley, 
CA)27. These cells produce β-galactosidase upon activation by recognizing MHC I-SIINFEKL 
presented on DCs that can be measured by chlorophenol red-β-D-galactopyranoside (CPRG, 
Roche Diagnostics) conversion assay. For this assay, 6 x 105 BMDCs/well were plated and 
rested for 8 h after which the above-mentioned stimulants were added and incubated overnight at 
37 °C in a 5% CO2 incubator. The stimulants were similar to the MHC I assay, except 1 µg/mL 
SIINFEKL was used. After incubation, the BMDCs were washed carefully with fresh phosphate 
buffered saline. 3x105 of the B3Z T cells were added to each well and co-cultured with the 
stimulated BMDCs for 24 h. Cells were then centrifuged, and the medium was carefully removed 






incubated at 37 °C in the dark for four hours and the released chlorophenol red was measured at 
570 nm using a plate reader (SpectraMAX 190, Molecular Devices, San Jose, CA).  
 
7.2.5 Inactivated virus 
Influenza H1N1 A/Puerto Rico/8/34 virus was purified from infected chicken embryo 
allantoic fluid. A solution of live virus was placed within 12 inches of a UV light for 30 min. 
After inactivation, an MDCK plaque assay was used to confirm no infectious particles remained 
in the solution. The resulting UV-inactivated virus was frozen at -80°C until 1 h prior to 
immunization, when it was thawed and kept on ice until administration. 
 
7.2.6 Immunizations 
For the CD8+ T cell studies, young mice were immunized with a combination 
nanovaccine administered either all subcutaneously at the nape of the neck (combination 
nanovaccine SC) or with a portion of the formulation administered intranasally (combination 
nanovaccine IN+SC). Mice (n = 8/group) administered the vaccine subcutaneously received 500 
µg of 20:80 CPTEG:CPH nanoparticles, 5 mg pentablock copolymer micelles, 15 µg HA, 15 µg 
NP from H1N1 A/PR/8/34 and 20 µg CDNs in 100 µL phosphate buffered saline (PBS). Mice 
that were administered vaccine via both routes received 5 mg pentablock copolymer micelles, 15 
µg HA, 15 µg NP, and 10 µg CDNs in 100 µL PBS subcutaneously and 500 µg of 20:80 
CPTEG:CPH nanoparticles with 10 µg CDNs in 50 µL PBS intranasally. Mice receiving the 
inactivated virus were administered 50 µL (819 HAU) intramuscularly. Control mice were 
administered saline. Aged mice (n = 7-8/group) were subcutaneously immunized with a 






pentablock copolymer micelles, 15 µg HA, 15 µg NP from H1N1 A/PR/8/34 and 20 µg CDNs or 
20 µg of Imiquimod (ImQ). Inactivated virus vaccine or saline was administered similar to the 
young mice regimens.  
For the antigen-specific CD4+ T cell studies, aged mice (n = 4-5/group) were 
subcutaneously immunized with 500 µg of 20:80 CPTEG:CPH nanoparticles, 5 mg pentablock 
copolymer micelles, 100 µg of OVA from H1N1 A/PR/8/34 and 20 µg CDNs or 20 µg of 
Imiquimod (ImQ). A schematic of the in vivo experiment is shown in Scheme 7.1. 
 
7.2.6 Virus challenge 
After 42 days, mice were challenged intranasally with live homologous (H1N1 
A/PR/8/34) or heterologous (H3N2 A/Hong Kong/1/68) influenza virus. Briefly, mice were 
anesthetized in a chamber with 3% isoflurane in 100% oxygen at 2.5 L/min. Next, 50 µL of live 
virus was administered onto the nares of each mouse before recovering from anesthesia. All mice 
were monitored twice daily after challenge.  
 
7.2.7 Adoptive transfer of antigen-specific CD4+ T cells 
Lymph nodes and spleens were isolated from DO11.10 Tg mice to make a homogenous 
cell suspension. The cells were stained with anti-KJ1-26 (a DO11.10 TCR antibody) and anti-
CD4 antibodies and analyzed with flow cytometry before the adoptive transfer via tail-vein to 
track the number of antigen-specific CD4+ T cells being transferred to WT BALB/c mice. About 







7.2.8 T cell analysis by flow cytometry 
Mice were euthanized at 3- and 8-days post-challenge. Lung, spleen, and/or draining 
lymph nodes (dLNs) were harvested and homogenized to single cell suspensions. Red blood cells 
were removed from lung and spleen samples by ammonium-chloride-potassium (ACK) lysis. 
Cells were surfaced labeled with anti-Thy 1.2 PE-Cy7, anti-CD8b APC, anti-CD44 
AlexaFluor488, anti-CD62L FITC, anti-CD4 PerCP-Cy5.5, anti-KLRG1 APC Cy7, anti-CCR7 
eFluor450, anti-CD104 SuperBright600, and NP147-155-MHC I-PE (H2-Kd)tetramer. For the 
CD4+ T cell experiments, cells were labeled with Zombie Aqua to test for viability, surface 
stained with anti-CD4 PerCP-Cy5.5, anti-KJ1-26-AlexaFluor647, anti-CD44 AlexaFluor700, 
anti-CD62L APC eFlour780. In addition, intracellular cytokine staining for anti-TNFα FITC and 
anti-IL-2 Pacific Blue was also performed. Cell fluorescence were measured using a FACS 
Canto flow cytometer (BD Biosciences) and data subsequently analyzed with Flow Jo (Treestar, 
Inc., Ashland, OR). 
 
7.2.9 Statistical analysis 
Statistical significance (p ≤ 0.05) among treatment groups was determined using 
GraphPad Prism (Prism 8, GraphPad Software, La Jolla, CA). The Kruskal-Wallis test was used 
to determine overall significance and Mann-Whitney tests were used for subsequent multiple 
comparisons. Tukey T-test was used to determine statistical significance for the in vitro assays.  
 
7.3 Results 
7.3.1 In vitro MHC I antigen presentation and CD8+ T cell activation by nanoadjuvants 
Dendritic cells (DCs) have the ability to cross-present exogenous antigens on MHC I to 






MHC I (H-2Kb)-SIINFEKL (OVA257-264 peptide) antibody to detect the ability of presentation by 
BMDCs after stimulation with OVA with or without different adjuvants. DCs stimulated with 
either nanoparticles or micelles or CDNs- the components of our combination nanovaccine - 
significantly increased MHC I-SIINFEKL presentation, compared to soluble OVA or 
unstimulated control (Figure 7.1A). The direct consequence of this enhanced presentation on 
CD8+ T cells was measured by using an in vitro co-culture assay with B3Z CD8+ T cells. The T 
cells co-incubated with DCs stimulated by the nanoadjuvants in combination with SIINFEKL 
showed significantly greater activation compared to SIINFEKL alone and unstimulated control 
(Figure 7.1B). We used TLR agonists such as MLPA and CpG as comparisons which also 
exhibited enhanced MHC I presentation and T cell activation. 
 
7.3.2 Combination nanovaccine enhanced in vivo recall CD8+ T cell responses in young 
mice 
To analyze the recall response of CD8+ T cells in vivo, mice were immunized with either 
the combination nanovaccine, or the inactivated virus vaccine (positive control). Saline mice 
were used as negative controls. All groups of mice were infected with (H3N2 A/Hong 
Kong/1/68) live influenza virus (heterologous challenge) and various tissues were isolated at 
days 3 and 8 post-infection. Non-vaccinated and non-infected mice were used as controls for the 
flow cytometry analysis. Thy1.2+CD8+ T cells after gating, were categorized into different 
memory subsets: those circulating within the lymphoid tissues (central memory T cells, TCM: 
CD44+CD62Lhi  ), those circulating in the extra-lymphoid tissues (effector memory T cells, TEM: 
CD44+CD62Llo ) and those localized at the site of infection for a long time- in this case, the lungs 
(tissue-resident memory T cells, TRM: CD103






NP147-155-MHC I tetramers were used to recognize influenza Ag-specific Thy1.2+CD8+ T cells 
in the lungs.  
We observed Thy1.2+CD8+ T cells with a memory phenotype recruited to the lungs and 
lymph nodes of all the vaccinated mice (i.e., independent of the formulation) post-infection 
(Figure 7.1A,B and Supplementary Figure 7.1). However, immunization with the combination 
nanovaccine led to greater enhancement in antigen-specific CD8+ T cells (NP-MHC I+) in the 
lungs and dLNs at both time-points, compared to saline (Figure 7.1A and B). In addition, the 
IN+SC formulation led to a sustained increase in antigen-specific CD8+ T cells in the lungs, 
compared to the SC formulation.  
The kinetics of the recruitment of TEM and TRM populations was observed to be 
dependent on the formulation, route of administration, and tissue location. Specifically, in the 
lungs, the number of TEM and TRM cells was found to be the highest for the IN+SC group at both 
time-points (Figure 7.1A). In contrast, in the dLNs, these cell populations were at similar levels 
for all three vaccinated groups of mice at day 3 post-infection but not at day 8 post-infection, 
when both the groups of combination nanovaccine elicited the highest increase in the recruitment 
of the TEM cells (Figure 7.1B). We did not observe significant differences in the numbers of the 
TCM cell population within the treatment groups (Supplementary Figure 7.2B and C).  
 
7.3.3 Combination nanovaccine enhanced in vivo recall CD8+ T cell responses in aged mice 
Given that the quality and quantity of T cell response in aged mice is different from 
young animals, we sought to determine if our combination nanovaccine formulation could 
enhance T cell immunity in aged mice. In our previous work, we had demonstrated that the 






is detrimental to antibody production and memory T cell responses16,17,21. Hence, as a 
comparison for this study, we immunized aged mice with our nanoparticles and micelles, co-
adjuvanted with either CDN (Combination nanovaccine SC) or with a TLR9 agonist, imiquimod 
(ImQ). All mice were challenged with H1N1 A/PR/8/34 (homologous challenge) and tissues 
were collected at 3 days post-infection. Combination nanovaccine SC- immunized mice 
developed the highest total numbers of CD8+Thy1.2+ T cells, TEM cells and TCM cells in the 
spleens and the dLNs (Figure 7.3A and B). Although it is noteworthy that the population of T 
cells that acquired a memory phenotype was significantly higher for mice immunized with the 
inactivated virus or the nanoparticles+micelles+ImQ vaccine groups, when compared to saline. 
In addition, we did not observe any significant differences in the number of T cells in the lungs 
of the aged mice (Supplementary Figure 7.2B) between the different groups, possibly owing the 
differences in kinetics of T cell recruitment between young and the aged.  
 
7.3.4 In vivo CD4+ T cell responses in aged mice enhanced by combination nanovaccine 
In addition to their role in conferring “help” for antibody responses, effector CD4+ T 
cells (T helper cells) have been reported to be essential for mounting an effective memory CTL 
response during a secondary infection31–33. To assess the induction of antigen-specific (Ag-
specific) CD4+ T cells in vivo following immunization, we utilized an adoptive transfer model 
with the DO11.10 Tg mice. These mice in the Balb/c background, carry TCRs that react to 
ovalbumin antigen (KJ1-26+). After the adoptive transfer to aged WT BALB/c mice, we 
immunized them with different vaccine formulations. Immunization with the combination 
nanovaccine led to the greatest expansion in Ag-specific CD4+ T cells and TEM cells in aged 






immunosenescence deteriorates the ability of CD4+ T cells differentiate into functional subsets, 
including proliferation and IL-2 production34, we analyzed the functionality of these cells and 
found lymph node cells from this group of mice to be having significantly higher percentages of 
TNFα+ and IL-2+ Ag-specific CD4+ T cells. 
 
7.4 Discussion 
There is an urgent need to develop broadly protective vaccines against influenza virus for 
all age groups. Understanding the T cell response and enhancing it using adjuvants is important 
for the design of such vaccines. In addition to adjuvants, the use of antigens with conserved T 
cell epitopes across various strains, is required. Influenza antigen-specific cytotoxic lymphocytes 
are cross-reactive and can recognize these conserved epitopes to eliminate infected cells. In our 
studies, the combination nanovaccine included HA and NP from H1N1 A/PR/8/34 and mice 
were challenged with H3N2 A/Hong Kong/1/68. From the Immune Epitope Database, we did not 
find any T cell epitopes common between the two subtypes for HA for BALB/c mice, 
eliminating the likelihood of cross-reactive protection by HA. However, multiple T cell epitopes 
for NP, such as NP147, were found to be conserved between the two subtypes, corroborating the 
role of conserved epitopes in providing heterosubtypic protection, as cited in the literature35,36.  
Upon encounter with the cognate antigen by T cells, the activation, expansion, and 
contraction phases are followed by the differentiation of the small percentage of the remaining 
activated T cells into memory population. This population can undergo rapid proliferation upon 
re-exposure to antigen and are categorized into various subsets depending on location, 
phenotype, and function30. Virus-specific CD8+ T cells have been reported to be appearing in the 






influenza virus37. Immunization with the combination nanovaccine IN+SC significantly 
enhanced NP-specific cells and TEM cells in young mice, compared to saline (at both day 3 and 8 
p.i.) and inactivated virus vaccine (at day 3 p.i.) (Figure 7.2). TEM cells that are more prevalent in 
the infected tissues due to the expression of integrins are more cytolytic than TCM cells and have 
been reported to provide superior protection against viral and bacterial infections38,39. In addition, 
combination nanovaccine IN+SC also induced the greatest number of TRM cells at day 8 p.i 
(Supplementary Figure 7.2) in the lungs. Utilizing an intranasal route of administration mimics 
the natural mode of infection and induces more TRM cells. Due to the effectiveness of this 
population in blocking infections against diverse pathogens in an array of tissues, attempts at 
generating TRM cells as a part of site-directed vaccination has been increasingly becoming 
popular40–43.   
We also observed enhanced post-infection T cell responses in the lymph nodes and 
spleens of aged mice immunized with the combination nanovaccine (Figure 7.3). DCs, migrating 
from lungs to LNs after acquiring antigens, activate naïve CD8+ T cells there, which are then 
recruited to the lungs to eliminate infection. Blocking this DC migration inhibits CD8+ T cell 
activation44. Specifically, CD8α+ DCs have been reported to be carrying and presenting viral 
antigen to the CD8+ T cells in the T cell zones in the spleens45. From our previous studies, we 
have demonstrated that the polyanhydride nanoparticles activate this subset of DCs in the spleens 
of aged mice16, which might be contributing to enhancing the CD8+ T cell response in the 
spleens.  
Finally, our studies shed new light on the role of inflammatory cytokines and oxygen 
species in the generation of memory T cell response. Inflammatory cytokines generated by TLR 






by CD8+ T cells46. From our studies, aged mice immunized with ImQ as the co-adjuvant, 
demonstrated poor CD8+ and CD4+ memory T cell responses, compared to our combination 
nanovaccine. It is noteworthy that we used the subcutaneous route of immunization for the aged 
mice. Although the intranasal route has shown to be induce protective mucosal immunity and is 
effective in children and young adults, there is currently no approved intranasal vaccine against 
influenza for people aged >50 years due to safety concerns. There are examples of other 
intranasal vaccine formulations for the aged being explored in the literature47–49. And considering 
our promising results with the combination route approach in the young mice with the 
combination nanovaccine, we would explore this in the future studies with aged mice.  
 
7.5 Conclusions 
Vaccines that enhance T cell responses in both young and aged are imperative for the 
provision of universal protection against influenza virus. In this work, we demonstrated that 
immunization with our combination nanovaccine formulation led to enhanced CD8+ T cell recall 
responses in both young and aged mice. The role of different routes of administration on the 
kinetics of T cell responses in the secondary lymphoid organs was also explored in young mice. 
The combination nanovaccine resulted in the highest percentage of antigen-specific CD4+ T cells 
with improved functionality compared to a TLR agonist. Collectively, these data suggest that the 
combination nanovaccine formulation is a promising platform for designing broadly protective 
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Figure 7.1. Components of the combination nanovaccine enhances in vitro MHC I antigen 
presentation and CD8+ T cell activation. (A) Mean fluorescence intensity of MHC I-
SIINFEKL for CD11c+ bone marrow derived dendritic cells (BMDCs) stimulated for 24 h with 
various stimulants. All groups received 5 μg of ovalbumin, except the unstimulated medium only 
control group. (B) Optical density at 570 nm denoting the presence of chlorophenol red 
proportional to the degree of activation of B3Z CD8+ T cells by BMDCs stimulated with various 
stimulants. All groups received 1 μg/mL of SIINFEKL, except the unstimulated medium only 
control. The letters denote statistical significance determined via Tukey t-test (p<0.05, n=3). 







Scheme 7.1. Schematic of the in vivo experiments: (A) Recall CD8+ T cell response analysis 
in young and aged mice, and (B) Antigen-specific CD4+ T cell response post-immunization in 








Figure 7.2. Combination nanovaccine enhanced memory T cell responses in young mice. 
BALB/c mice (6-8 weeks old) were immunized with the combination nanovaccine 
(polyanhydride nanoparticle + pentablock copolymer micelle + cyclic dinucleotide), either all 
subcutaneously at the nape of the neck (SC) or half SC and half intranasally (IN+SC) with HA 
and NP from H1N1 A/PR/8/34. Other treatments included inactivated virus vaccine and saline. 






immunization. Lungs and lymph nodes were harvested on day 3 and 8 post-infection and 
analyzed for T cells using flow cytometry. Live and single cells were first gated as Thy1.2+CD8+ 
using FlowJo software. Number of antigen-specific T cells (MHCI-NP+) and T effector memory 
cells (TEM: Thy1.2
+CD8+CD44+CD62Llo) in the (A) lungs and (B) draining lymph nodes, per 
100,000 lung cells, at days 3 and 8 post-infection. The letters A-C denote statistical significance 
determined by Kruskal-Wallis and Mann-Whitney tests with n=6 mice per group and p<0.05. 









Figure 7.3. Combination nanovaccine enhanced memory T cell responses in aged mice. 
Aged BALB/c mice (18-20 months old) were immunized with the polyanhydride nanoparticle, 
pentablock copolymer micelle either co-adjuvanted with 20 μg of cyclic dinucleotide (CDN) or 
imiquimod (ImQ), subcutaneously at the nape of the neck (SC) with HA and NP from H1N1 
A/PR/8/34. Other treatments included inactivated virus vaccine and saline. All mice were 
intranasally infected homologous with live H1N1 A/PR/8/34 at day 42 post-immunization. 
Lungs, spleens, and lymph nodes were harvested on day 3 post-infection and analyzed for T cells 
using flow cytometry. Live and single cells were first gated as Thy1.2+CD8+ using FlowJo 
software. Number of Thy1.2+CD8+ T cells, T effector memory cells (TEM: Thy1.2
+CD8+ 
CD44+CD62Llo) and T central memory cells (TCM: Thy1.2
+CD8+ CD44+CD62Lhi) in the (A) 
spleens and (B) draining lymph nodes, at day 3 post-infection. The letters A-C denote statistical 
significance determined by Kruskal-Wallis and Mann-Whitney tests with n=6 mice per group 







Figure 7.4. Combination nanovaccine enhanced antigen-specific CD4+ T cell responses in 
aged mice. Lymphocytes from DO11.10 Tg mice (0.5 x106 CD4+KJ1-26+ cells) were adoptively 
transferred via tail vein into aged BALB/c mice(18-20 months old) on Day 0 and the mice were 
immunized with the polyanhydride nanoparticle, pentablock copolymer micelle co-adjuvanted 
with 20 μg of cyclic dinucleotide (CDN) or with imiquimod (ImQ), subcutaneously at the nape 
of the neck (SC) with 100 μg ovalbumin. Other treatments included inactivated virus vaccine and 
saline. Lymph nodes were harvested on day 3 post-infection and analyzed for T cells using flow 






Percentage of antigen-specific CD4+ T cells (CD4+KJ1-26+), T effector memory cells (TEM: 
CD4+KJ1-26+CD44+CD62Llo) and percentage of antigen-specific cells that were TNFα+ or IL-2+ 
in the draining lymph nodes of aged mice, at days 3 post-immunization. Statistical significance 
denoted by ** was determined by Mann-Whitney tests with n=4-5 mice per group and p<0.005. 
Error bars represent standard error of mean. Dashed line represents background levels of the cell 
percentages in lymph nodes of saline mice. 
 
 
Supplementary Figure 7.1. Gating strategy for T cell analysis with young mice. A 
representative dot plot analysis from FlowJo used to determine the total number of T cells 







Supplementary Figure 7.2 T cell responses in young mice. Total number of tissue resident 
memory T cells (TRM: CD103
+) and central memory T cells (TCM:CD44
+CD62Lhi) in (A) lungs 
and (B) mediastinal lymph nodes of young mice on day 3 and 8 post-infection. The letters A-C 
denote statistical significance determined by Kruskal-Wallis and Mann-Whitney tests with n=6 









Supplementary Figure 7.3 T cell responses in aged mice. Total number of Thy1.2+CD8+ T 
cells, T effector memory cells (TEM: Thy1.2
+CD8+ CD44+CD62Llo) and T central memory cells 
(TCM: Thy1.2
+CD8+ CD44+CD62Lhi) in the lungs aged mice on day 3 post-infection. Statistical 
significance determined by Kruskal-Wallis and Mann-Whitney tests with n=6 mice per group. 
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CHAPTER 8.    GENERAL CONCLUSIONS AND FUTURE WORK 
8.1 Conclusions 
The poor efficacy of the current flu vaccine in older adults and the growing healthcare 
burden thereof calls for the re-evaluation of strategies for vaccine design for older adults. 
Vaccine design for older adults requires customization to make the vaccine well-suited for aging 
immune systems. Subunit vaccines using multiple influenza antigens offer a favorable safety 
profile and an opportunity to incorporate different adjuvants that can augment deficiencies in 
aged immune systems in different ways. Since it is implausible for one adjuvant to address all 
the deficiencies, the research in this thesis proposes a combination adjuvant approach for 
influenza vaccines for older adults where the adjuvants work synergistically to enhance the 
immune response.  
Polyanhydride nanoparticles encapsulating hemagglutinin and nucleoprotein have been 
shown in previous studies to provide sustained release of structurally stable influenza antigens 
and improve vaccine efficacy in young mice1. Pentablock copolymer hydrogels have also been 
demonstrated in previous studies to significantly improve antibody responses2. In a separate 
study with influenza antigens, H5 HA and NP, a vaccine formulation consisting of a combination 
of these two adjuvants led to greater vaccine efficacy in young animals3.  
Balancing the safety and immunogenicity, especially for vaccines for older adults is 
critical. The evaluation of safety and biocompatibility of the polyanhydride nanoparticles has 
been previously demonstrated4. Hence, in this work, we first established the safety profile of the 
pentablock copolymer formulation (Chapter 3) and the formulation was further optimized using 
lower polymer concentration to form a micellar solution instead of a gel. Chapter 4 discusses 






copolymer micelles and a model protein ovalbumin, suggesting that depot formation of the 
pentablock copolymer gel is not the sole mechanism of action of this polymer adjuvant. 
However, this antibody response was observed to be rapid and short-lived. In addition, there was 
no activation of antigen presenting cells, which was tested using three different approaches. The 
analysis of induction of signal 2, co-stimulatory marker expression, and signal 3, cytokine 
secretion, in APCs stimulated with micelles showed no evidence of APC activation. In addition, 
the amounts of secreted innate effector molecules such as superoxides were found to be minimal 
and the mitochondrial metabolic phenotype was similar to that of unstimulated cells. All these 
observations pointed towards: (a) the potential applicability of micelles as adjuvants in vaccines 
for older adults; and (b) the need for studies to understand the mechanism(s) by which short-
lived plasma cells are induced without activation of APCs and hence without the involvement of 
T helper cells. The studies demonstrating the mechanism of B cell activation by the crosslinking 
of BCRs uniquely by the PBC micelles were performed in Chapter 5. In these studies, it was 
shown using a wild-type (WT) and a transgenic mouse model (B cells with antigen-specific 
BCRs) that the PBC micelle-antigen complexes activated B cells via crosslinking and induced 
proliferation in both young and aged mice. This activation also led to the production of cytokines 
and antibodies. The kinetics of in vivo antibody responses generated by these complexes was 
also studied in mice with or without the addition of a traditional adjuvant, MPLA. Immunization 
with both PBC micelle and MPLA provided significant enhancement in antibody titers over 
soluble antigen alone as early as 14 days and this response was sustained for 70 days post-
immunization. Furthermore, it was also demonstrated that the micellar phase and the inherent 
properties of the polymer forming these micelles were critical for the crosslinking of BCRs that 






Chapter 6 builds on the previous work that demonstrated the efficacy of a combination 
nanovaccine in young mice. In these studies, a co-adjuvant (i.e., CDNs) that showed promise in 
previous studies was used together with the polyanhydride nanoparticles and pentablock 
copolymer micelles. CDNs were shown to induce long-lived enhanced antibody titers which 
correlated with low NO production and high BAFF production, both in vitro in APCs and in vivo 
in aged mice immunized with CDNs in contrast to various TLR agonists5. Stimulation with 
CDNs led to the induction of a mitochondrial activation phenotype different from that induced 
by the TLR agonists, which was found to be conducive for vaccine design to induce immunity in 
aged mice. Through this work, it was demonstrated that the combination of these three adjuvants 
led to significant enhancement in total and neutralizing antibody titers in aged mice. The mice 
were also protected from a high dose of homologous influenza virus challenge.  
Finally, in Chapter 7, the T cell recall responses generated by the combination 
nanovaccine in young and aged mice were investigated. An effective T cell response is important 
for the induction of long-lived protection against a heterologous influenza virus challenge. The 
combination nanovaccine was found to induce robust memory and antigen-specific CD8+ and 
CD4+ T cell responses in the mice, demonstrating that this formulation is a promising platform 
for the design of a broadly protective influenza vaccine for older adults. 
 
8.2 Future work 
While the combination nanovaccine has shown promising results in young and aged mice 
with respect to generating robust humoral and cellular immune responses and providing 
homologous protection, further studies are necessary to analyze heterologous protection in aged 






immunization (Chapter 7), will likely be different in aged mice and needs to be explored. Aside 
from that, mechanistically, the decline in immune cell functions in the aged has been linked to 
their metabolic activity6–9 . Hence, to design an effective vaccine for older adults, optimization 
that accounts for the effect of the individual vaccine components on mitochondrial functions, 
need to be performed.  
 
8.2.1 Heterologous protection by the combination nanovaccine in aged animals 
While an intranasal route of immunization provides mucosal and local immunity at early 
time-points, subcutaneous immunization leads to the generation of a robust systemic and long-
lasting immunity. Hence for an effective influenza vaccine, it may be desirable to utilize a 
combination of these two routes. Such an approach with the combination nanovaccine has been 
demonstrated to enhance T cell responses in young mice (Chapter 7). However, since the quality 
and quantity of responses are different in aged mice, further studies need to be performed to 
demonstrate the success of such a multi-route approach with the combination nanovaccine in 
aged mice. Evidence in the literature suggests that the airway- and lung tissue-resident memory 
cells, such as those generated in our studies with young mice with intranasal + subcutaneous 
immunization, have been effective at preventing a heterologous viral infection10,11. Therefore, 
protection to a heterologous influenza virus challenge post-immunization with the combination 
nanovaccine via intranasal and subcutaneous routes will need to be assessed. For that, 
measurement of lung viral load, survival and tissue histopathology evaluations will need to be 







8.2.2 Effect of the components of combination nanovaccine on the metabolism of aged 
immune cells 
Defects in antigen presenting cells and B cells due to aging have been shown to have 
strong association with the mitochondrial function12,13. Specifically, the decreased phagocytic 
and cross-presentation capacities of the APCs in aged has been associated with lower 
mitochondrial potential and greater ROS production. With the polyanhydride nanoparticles, PBC 
micelles, and CDNs, we have already demonstrated minimal ROS production5,14,15 which may 
contribute towards improved APC functions (Chapter 7). However, with respect to B cells, the 
role of this decreased ROS production by the nanoadjuvants is yet to be analyzed. It has been 
reported that level of mitochondrial ROS (mROS) directly determines the fate of B cells - either 
towards plasma cell differentiation (PCD) or towards class-switch recombination (CSR)13. This 
regulation occurs due to the effect of mROS levels on haeme synthesis which in turn, regulates 
the expression of important transcription factors such as, Bach2 and Blimp1 during B cell 
activation16,17. Increased Blimp1 (and hence decreased Bach2) function promotes PCD, whereas 
decreased Blimp1 function promotes CSR. Hence, in addition to analyzing the mitochondrial 
mass and potential in the cells, these transcription factors also need to be studied in the context of 
the nanoadjuvants. 
 
8.2.3 Efficacy of combination nanovaccine in other aged animal models 
After optimization of the vaccine formulation with respect to dose of adjuvants and 
antigens and routes of immunization in aged mouse models, the lead vaccine candidate needs to 
be tested for safety and efficacy in larger (and more relevant) pre-clinical animal models such as 
ferrets and non-human primates. For influenza, ferrets represent a gold standard due to 






transmit the virus to healthy animals18. Similar to mice and humans, aged ferrets have also been 
reported to have diminished T cell and neutralizing antibody responses to influenza virus19. 
Additionally, heterosubtypic immunity was found to be significantly weakened in aged ferrets. 
Hence, studies with the combination nanovaccine in aged ferrets may provide more insights into 
the efficacy of the formulation for both homologous and heterologous protection. It is important 
to note that the clinical measures of infection for these studies may differ from the ones used in 
mice. In addition to tracking weight loss and lung functions, temperature, discharge of mucus, 
sneezing, and analysis of nasal wash viral loads will need to be performed.  
Besides ferrets, non-human primates (NHPs) on both ends of the age spectrum have been 
utilized as a reliable large animal pre-clinical model for testing influenza vaccines, owing to their 
genetic and physiological similarities to humans20,21. They have also been utilized to extensively 
study aging biology and immunosenescence as their co-morbidity patterns are similar to humans, 
including development of diseases such as hypertension, diabetes, neurodegeneration, etc22,23. 
Understanding antigen-specific cellular responses and antibody responses in aged NHPs upon 
immunization with the combination nanovaccine will aid in further corroboration of the vaccine 
efficacy and provide a more accurate picture regarding potential efficacy in older adults. All of 
these studies will set the stage for the combination nanovaccine to be readied for clinical trials in 
humans, pending FDA approvals. 
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